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 Inflammation is a complex pathophysiologic process that occurs in 
response to tissue injury induced though various stimuli. It involves 
cellular and humoral responses in which various cell types and 
inflammatory mediators are engaged. The inflammatory response must be 
tightly controlled, otherwise it results in chronic inflammation and perhaps 
continuous tissue damage. During the activation of the complement 
cascade, several small fragments, known as anaphylatoxins, are released. 
One of these anaphylatoxins is produced from the complement protein C5 
and is known as C5a. C5a is a multifunctional polypeptide that is involved 
in cellular immune responses. The receptors for C5a, C5a1 and C5a2, are 
among the large family known as G protein-coupled receptors. Unlike 
C5a1, C5a2 is incapable of signalling through G proteins but can induce β-
arrestin translocation and recruitment. C5a2 function is still enigmatic and 
it has been suggested as a decoy receptor for its ligands, as a signalling 
receptor or as a signalling modifier of C5a1, possibly through the formation 
of heterodimers. 
 In the current study, we aimed to study possible interactions between 
the C5a1 and C5a2 receptors. To achieve these goals, heterologous 
expression of different C5a receptors was studied in clearly defined 
settings using transfected RBL cells. The possibility of direct physical 
interaction between the two receptors was explored using fluorescence 
resonance energy transfer (FRET) and bioluminescence resonance energy 
transfer (BRET) using tagged C5a1 and C5a2 receptors. Possible 
dimerization was further examined using untagged receptors through co-
internalization of the C5a1 and C5a2 receptors. Various signalling assays 
were used to analyse the possible effect of C5a2 on C5a1 such as 
degranulation, intracellular Ca2+ mobilization, MAPK (ERK1/2, p38 and 
III 
 
JNK) signalling and internalization assays. FRET results showed possible 
homodimerization of C5a1 receptors but not heterodimerization with C5a2. 
BRET and receptor co-internalization studies also could not detect clear 
heterodimerization between C5a1 and C5a2. The possible indirect effect of 
C5a2 on C5a1 was assessed by comparing the C5a1 signalling upon co-
expression with C5a2. Intracellular Ca2+ mobilization was similar when 
C5a1 expressed with or without C5a2. However, the RBL degranulatory 
response to C5a was lower when C5a2 was co-expressed with C5a1. 
Phosphorylation of ERK1/2 was also decreased when C5a2 was co-
expressed with C5a1. In addition, the presence of C5a2 decreased C5a1 
internalization. Taken together, when co-expressed in RBL cells, possible 
interaction between C5a receptors was observed. This interaction is not 
necessarily due to direct physical interaction but could be through 
scavenging effect on the ligand or sequestration of intracellular partners. 
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1 Chapter 1: Introduction 
1.1 Overview: 
     The complement system is composed of proteins and glycoproteins 
(about 35-40) present either in the liquid phase in the plasma or on cell 
surfaces. Most of the soluble molecules are produced by the liver, but they 
can be produced locally in many tissues such as brain and kidney.  
     The complement system is part of the innate immune system and play 
an important role in coordinating the innate and adaptive immune 
responses (Walport, 2001, Carroll, 2004, Ricklin et al., 2010).The 
fundamental function of the complement system is to identify potentially 
dangerous nonself cells and macromolecules and facilitate their removal 
by the phagocytic cells (opsonisation) or direct action through perforation 
of the lipid bilayer (e.g bacteria). Moreover, it has a significant homeostatic 
role by removal of abnormal or damaged self-components, including 
necrotic and apoptotic cells; and abnormal protein aggregations as well as 
immune complexes. Therefore, there are two important roles of 
complement: an immune response to pathogens and clearance function to 
remove the damaged host components. Because of the ability of 
complement to attack cells by opsonisation and lysis, uncontrolled 
complement activation may lead to damage to host cells and tissues. The 
release of the anaphylatoxins such as C5a, C3a and C4a (Hugli, 1986) 
during complement activation results in inflammation. Many control 
mechanisms (soluble and on host cell surfaces) are involved in the 
regulation of complement activation (reviewed in Baines and Brodsky, 
2017). Nevertheless, many diseases are associated with failure of these 
regulatory mechanisms, which may be either the result of excessive 
complement activation (e.g. rheumatoid arthritis) or insufficient 
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complement activation (e.g. infections or systemic lupus erythematosus) 
(reviewed in Carroll and Sim, 2011).  
     One of the important molecules within the complement cascade is C5, 
which is the precursor of the effector molecules: C5a and C5b.  C5b has a 
well-known function in triggering the formation of the membrane attack 
complex (MAC) that is responsible for cell lysis, while C5a through its 
classical receptor C5a1 is a potent inflammatory mediator and 
chemoattractant (reviewed in Klos et al., 2013). Consequently, it is 
considered a crucial factor in the pathogenesis of many diseases such as 
ischemia-reperfusion injuries, sepsis, asthma, rheumatoid arthritis, and 
inflammatory bowel disease. Nevertheless, anti-inflammatory effects of 
C5a have also been reported and thought to be also mediated via its 
classical receptor C5a1 (Bosmann et al., 2012). 
     However, a recently discovered second receptor for C5a, C5a-like 
receptor 2 (C5a2 or C5aL2), does not seem to work like C5a1 creating a 
controversy among complement researchers (reviewed in Li et al., 2013). 
     The concept of forming dimers or oligomers (homo/hetero-oligomer) 
by G protein couple receptors (GPCR) is a recently developed one. There 
is also increasing consideration that the dimerization of GPCR may be 
necessary for function. Therefore, studying the dimerization of C5a 
receptors may clarify some of the controversy of the C5a2 receptor 
function and may have some implications for the receptor pharmacology. 
 
1.2 History of complement research 
     The activity of the complement system was first observed for the first 
time between 1884 and 1894. It was reported in 1888 that the fresh plasma 
had a bactericidal activity that was lost by heating to 55°C (reviewed in 
Chapter one Introduction 
4 
 
Carroll and Sim, 2011). In 1891, a heat sensitive substance was identified 
and named as "alexin" (reviewed in Skarnes and Watson, 1957). Then, it 
was proposed that the antibacterial activity in blood involved two factors: 
a heat-sensitive factor (analogous to alexin) and a heat-resistant factor 
(now known as antibodies) (reviewed in Carroll and Sim, 2011). The name 
“alexin” was then replaced with “complement” describing its role in 
complementing the activities of antibodies in inducing bacterial lysis  
(Kaufmann, 2008). 
       Four complement components were purified and characterised 
partially in 1941 (Pillemer et al., 1941). Between the 1950s and 1960s, the 
phenomenon of immune adherence (attaching complement coated particles 
to human red blood cells), complement activity assay standardization; the 
isolation of 9 distinct components from guinea pig; and the second 
complement activation pathway (called the properdin pathway, now the 
alternative pathway) were investigated in detail (reviewed in Carroll and 
Sim, 2011). 
         In the 1970s and 1980s, several complement protein components 
were isolated and sequenced; and thereafter genomic cloning and 
sequencing furthered our understanding of complement biology (Muller-
Eberhard, 1988, Müller-Eberhard, 1975, Campbell et al., 1988).  
          Although research is still progressing, the complement homeostatic 
role has been described, which involves the clearance and removal of 
damaged self-particles (Walport et al., 1998). 
 Many genetic variants of complement proteins have been recognised 
to have altered functions and probably associated with diseases. For 
example, a factor H (a regulatory protein) polymorphism was found to be 
associated with AMD (Day et al., 1988, Hageman et al., 2005, Herbert et 
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al., 2007). Subsequently, altered complement protein function was found 
to be related to polymorphisms in other proteins such as factor I and factor 
B (Clark et al., 2006, Nilsson et al., 2011, Gold et al., 2006).  
 Many complement proteins’ three-dimensional structures were 
investigated by X-ray crystallography and NMR and this could form the 
basis for better understanding of their functions and interactions (Arlaud et 
al., 2007, Gros et al., 2008).  
In the 1970s, the anaphylatoxin C5a was purified and characterized 
from activated sera and its biological functions explored (Vallota and 
Muller-Eberhard, 1973, Vallota et al., 1973). All the functions of C5a were 
at first attributed to a single receptor, which was cloned in 1991 (Boulay et 
al., 1991, Gerard and Gerard, 1991). However, the presence of other 
receptors for C5a was thought possible because of the observation of some 
puzzling results. The differences in response of leukocytes to the C5a 
agonists and antagonists were thought to be the result of either different 
posttranslational modification, unique gene products (Gerard et al., 1989), 
or perhaps due to differences in the interaction with intracellular partners 
(Paczkowski et al., 1999, Eglite et al., 2000). In 2000, a previously 
described orphan receptor, GPR77, was found to be a second receptor for 
C5a (C5a receptor-like 2, C5L2; or C5a2) and was cloned by Ohno et al., 
2000 (Ohno et al., 2000, Lee et al., 2001, Cain and Monk, 2002). 
 The momentum for developing reagents that can manipulate 
complement proteins’ activity has increased recently (Qu et al., 2011, 
Schwaeble et al., 2011, Morgan and Harris, 2003, Morgan and Harris, 2015, 
Woodruff et al., 2011). All complement pathways activation leads to 
cleavage of complement protein C5 and results in the formation of the 
anaphylatoxin C5a in addition to C5b. C5b is required for the formation of 
Chapter one Introduction 
6 
 
the membrane attack complex (C5-9), which has cytolytic and non-
cytolytic immune functions. C5a is a potent inflammatory mediator, in 
addition to various other functions, including some anti-inflammatory 
behaviour.  Therefore, the C5-C5a receptor axis is gaining increasing 
pharmacological attention and an anti C5 monoclonal antibody (eclizumab) 
is one of the products that is approved for clinical use in paroxysmal 
nocturnal haemoglobinuria and atypical haemolytic uremic syndrome   
(reviewed in Woodruff et al., 2011, Risitano and Marotta, 2016, Baines 
and Brodsky, 2017).  
      
1.3 The complement activation pathways: 
The complement system involves proteins that are secreted in inactive 
forms into the serum, functioning in a proteolytic cascade after activation. 
The results of these enzymatic reactions are often two fragments, a large 
fragment and a small fragment. The large fragment has an attachment site 
to the triggering surfaces and enzyme site for the cleavage of the 
subsequent complement component in the activation sequence (Chapel et 
al., 2014). Some of the small fragments that are generated by the cleavage 
have important inflammatory and/or homeostatic functions. For example, 
the cleavage of the complement component C5 into C5a and C5b by the 
enzymatic function of the activated complement complex called C5 
convertase (Figure1.1). 
The activation of some complement proteins trigger their binding to 
the next proteins in the cascade and arrange themselves into complexes on 
the cell membrane such as the membrane attack complex (MAC), 
sometimes called terminal attack complex. 
 
 




Figure 1.1: Functions of various proteins in the complement cascade. The figure 
illustrates the various functions of complement proteins such as, enzymatic activity, 
chemoattraction and formation of membrane attack complex. Some of the 
complement proteins when they are activated form complexes with enzymatic 
functions such as C5 convertase. The C5 precursor protein is cleaved into small (C5a) 
and large (C5b) fragments by the enzymatic function of the C5 convertase. The small 
fragment C5a exerts several functions related to chemoattraction, inflammation and 
homeostasis. The large fragment C5b has the potential to activate the next component 
in the complement cascade. Other complement proteins such as C6, C7, C8 and C9 
when they are activated bind to each other and arrange themselves into a complex 
called the membrane attack complex (MAC). The MAC inserts itself inside the cell 
membrane and forms pores, which results in cell lysis. 
 
      The activation of complement proteins occurs through serial 
proteolytic processes that lead to cleavage of the inactive molecules to 
produce the following active protease in the cascade. There are three 
known pathways of complement activation (reviewed in Sarma and Ward, 
2011) (Figure 1.2). First, the classical pathway, which usually involves the 
recognition of IgM or IgG1 immune complexes with pathogens or nonself 
antigens, and molecular patterns on pathogen surfaces. These immune 
complexes activate the multimeric C1 protein, which is composed from 
C1q, C1r, and C1s. Secondly, the lectin pathway, which is similar to the 
classical, depends on the pattern recognition receptors for detecting nonself 
substances. Mannose-binding lectins or ficolins recognise and bind to 
carbohydrate groups on the surface of pathogens. After this binding, the 
mannose-binding lectin-associated serine proteases (MASPs) are activated. 
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In both the classical and lectin pathways, sequential activation and 
cleavage steps for several complement components (including C2, C3 and 
C4) results in the formation of C5 convertase, which is C4b2a3b. In 
addition to the release of the anaphylatoxins C3a and C4a, which 
accompanies the activation of the classical and lectin pathways.  
 
 
Figure 1.2: Complement activation pathways. The complement activation pathways 
include the classical, lectin and alternative pathways are described. The classical 
pathway and lectin pathways are closely related pathways and result in the formation 
of the same C5 convertase, C4b2a3b. The classical pathway starts with activation of 
the first complement component C1qrs. The lectin pathway starts with the activation 
of the mannose-associated lectin-associated serine proteases (MASPs). The 
alternative pathway starts with the hydrolysis of C3 complement component and 
results in the formation of C3bBbC3b, which is C5 convertase of the alternative 
pathway. All the three pathways lead to the cleavage of complement component C5 
and formation of the membrane attack complex (MAC) after activation and binding of 
C6, C7, C8, and C9 components. The activation of the complement system is 
accompanied by the release of the anaphylatoxins C3a, C4a and C5a. 
 
The third pathway is the alternative pathway that depends on C3 
hydrolysis spontaneously with no need for antibodies like the classical 
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pathway. The activation of the alternative pathway leads also to sequential 
activation and cleavage that results in the formation of C5 convertase, 
which is in this case C3bBbC3b. The activation of the alternative pathway 
is accompanied by the release of C3a anaphylatoxin.  
Consequently, all three pathways lead to the cleavage of C5 into C5a 
and C5b. C5b then triggers the formation of the membrane attack complex. 
The formation of the membrane attack complex is the final step in this 
chain, which is a transmembrane channel that leads to cell lysis and death. 
C5a is another anaphylatoxin that exerts various functions related to 
inflammation and haemostasis. 
         There are several inhibitory factors that prevent complement from 
attacking host tissues when it is activated in proximity to cells or in the 
fluid phase. These factors include CD59 and the decay-accelerating factor. 
Cells lacking these factors, for example pathogens or xenografts, will 
predispose the affected tissue or cells to an amplified complement attack.  
       Upon detecting threats there will be a potent and rapid reaction due to 
the presence of the high concentration of complement proteins. However, 
inflammatory disorders may be developed as a consequence of failure in 
the controlling mechanisms (Klos et al., 2013). 
Activation of the complement system provides the means to remove 
the target antigens. This purpose could be achieved through the lysis of the 
whole cell or microorganism by the complete sequence activation and 
formation of the MAC. However, opsonisation of the invading micro-
organisms or the immune complexes is probably the key role. Opsonisation 
makes the antigens more easily attacked and digested by the immune cells 
such as macrophages.   
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1.4 Complement C5a  
          The large C5 protein (190 kDa) is composed of a beta chain 
(approximately 75 kDa) and an alpha chain (approximately 120 kDa) from 
which the C5a is split. Human C5a has a mass of about 15 kDa with 74 aa. 
It is a globular protein composed of helices and disulfide bridges in the 
core to stabilize these helices with a flexible tail at the C-terminal end 
(Huber-Lang et al., 2003). 
     When the carboxyl-terminal residue (Arg) is cleaved from C5a by 
carboxypeptidases, the biological function is altered and then it is called 
C5a  desArg (Manthey et al., 2009). 
     At low concentrations (nanomolar), C5a acts as a potent 
chemoattractant for different myeloid cell types such as 
polymorphonuclear neutrophils (PMN), macrophages, monocytes, 
basophils, and eosinophils. However, C5a can stimulate the generation of 
superoxide and enzyme release at higher concentrations (mainly in PMNs) 
(Gerard and Gerard, 1994). A reduction in acute inflammatory response 
was observed through the genetic absence of C5a receptors or blockade of 
C5a, which also affected murine neutrophil functions (Czermak et al., 
1999, Rittirsch et al., 2008) 
     Moreover, other functions have been reported for C5a including 
apoptosis, smooth muscle contraction, and vasodilation (reviewed in 
Sarma and Ward, 2012). Many of these functions have been reported also 
be stimulated by C5a desArg but higher concentrations are required to 
induce the biological responses. Nevertheless, there may be some 
differences in the activities between C5a and C5a desArg. For example, 
human basophils, in the presence of interleukin 3 (IL-3), can produce 
leukotriene C4, IL-4, and IL-13 in response to C5a, while less release of 
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leukotriene C4 occurs in response to C5a desArg which might act as a super 
agonist for the release of IL-13 (Eglite et al., 2000). Furthermore, it has 
been suggested that C5a can enhance the formation of a heterodimer 
between C5a1-C5a2, while C5a desArg lacks this function. In addition, 
there were significant differences in the secretion of IL-10 from 
macrophages derived from human monocytes after exposure to C5a or C5a 
desArg (Croker et al., 2013).  
 On the other hand, abnormal production of high levels of C5a was 
reported to compromise host defences (Riedemann et al., 2003a). Bosmann 
et al. provided evidence for anti-inflammatory effects of C5a and 
suggested a mechanism for the effect of C5a on the reduction of acute 
inflammation (Bosmann et al., 2012). This suppression was mediated by 
C5a1, but not C5a2, receptor. C5a is thought to activate PI3K-Akt and 
MEK1/2-ERK1/2 pathways, which leads to production of IL-10. IL-10 in 
turn inhibits IL-17A and IL-23, which appear during endotoxemia. Other 
studies suggested that production of IL-10 and TGF-β was induced by C5a 
and favoured generation of Tregs (Vadrevu et al., 2014, Engelke et al., 
2014). Recently, immunosuppressive responses has been reported to be 
promoted by C5a, which was thought to be via C5a1 receptor (An et al., 
2016). In addition, a more recent study has reported that C5a1 receptor 
showed inhibition effect on T helper 1 cell polarization, which allows 
certain strains of Mycobacterium tuberculosis to propagate (Sabio y García 
et al., 2017). Therefore, there is a growing body of evidence that suggests 
that inflammatory response can be regulated positively and negatively by 
C5a production and that the role of C5a in regulation of the innate and 
adaptive immune response is complex and could be determined by the local 
microenvironment.  
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1.5 Complement C5a receptors: 
1.5.1 C5a1 receptor (C5a1, C5aR): 
     The 7-transmembrane receptor, C5a1 is a member of the G protein- 
coupled receptor superfamily within the rhodopsin family. It binds both 
C5a and C5a desArg but with a lower affinity for the desarginated form 
(Boulay et al., 1991, Gerard and Gerard, 1991)  The typical signalling 
pathway involves activation of heterotrimeric G proteins upon binding to 
C5a.The G proteins are formed from subunits. The guanosine triphosphate 
(GTP) displaces guanosine diphosphate (GDP), which is attached to α 
subunit and leads to the dissociation of β and γ subunits of the G protein 
from the α, allowing the signal to be transmitted further downstream. C5a1 
receptor was reported to interact with different G proteins in different cell 
types. In neutrophils, C5a1 receptor was found to couple to pertussis toxin 
(PTX) sensitive G αi2 (Sheth et al., 1991, Skokowa et al., 2005). However, 
in monocyte like cells, C5a1 receptor can interact with PTX-insensitive 
Gα16 (in human)/G15 (Davignon et al., 2000, Monk and Partridge, 1993, 
Amatruda et al., 1993). Unlike most other GPCR, C5a1 was found to pre-
couple to G proteins (Siciliano et al., 1990). 
One downstream signal of C5a1 receptor activation is Ca2+ 
mobilization, which is also cell type dependent. In neutrophils, Ca2+ is 
released mainly from intracellular stores after C5a stimulation, while 
extracellular influx was observed in the monocyte lineage (Monk and 
Partridge, 1993). In addition, rapid and transient Ca2+ response was 
reported in mast cells (Hartmann et al., 1997). However, a more prolonged 
Ca2+ response was demonstrated in microglial cells (Moller et al., 1997). 
The release of Ca2+ from intracellular compartments was thought to be 
dependent on sphingosine-1-phosphate (S-1-P) production in neutrophils 
and macrophages (Ibrahim et al., 2004). S-1-P, which also plays a role in 
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lymphocyte trafficking, is produced in response to C5a stimulation in 
macrophages (Maceyka et al., 2012). Several other signaling pathways 
were reported to be activated through C5a1 such as the phospholipase C 
(PLC) (Jiang et al., 1996, Klinker et al., 1996)  phospholipase D (Mullmann 
et al., 1990), phosphoinositide 3-kinase/Akt (Wrann et al., 2007), PKC, and 
mitogen activated protein kinase (MAPK) (la Sala et al., 2005, Monsinjon 
et al., 2003, Coffer et al., 1998) pathways. 
The PTX-sensitive G proteins induce MAPK signalling mainly 
through βγ subunits. These subunits were thought to activate PI3K that 
leads to MAPK signalling (Stephens et al., 1996, Chiou et al., 2004). C5a 
was demonstrated to differentially activate MAPK pathways. C5a can 
stimulate ERK1/2 and p38 through independent pathways. ERK1/2 
activation was found to be dependent on PLC, PI3K, and Akt activation 
after activation of the PTX sensitive G proteins. However, p38 was only 
dependent on the G protein activation and inhibition of the other proteins 
(PLC, PI3K, and Akt) did not affect its signalling (Chiou et al., 2004).   
The termination of signalling is mediated by the GRKs (G protein-
coupled receptor kinases) that phosphorylate the C-terminal cytoplasmic 
tail of the receptors, stimulating β-arrestins recruitment (reviewed in Sarma 
and Ward, 2012). In the C-terminus of C5a1, the serine residues are the 
main targets for GRKs. Two pairs of serine residues, Ser332 and Ser334 
or Ser334 and 338, are the targets for phosphorylation by GRK2 and 
GRK3. Subsequently, other serine residues in the C-terminus are 
phosphorylated and internalization occurs (Boulay et al., 1991). 
       β-arrestins assist in GPCR internalization through clathrin coated pits 
after blocking the binding of G protein, causing desensitization of the 
receptor (Rajagopal et al., 2010). 
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  GPCR signalling is a complex process and not a simple on/off switch. 
Many factors are involved in the resultant signal. These factors may relate 
to the agonist, the receptor conformational changes, or the preferred 
activated pathways (Rajagopal et al., 2010). In addition to G protein 
dependent signalling pathway, there is G protein independent signalling 
via the  β-arrestin  that involves MAP kinase activation (Rosenbaum et al., 
2009).      It has been suggested that the selection of the pathway through 
which the signaling takes place namely, the G protein or β-arrestin, 
depends on the agonist and the subsequent conformational changes of the 
receptor (Rajagopal et al., 2010).  β-arrestin can inhibit the signaling 
through G protein while permitting an alternative downstream signaling 
pathway at the same time. β-arrestin undergoes conformational changes  
and modifications that are responsible for the different functions (Shenoy 
and Lefkowitz, 2011). 
     In 1991, two groups independently cloned C5a1 (Gerard and Gerard, 
1991, Boulay et al., 1991) . It is composed of 350 aa with a mass of 42 
kDa. C5a1 consists of seven transmembrane regions, which are connected 
by extracellular and intracellular loops (Figure 1.3). The N-terminus 
segment is located extracellularly, while the intracellular tail contains the 
C-terminus (Sarma and Ward, 2012).  
     In human C5a1 receptors, Asn2 is a potential site for N-linked 
glycosylation. The ligand affinity and receptor expression are slightly 
affected by removal of glycosylation (Pease and Barker, 1993).    At the N-
terminus of C5a1, there are three tyrosine residues. Two of them (Tyr11, 
Tyr14) are sulphated and play an essential role in ligand binding (Scola et 
al., 2007, Farzan et al., 2001). 
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    At the C-terminus, the main phosphorylation sites are located (Giannini et 
al., 1995). These sites play an important role in receptor internalization 
(Naik et al., 1997). 
 
Figure 1.3: Complement C5a receptors. C5a1 and C5a2 receptors structures are shown 
with seven transmembrane domains connected by intracellular and extracellular 
loops. The differences in the DRY (Asp-Arg-Tyr) motif following the 3rd TM domain is 
shown, which in C5a1 is DRF (Asp-Arg-Phe), while in C5a2 is DLC (Asp-Leu-Cys). 
 
1.5.2 C5a2 receptor (C5a2R, C5L2): 
     An orphan receptor, GPR77, was first reported by Ohno et al. 2000 as 
expressed on immature (but not mature) dendritic cells. It shares 58% 
homology with C5a1 receptor and 55% with C3a receptor in the 
transmembrane domain (Lee et al., 2001). It has been determined that the 
gene is located on chromosome 19 in the same region as the C5a1 gene. 
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 In 2002, Cain and Monk demonstrated that this orphan receptor 
GPR77, now termed C5a2, can bind C5a with high affinity and can bind 
C5a desArg with 10-fold higher affinity than C5a1 receptor (Cain and 
Monk, 2002). Mouse C5a2 was reported to have 4000-fold higher affinity 
for C5a desArg than C5a (Scola et al., 2007). It has been suggested that 
C5a2 binds to C5a and C5a desArg by different mechanisms (Scola et al., 
2007). C5a2 shares the same pattern  of N-terminal acidic and tyrosine 
residues with C5a1 that seems to be an important region for the binding of 
C5a desArg to the extracellular domain (Scola et al., 2007). Other 
similarities between the two receptors are found in the regions that interact 
with C-terminus of C5a, which involves a number of hydrophobic and 
charged residues (Buck et al., 2005, Monk et al., 2007). Moreover, it is also 
reported that C5a2 can bind C3a and C4a at distinct sites from that of C5a 
binding (Cain and Monk, 2002, Kalant et al., 2003). It is also supposed that 
C5a2 can bind C4a desArg and C3a desArg (also known as acylation-
stimulating protein or ASP) and acts as a functional receptor for ASP 
leading to stimulation of triglyceride synthesis and glucose transport in 
adipose tissue (Kalant et al., 2005, Kalant et al., 2003).  However, this is a 
controversial subject, because Okinaga et al 2003 did not detect interaction  
of C5a2 with C3a or C4a (Okinaga et al., 2003). In addition, another report 
has shown that neither C3a nor C3a desArg can interact with C5a2 receptor 
and it is unrelated to the metabolism of carbohydrate and lipid (Johswich 
et al., 2006). 
     The 7-transmembrane C5a2 is considered as a member of the A8 
subfamily in the G protein superfamily of receptors with other 
chemoattractant receptors such as C5a1 and C3a receptors (Joost and 
Methner, 2002). However, C5a2 is unable to couple to heterotrimeric G 
proteins (Cain and Monk, 2002, Scola et al., 2009, Kalant et al., 2003). 
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This is thought to be due to an alteration in the highly conserved DRY 
motif, which is located following the third transmembrane domain. In C5a1, 
this DRY motif is aspartate-arginine-phenylalanine (Asp-Arg-Phe). While 
C5a2 has a leucine instead of arginine at this region (Figure 1.3) (Okinaga 
et al., 2003). No Ca2+ mobilization, ERK1/2 pathway activation or 
degranulation occur in C5a2-transfected cells in response to C5a or C5a 
desArg (Cain and Monk, 2002, Okinaga et al., 2003, Johswich et al., 2006, 
Kalant et al., 2003). 
          Perhaps in accordance with their location on the same chromosome, 
C5a1 and C5a2 are generally co-expressed on similar cells and tissues but 
with overall lower expression for C5a2 receptors  (Li et al., 2013, Okinaga 
et al., 2003, Bamberg et al., 2010). In general, C5a2 is widely expressed on 
immune cells such as macrophages, neutrophils, monocytes, lymphocytes, 
and immature dendritic cells (Ohno et al., 2000, Chen et al., 2007).  
Moreover, as with C5a1, it is also expressed on non-inflammatory cells 
including vascular smooth muscle, skin fibroblasts, adipocytes, astrocytes 
(reviewed in Li et al., 2013, Monk et al., 2007). 
      Although this coexistence may suggest a functional interaction, a 
recent report that demonstrates distinct renal expression patterns for C5a1 
and C5a2 (van Werkhoven et al., 2013) may indicate that these receptors 
may differ in their key promoters or post translational modification. 
      Within the cell, although C5a1 is predominantly on the plasma 
membrane, in agreement with most other GPCR, C5a2 has been suggested 
to have tendency for more intracellular localization. This has been reported 
in transfected rat basophil leukaemia (RBL) cells using flow cytometry and 
ligand binding to demonstrate the more intracellular expression in 
comparison with C5a1 (reviewed in Li et al., 2013).  The same localization 
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has been displayed in human neutrophils and it is proposed that this 
predominant intracellular position of C5a2 may affect its interaction with 
C5a1 (Bamberg et al., 2010).  It is still unclear whether C5a2 is intracellular 
among all cell types and in different disease conditions (Li et al., 2013). It 
has been reported that there is a wide natural difference in the surface 
expression of C5a2 receptors among human individuals (Scola et al., 2009). 
Huber-Lang et al., (2005) demonstrated  a positive correlation between 
survival rate in sepsis and the surface expression of C5a2 in neutrophils 
(Huber-Lang et al., 2005).  
      The regulation of C5a2 expression seems to be affected by different 
factors. C5a itself can influence the expression of C5a2. It has been 
reported that during sepsis, the lysates of rat polymorphonuclear cells have 
low levels of C5a2 protein as an effect of exposure to C5a and it is 
independent from C5a1 expression (Huber-Lang et al., 2005). This is 
supported by another study that shows that there was no significant 
differences between C5a1-/- mouse and the wild type neutrophils in terms 
of expression of C5a2 (Rittirsch et al., 2008). Another factor that affects 
C5a2 is LPS, which has been shown to decrease C5a2 expression in 
peripheral blood mononuclear cells, associated with increased pro-
inflammatory responses to C5a (Raby et al., 2011). Moreover, it has been 
identified that some hormones may affect these receptors. For example, 
oestrogen receptor agonists can upregulate C5a1 expression. However, 
C5a2 is differentially affected by these hormones, a subject that needs 
further investigation (Farkas et al., 2012). Many other factors that affect 
the up-regulation of C5a2 were reported such as interferon γ, insulin and 
noradrenaline (Li et al., 2013, Gavrilyuk et al., 2005). 
       Concerning the receptor functions, C5a2 is still enigmatic. Generally, 
there are three theories to explain the behaviour of this receptor. Two of 
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them suggest anti-inflammatory roles (Bamberg et al., 2010, Scola et al., 
2009), while the other supports a pro-inflammatory function (Rittirsch et 
al., 2008, Chen et al., 2007): 
 
1. Recycling decoy receptor theory 
         Due to the lack of coupling with G protein (Cain and Monk, 2002, 
Okinaga et al., 2003), a "recycling decoy receptor" hypothesis has been 
described. This model proposes that C5a2 takes C5a and prevents or 
decreases its binding to, and activation of C5a1 (Scola et al., 2009). After 
binding of C5a to C5a2, the complex is internalized where the C5a is 
removed and the C5a2 returns to the surface. Therefore, the C5a is 
sequestered or degraded and the inflammatory response is prevented. 
 
2. Anti-inflammatory role through β-arrestin signalling 
         In the second anti-inflammatory model, Bamberg et al have 
suggested that the inflammatory response to C5a is regulated by C5a2 
making complexes with β-arrestin (Bamberg et al., 2010). Upon binding to 
C5a, C5a1 is internalized and interacts with C5a2 and both receptors are 
phosphorylated by G protein receptor kinases, which promotes an 
interaction with β-arrestin.  It is thought that ERK1/2 is activated when β-
arrestin complexes with C5a1, while inhibition of ERK1/2 occurs if β-
arrestin complexes with C5a2. The two  pathways compete to give the net 
signal (Bamberg et al., 2010). 
 
3. Proinflammatory hypothesis 
          C5a2 was also considered to have a pro-inflammatory function, 
which is in direct contrast to the previous two models. It has been shown 
that C5a2 can work as a positive modulator for the signalling of  C5a1 and 
C3a receptors in mouse neutrophils (Chen et al., 2007). Another study 
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demonstrated that in cecal-ligation and puncture model of sepsis in mice, 
C5a2 deficiency or blockade provided modest protection in “mid-grade” 
sepsis, while the combined blockade of both C5a1 and C5a2 receptors was 
the only protective measure against “high-grade” sepsis according to that 
study (Rittirsch et al., 2008). This suggests the harmful consequences of 
sepsis are a result of synergistic contributions of both C5a1 and C5a2 
receptors. In addition, C5a2, but not C5a1, signalling was postulated to be 
a trigger for the release of inflammatory mediator high-mobility group box 
1 (HMGB1) from the white blood cells (Rittirsch et al., 2008).  
         Due to the unclear role of the C5a2 receptor, its therapeutic potential 
is still unknown. The function of C5a2 in health and disease needs to be 
well understood before logical attempts can be made to target it for clinical 
therapy in the future.  Activating the receptor or promoting its cellular 
expression may be a successful potential therapy in case the receptor has 
an anti-inflammatory role, while the opposite will be in case it has a 
proinflammatory behaviour. Several laboratories have been trying to target 
the receptors in different ways. Recently, two selective peptides have been 
shown to induce β-arrestin recruitments to C5a2 (Croker et al., 2016). 
Antibodies that target C5a2 have also been developed (Rittirsch et al., 2008, 
Bamberg et al., 2010). Moreover, the originally described C5a1 inhibitor, 
the C5a mutant A8∆71-73 , also has been reported to inhibit C5a2 (Otto et al., 
2004). 
      Pharmacologically, it is not easy to target C5a2 due to its location 
inside the cell. Furthermore, other factors challenge the therapeutic effects 
such as the lack of clear signalling and activation ramifications. 
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1.6 Pathologies associated with inappropriate complement 
activation: 
The complement system, when it is activated, can attack foreign 
particles and lyse cells. In addition, it produces anaphylatoxins (such as 
C5a) that play a role in chemotaxis and inflammation. This capacity if 
inappropriately controlled can lead to damage to host tissues. These tissue 
damage effects have been explored since 1970s. Inappropriate complement 
activation is associated with many disorders. These disorders include 
sepsis (Huber-Lang et al., 2002b), systemic lupus erythematosus 
(Pickering and Walport, 2000), drug-induced lupus (Sim et al., 1984), 
multiple sclerosis (Ingram et al., 2014), amyotrophic lateral sclerosis (Lee 
et al., 2017), rheumatoid arthritis (Woodruff et al., 2002), gouty arthritis 
(Khameneh et al., 2017) neurodegeneration (Woodruff et al., 2008, 
Fonseca et al., 2009, Pavlovski et al., 2012, Ager et al., 2010, Hernandez 
et al., 2017), ischemia reperfusion injuries (Arumugam et al., 2003, Proctor 
et al., 2004, Woodruff et al., 2004, Poppelaars et al., 2017), asthma and 
allergies (Gerard, 2005, Abe et al., 2001, Baelder et al., 2005, Lambrecht, 
2006), paroxysmal nocturnal haemoglobinuria (Hill et al., 2005, Hillmen 
et al., 2004), atypical haemolytic uremic syndrome (Noris et al., 2014), 
age-related macular degeneration (Zipfel et al., 2010), inflammatory bowel 
diseases (Woodruff et al., 2003, Johswich et al., 2009, Jain et al., 2013), 
acute liver failure (Lei et al., 2016) C3 glomerulopathy (Williams et al., 
2017) and even in cancer (Rutkowski et al., 2010). Some of these 
pathologies are associated with diminished complement activity, while the 
others are associated with over activation and dysregulation of its activity.  
Complement deficiencies result either from rare genetic aetiologies 
(Colten and Rosen, 1992) or from consumption of complement proteins 
during infections, inflammations, wounds or surgery. Insufficient 
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complement activity may predispose to increase susceptibility to infections 
especially bacterial or fungal. In addition, diminished clearance of 
apoptotic cells could lead to the development of autoimmune disorders 
such as SLE (Pickering and Walport, 2000) and neurodegenerative 
disorders such as Alzheimer’s disease (Mukherjee and Pasinetti, 2000). 
On the other hand, excessive or prolonged activation of the 
complement system may result from chronic or excessive presence of 
activators. These activators involve microorganisms such as bacteria and 
yeasts, immunocomplexes, or damaged tissues. In addition, decreased 
production of complement down-regulators may also predispose to 
complement over activation. In many conditions such as rheumatoid 
arthritis, ischaemia reperfusion (IR), myasthenia gravis and multiple 
sclerosis,  the tissue damage is due to attack on host tissue by complement 
(Morgan and Harris, 2003).  For example, in IR, the tissues are exposed to 
interruption of blood supply as the case in myocardial infarction or 
ischemic stroke. Then, when the circulation is returned to the affected 
tissues, complement activation occurs and attacks the host blood vessels 
because it considers the anoxic endothelium as altered-surfaces or foreign. 
This kind of damage is similar to the damage that happens to transplanted 
organs.  Therefore, research interest is growing for the development of 
complement inhibitors that can protect against such damage. 
The complement system was found to have an ambivalent role in 
cancer development. It was thought that C5a implication in cancer is 
through promoting angiogenesis, proliferation, invasion, production of 
growth factors, prevention of apoptosis, suppression of antitumor 
immunity (reviewed in Rutkowski et al., 2010, Darling et al., 2015, 
Markiewski et al., 2008). However, at low concentrations, C5a was 
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suggested to have a tumor inhibition activity by facilitating the infiltration 
of macrophages and natural killer cells (reviewed in Darling et al., 2015) 
Sepsis is another systemic inflammatory response that is associated 
with uncontrolled activation of the complement system. It involves release 
of anaphylatoxins such as C3a and C5a excessively and ensuing 
neutrophils dysfunction (Goya et al., 1994, Hecke et al., 1997, Solomkin 
et al., 1981, Botha et al., 1995). The role of C5a in sepsis has been 
described as “too much of a good thing” (Gerard, 2003). Blood 
polymorphonuclear cells have lower ability to bind C5a in experimental 
sepsis (Huber-Lang et al., 2001) through down-regulation of C5a1 receptor 
(Guo et al., 2003a). However, IL6 dependent up-regulation of C5a1 was 
found in kidneys, lung, heart and liver (Riedemann et al., 2003b). In 
addition, in animal models of sepsis, animals’ survival rate was improved 
with blockade of C5a or C5a1 (Czermak et al., 1999, Huber-Lang et al., 
2002a). Another study showed that in sepsis, the blockade of C5a1 or C5a2 
receptors was associated with improved survival from mid-grade cecal 
ligation and puncture (CLP) sepsis (30-40% survival). The combined 
blockade was the only protective condition in high-grade sepsis (100% 
lethality), which suggests C5a1 and C5a2 were possibly acting 
synergistically (Rittirsch et al., 2008). Moreover, in C5a1- or C5a2 
deficient mice with CLP, the G-CSF plasma levels were substantially 
lower in wild type mice (Bosmann et al., 2013b). On the other hand, a 
decrease in IL6 levels was reported in sepsis after anti-C5a1 infusion, 
whereas IL6 was increased up to nearly fourfold after treatment with anti-
C5a2. The same study observed similar effects on IL6 release from normal 
blood neutrophils pretreated with anti-C5a2 after stimulation with LPS and 
C5a (Gao, 2005).  In addition, in CLP rat, C5a2 receptors expression was 
decreased in PMN cells in a time dependent manner. C5a2 expression was 
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preserved after blockade of C5a in vivo in experimental sepsis. Similarly, 
C5a2 surface expression was decreased in patients with progressive sepsis, 
and in patients with multiorgan failure, the expression was virtually 
abolished. In contrast, retention of C5a2 receptors was observed in sepsis 
survivors (Huber-Lang et al., 2005).   
The role of C5a and its receptors was also explored in experimental 
models of pulmonary inflammation and allergies. In asthma, C5a1 receptor 
has been reported to promote the development of asthma (Baelder et al., 
2005). C5a2 receptor did not show a clear role in pulmonary diseases. It is 
thought that C5a2 has a complex and dual role in allergic asthma 
pathogenesis and this critical role is beyond the function of a decoy 
receptor for its ligands (Zhang et al., 2010).  In C5a dependent immune 
complex pulmonary injury, an exaggerated inflammatory response was 
observed in C5a2 deficient mice, which suggests that C5a2 has a role in 
limiting C5a and C5a desArg effects (Gerard, 2005). In addition, in LPS-
induced lung injury in C5a2-/- mice, C5a2 was also suggested to play an 
important anti-inflammatory role at least by negative modulation of C5a1 
receptor (Wang et al., 2016). On the other hand, a decreased build-up of 
inflammatory cells was described in the lungs of C5a2 deficient mice in an 
experimental model of asthma (Chen et al., 2007). In acute lung injury, the 
C5a1- and C5a2- mediated tissue damage and inflammation was suggested 
to be due to the appearance of extracellular histones (Bosmann et al., 
2013a). 
C5a2 was also found to play a role in suppressing C5a-C5a1 
signalling in allergic contact dermatitis (Wang et al., 2013). 
  The role of C5a and its receptor in metabolic processes has been 
explored by many studies. ASP has been proposed as an adipokine that has 
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metabolic and immune functions. It may play a role in triglyceride 
synthesis and glucose transport. It was proposed that this ASP is identical 
to C3a desArg through sequence analysis and purification from human 
serum (Cianflone et al., 1987). In adipocytes and other cells, C5a2 was 
reported to act as a receptor for ASP (Kalant et al., 2005, Kalant et al., 
2003). C5a2 deficient mice placed on a high-sucrose and high-fat diet 
demonstrated insulin resistance and increased serum proinflammatory 
cytokines (Fisette et al., 2013). This could be due to interruption of the 
interaction between C5a2 and ASP. However, this is a controversial subject 
because the direct interaction between ASP and C5a2 could not be detected 
by other groups (Johswich et al., 2006).  
The C5a receptors are also thought to have a role in the 
communication between the immune, nervous, and endocrine systems. 
This communication could play a pivotal role in controlling inflammation 
that is primarily mediated by the hypothalamic–pituitary–adrenal axis. 
Both C5a1 and C5a2 receptors were reported to be expressed in anterior 
pituitary gland. They were supposed to play a role in inhibiting the release 
of macrophage migration inhibitory factor (MIF) and triggering 
adrenocorticotropic hormone (ACTH) release and, therefore, participate in 
damping down inflammation (Francis et al., 2008). However, it is unclear 
if this effect is mediated by C5a1 or C5a2. C5a2 expression has also been 
reported in astrocytes, which is regulated by noradrenaline and exerts anti-
inflammatory properties (Gavrilyuk et al., 2005). Another hormone that 
was found to regulate C5a2 expression is progesterone. It acts to down-
regulate C5a2 expression in preadipocytes and mature adipocytes (Wen et 
al., 2008). 
Therefore, the complement system generally, and C5a and its 
receptors specifically, play important and sometimes vital roles in 
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development of diseases that could be life threating such as sepsis. Thus, 
studying this area deserves more attention to possibly identify the factors 
that are involved in the pathogenesis of such diseases and may results in 
development of novel therapies that could limit the morbidity and mortality. 
 
1.7 Complement therapeutics: 
Inappropriate complement activation clearly plays an important role 
in the pathogenesis of a multitude of diseases. Therefore, targeting the 
generation of its components or their functional pathways has become an 
attractive drug development target. Since all the complement pathways 
activation results in cleavage of C5 and production of C5a and C5b, which 
are key perpetuators in the initiation and propagation of inflammatory 
events in many diseases, targeting the complement system activation at this 
step is a useful strategy. The C5a production can be inhibited at different 
levels. It could be targeted at the stage of C5 cleavage to prevent its 
generation. In addition, C5a can be a target itself after production. 
Furthermore, the C5a signalling through its receptors could be another 
attractive target. 
1.7.1 Inhibiting generation of C5a:  
C5a is produced after cleavage of C5 by C5a convertases, C4b2a3b 
and C3bBbC3b from the classical/lectin and alternative pathways 
respectively. These convertases are formed by the association of the C3 
byproduct, C3b, with other components of the complement pathways. One 
option to inhibit C5a production is through the inhibition of C5a 
convertases. This approach is already found in nature. Several natural 
complement regulators such as CR1, CD46 and CD55 are working by 
limiting the C5 convertases activity (Nangaku, 1998). In addition, some 
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bacteria such as S. aureus produce molecules that can inhibit C5a 
convertases (Jongerius et al., 2007). However, all these molecules are non-
selective and target C3 convertases in addition to C5 convertases. Another 
method to prevent cleavage of C5 is by targeting the protein itself and 
rendering it not susceptible to enzymatic cleavage by the C5 convertases. 
In mouse model of C3 glomerulopathy, a recent study has shown that renal 
failure was prevented by inhibiting C5 (Williams et al., 2017). An example 
of such strategy is the anti-C5 antibody eculizumab (SolarisTM). It binds to 
C5 with high affinity and prevent its cleavage (Matis and Rollins, 1995). 
In paroxysmal nocturnal haemoglubinurea, eculizumab has been used 
successfully, and promising results have been obtained from patients with 
atypical hemolytic uremic syndrome (reviewed in Woodruff et al., 2011). 
1.7.2 C5a as a target: 
Although inhibiting C5 has been shown to be a useful therapeutic 
strategy in preventing the production of C5a and MAC, in certain cases it 
may more desirable to develop a more selective method in targeting one of 
the two cleavage products of C5. This could preserve the immune function 
of the other one. This has directed the pharmaceutical attention to target 
C5a solely. Like C5 inhibition, this method is used by certain bacteria to 
target C5a directly. For example, group A streptococci produce the C5a 
peptidase, ScpA, which cleaves 7 residues from the C-terminus of C5a to 
inactivate it (Kagawa et al., 2009). Several C5a inhibitors have been 
developed and they are at various stages of clinical development (Ricklin 
and Lambris, 2013, Woodruff et al., 2011). An interesting approach was 
inducing the production of C5a neutralizing antibodies by the host through 
vaccinating with maltose binding protein with C5a as a recombinant fusion 
construct (MBP-C5a) (Nandakumar et al., 2010). This immunotherapy 
resulted in generation of host-specific antibodies to C5a with no significant 
Chapter one Introduction 
28 
 
alteration to C5/C5b activity. In a mouse model of Alzheimer’s disease, 
C5a-peptide active vaccine was reported as a safe and well-tolerated new 
therapeutic approach (Landlinger et al., 2015). This could be a useful 
strategy to exploit host immune response to produce sustained antibodies 
for its own benefit in addition to avoidance of formation of neutralizing 
antibodies towards the injected therapeutic antibodies or inhibitors.  
1.7.3 C5a1 receptors as a target:  
The other methods of inhibiting the C5-C5a1 receptors axis is by 
targeting C5a1 receptors. The pharmacological preparations that target 
C5a1 receptors are one of the largest developing groups of compounds, 
which are attractive to pharmaceutical companies (reviewed in Woodruff 
et al., 2011). The benefit of such approach is the specificity of targeting an 
individual complement component and sparing the other components for 
the immune defensive functions. In addition, C5a1 receptor has various 
roles in many diseases  (Ager et al., 2010).   
 Targeting C5a2 receptor is still a debatable subject within the 
literature because its role in health and pathophysiology is yet unclear. Its 
enigmatic function, in addition to potential reliance on C5a1 receptor for 
possible activity and its predominant intracellular position make this 
receptor not easy for targeting and drug development (Cain and Monk, 
2002, Scola et al., 2007, Bamberg et al., 2010). Therefore, studies are 
needed to be carried out to clarify the function of C5a2 receptor and its 
effect on C5a1 and this could help in development of new strategies to 
target these receptors.  
 Inhibition of complement activities for a long time may affect the 
beneficial aspects of complement function and developing complement 
targeting therapeutics needs to take this subject in consideration. For 
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example, meningococcal disease susceptibility may arise after interfering 
with C5 cleavage. In addition, Leishmania major infections could be 
exacerbated by the C5a inhibition due to diminished Th1 immune response 
(Hawlisch et al., 2005). A dual role of C5a was reported in an animal model 
of asthma (Kohl et al., 2006). C5a was also suggested to have a role in 
protecting neurons from apoptosis induced by glutamate (Mukherjee and 
Pasinetti, 2001); it is essential in liver regeneration (Strey et al., 2003) and 
has anti-inflammatory role in pancreatitis (Bhatia et al., 2001). 
Furthermore, it was considered as a potent inhibitor of angiogenesis 
(Langer et al., 2010). C5a role in neurodevelopment (Denny et al., 2013) 
and neurorepair (Beck et al., 2010) was also reported. Therefore, it still 
needs to be determined whether the long-term of use of complement 
therapeutics will affect these beneficial functions. 
 One of the possible approaches to solve the problem of the potential 
unwanted effects after long-term C5/C5a inhibition, is by improving the 
specificity of targeting. This could be done by limiting treatment to specific 
tissues. It has been reported that developing mini-bodies against C5 fused 
to a peptide was a successful strategy because this construct was selectively 
delivered to inflamed synovium (Macor et al., 2012). Therefore, this 
approach leads to local inhibition of complement function without 
affecting the functions circulating complement components.  
 
1.8 Receptor dimerization and oligomerization: 
       An increasing body of evidence assumes that the GPCR can interact 
with other receptors of their family in the form of either homodimers, 
heterodimers or higher-order oligomers. As most cells are expressing many 
types of receptors on their surfaces, it may be possible to propose that 
multiple GPCR may be involved in formation of different oligo/dimers.   
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    The exact factors and conditions that affect the formation of these dimers 
are not clear. It has been suggested that the relative affinity and the rate of 
expression of the receptors may influence the ratio of hetero-/homodimer 
(Ayoub et al., 2004). 
      The engagement in heterodimers can affect the characteristics and 
behaviours of the receptors towards the ligand (Jordan and Devi, 1999). It 
has been described that two-non-functional receptors can interact and form 
a functional receptor. This is due to the requirement of the presence of both 
receptors to be delivered to the cell surface (i.e. GABAB receptors and the 
vast majority of the olfactory receptors).  
 
      Considering that the GPCR have significant pharmacological attention, 
a clear understanding of the heterodimers’ ligand binding features may 
play an important role in the development of new therapies.  
 
       The effect of receptor interactions on receptor pharmacology is one 
of the intensive areas of research. The formation of receptor dimers or 
oligomers could result in changes of ligand affinities. This could be due to 
allosteric interactions between the receptors. In addition, a new binding site 
could result from transmembrane regions swapping between the interacting 
receptors. The opioid receptors are prominent examples in this context. 
These receptors are involved in many physiological conditions such as 
analgesia and pain perception. The main cloned opioid receptors are delta 
(DOR), kappa (KOR) and mu (MOR). Heterodimerization between DOR 
and KOR has distinct pharmacological implications compared to their 
homodimerization (Levac et al., 2002). The selective DOR and KOR 
agonists and antagonists have shown decreased binding affinities, while 
the non-selective antagonists showed increased binding affinity. A novel 
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binding site is also created between the DOR and MOR receptors, which 
affects the binding affinities of the synthetic selective ligands (including 
morphine) and the endogenous opioid peptides. It has been reported that 
blocking DOR can enhance analgesia induced by MOR. A bivalent ligand 
that can work as agonist for the MOR and antagonist for the DOR has been 
developed (Daniels et al., 2005). This new pharmacological strategy of 
bivalent ligands can help in development of analgesics with less side 
effects. 
           Due to  the  significant functional changes that have been observed 
in some heteromers, such as binding and signalling, it is proposed that 
heterodimerization could have a considerable influence on receptor 
response (Gazi et al., 2002). For example, monomeric expression of the 
DOR and MOR results in inhibition of adenylyl cyclase through a pertussis 
toxin-sensitive pathway. This toxin catalyses the ADP ribosylation of Gi/o-
proteins with notable exception of Gz. However, co-expression of both 
DOR and MOR inhibits adenylyl cyclase by a pertussis toxin-insensitive 
rout, which suggests the involvement of Gz. In similar way, the dopamine 
D1 and D2 receptors couple to Gs and Gi proteins, respectively, when 
expressed separately. Nevertheless, the D1-D2 heterodimer couples to 
Gq/11.  
 Internalization of receptors after ligand binding is part of the 
desensitization process of majority of GPCR. It is not clear for homodimers 
whether both receptors need to bind the ligand to be endocytosed. However, 
many examples were reported that co-internalization could occur in 
response to agonist of only one of the receptors (reviewed in Dickenson et 
al., 2013). For the β2-adrenoceptor-DOR heterodimers, co-internalization 
of both receptors occurs after agonist stimulation of either receptor 
(isoprenaline for β2-adrenoceptors or etorphine for opioid receptors). 
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However, this co-internalization does not occur with β2-adrenoceptor-
KOR heterodimers (Jordan et al., 2001).  
 Internalization in certain cases is part of the signalling process. This 
is the case for β2-adrenoceptors. Mitogen-activated protein kinase pathway 
activation occurs after internalization of the receptors by β2-agonists. This 
signalling is reduced when β2-adrenoceptor are co-expressed with KOR 
(Jordan et al., 2001). Therefore, heterodimerization could be a method for 
regulation of receptors function.  
  It is estimated that about 30% of all pharmaceutical drugs target are 
GPCR. Therefore, they can be considered a major therapeutic target. The 
GPCR heterodimerization may provide an additional novel drug discovery 
path. As mentioned earlier, pain treatment with a bivalent ligand for MOR-
DOR heterodimers may prove a useful treatment (Dietis et al., 2009). 
Another example on the clinical relevance of GPCR dimerization is from 
the study of chemokine receptors. Two receptors were thought to function 
as receptors for the entry of HIV into the cells. These are CXCR4 and 
CCR5. Both receptors heterodimerize with CCR2. A single nucleotide 
polymorphism of CCR2 was associated with increased heterodimerization 
with CXCR4 and CCR5 and was linked to a decrease in HIV progression. 
Since such heteromer formation has clinical significance, promoting its 
formation by ligands or antibodies could be of use in HIV treatment. 
Moreover, GPCR heterodimerization was linked to the pathogenesis of 
certain diseases. The first evidence of such link was appeared in 2001. It 
was found that in pre-eclampsia cases angiotensin AT1 and bradykinin B2 
receptor heterodimer levels increase compared to normotensive 
pregnancies. This increase results in increase in blood pressure due to 
increase in response to angiotensin II (reviewed in Dickenson et al., 2013).  
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  Regarding C5a receptors, studies have shown that C5a receptors can 
form homodimers or higher orders oligomers (Klco et al., 2003, Floyd et 
al., 2003, Rabiet et al., 2008), while other studies elicited the formation of 
C5a1 heteromers with C5a2 or with other receptors such as CCR5 
(Poursharifi et al., 2013, Huttenrach et al., 2005, Croker et al., 2013). 
However, the functional consequences of these interactions still need to be 
more explored.  
        Dimerization may play a role in receptor interaction with its 
downstream partners such as β-arrestin and receptor kinases after the 
activation of the receptor by the agonist, and may be required for 
internalization of the receptor. If the dimerization occurs between the 
targeted receptor and other receptor species then both of them might be co- 
internalized, for example: β2-adrenergic receptor dimer (Sartania et al., 
2007);  β2-adrenergic receptor heterodimers with V2 vasopressin receptors 
(Klein et al., 2001), or with α-opioid receptors (Jordan et al., 2001); and of 
C5a1 and CCR5 chemokine receptor heterodimerization (Huttenrach et al., 
2005). In the last example, the inactive unliganded receptor may be cross-
phosphorylated when the homo or hetero-dimerization occurs with another 
receptor, which is phosphorylated by the GRKs. Efficient down regulation 
of CCR5 chemokine receptor occurs when it forms heterodimers with C5a1, 
activated with C5a, due to the cross-phosphorylation and co-internalization 
of this heterodimer. 
       It has been proposed that the non-signalling receptor CXCR7 (Levoye 
et al., 2009) forms dimers with CXCR4, which then associates 
constitutively with β-arrestin and decouples from Gαi that leads to the 
potentiation of  CXCR12-dependent MAP kinase signalling for promoting 
cell migration (Decaillot et al., 2011). It may be expected for C5a2 to act 
in the same way with C5a1 depending on β-arrestin downstream signalling 
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rather than the classical G protein pathway. Association of β-arrestin with 
C5a2 receptors was reported and it is thought to have a modulatory role on 
C5a1 receptors and possibly fine tuning the host defence (Bamberg et al., 
2010). The ability of C5a2 to recruit β-arrestin2 in macrophages was also 
reported and it is thought to perhaps exert an inhibitory effect on C5a1 
signalling through modulating ERK1/2 signalling (Croker et al., 2014). 
Some researchers suggest that the underlying mechanism might be due to 
differential downstream signalling rather than the dimerization (Chen et al., 
2007, Bamberg et al., 2010). 
 
1.9 Techniques for measuring the dimerization of receptors: 
The dimerization of GPCR is studied using various biochemical, 
biophysical, and functional techniques (Dickenson et al., 2013). In many 
cases, the dimerization was explored using heterologous expression of 
receptors in transfected cell lines. The receptors are either tagged with 
fluorescent or immunological tags. Issues could be raised about using such 
approach because receptor overexpression in comparison to the 
endogenously expressed receptors could affect the results. Dimerization of 
endogenous GPCR has been reported for rhodopsin in retinal disc 
membranes (Fotiadis et al., 2003). These membranes are characterised by 
very high rhodopsin expression levels.  
 
1.9.1 Biochemical techniques: 
Many biochemical approaches have been used to detect GPCR 
dimerization. Using SDS-polyacrylamide gels for measuring the molecular 
mass of a migrating proteins complexes, which may be expected to show 
the molecular weight of dimers or oligomers (Nimchinsky et al., 1997). 
Another approach is by using co-immunoprecipitation (Cvejic and Devi, 
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1997, Hebert et al., 1996). The first evidence for the possibility of GPCR 
existing in dimers was provided using this technique for the β2-
adrenoceptor homodimerization. The concern regarding such technique is 
the possibility of the formation of artificial aggregations after solubilisation 
of hydrophobic membrane receptors before the immunoprecipitation.  
 
1.9.2 Biophysical approaches: 
1.9.2.1 Fluorescent resonance energy transfer (FRET): 
       FRET was discovered 80 years ago, and Theodor Forster, in 1940s, 
quantitively described and established a basis for it. In biological research, 
however, only more recently FRET has been harnessed as a tool (reviewed 
in Dye, 2005). 
      FRET occurs between two molecules: one (donor) that, after excitation, 
emits energy to a second molecule (acceptor) (Selvin, 2000, Szollosi et al., 
1998). The energy is generated via the vibrational relaxation of the excited 
donor until it reaches its ground excitation level. If the acceptor is a 
chromophore, the received energy will eventually be emitted as a 
fluorescence (sensitized emission).   
       At a sufficiently small distance (10–100 Å) and appropriate orientation 
between the donor and acceptor, energy transfer happens (Truong and 
Ikura, 2001, Heyduk, 2002). FRET is considered to be an attractive method 
to measure the conformational changes of the receptors due to the very high 
sensitivity to small modifications (Ayoub et al., 2004). A small increase in 
the distance between the donor and acceptor leads to a dramatic decrease 
in FRET because the energy transfer is inversely proportional to the sixth 
power of the separating distance between them.  
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      To monitor a particular protein by these strategies, two approaches 
have been used (Figure 1.4). First, to measure intramolecular FRET by 
making a construct composed of the protein of interest with the donor and 
acceptor attached to its extremities. This could help in measuring the 
conformational changes of a protein. Second, measuring the energy 
transfer between molecules (intermolecular) by attaching the donor to one 
molecule and the acceptor to the other. GPCR dimerization or 
oligomerization could occur independent of ligand binding (Uberti et al., 
2003). However, other receptors are affected by the ligand and the energy 
transfer changes depend on the ligand dose, which may suggest the concept 
that the distance between  the  donor and acceptor or their orientation can 
be modified by the conformational changes after ligand binding (Ayoub et 
al., 2004).  
  
Figure 1.4. Fluorescent resonance energy transfer types. A. intramolecular, the two FRET 
labels cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) are attached 
to ends of a protein. If the protein undergoes conformational changes that bring both 
ends together, the CFP and YFP would be brought together inducing FRET signal. B. 
Intermolecular, one protein molecule (A) tagged with CFP and the other (B) with YFP. The 
FRET efficiency increases when the two proteins interact bringing the fluorophores close 
to each other. 




        Various receptors have been studied by using this approach (Boute et 
al., 2001, Overton and Blumer, 2000, Dinger et al., 2003, Couturier and 
Jockers, 2003, Rocheville et al., 2000a, Kroeger et al., 2001, McVey et al., 
2001, Stanasila et al., 2003).  Three essential properties must be present in 
the donor and acceptor for the FRET to occur: (1) distance, they must  be 
close (10-100 Å) to each other, (2) geometric orientation must be suitable, 
and (3) spectral overlap must be significant  between the two chromophores 
(Dye, 2005). 
        Cell surface proteins interaction can also be investigated by FRET 
using fluorescently labelled antibodies, which are specific to the interacting 
proteins (Horvath et al., 2005, Broudy et al., 1998). Intracellularly, 
however, it may be difficult to detect protein-protein interaction using 
antibodies. Therefore, new techniques have been developed to detect 
intracellular interactions by fluorescent proteins, which can be added to the 
target proteins and expressed as fusion proteins. The derivatives of green 
fluorescent protein (GFP), from Aequorea victoria, for example cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP), or the red 
fluorescent protein (dsRed), from Discosoma sp, are most commonly used 
to perform FRET intracellularly (Mizuno et al., 2001, Campbell et al., 
2002).  
1.9.2.2 Bioluminescence Resonance Energy Transfer (BRET): 
       BRET occurs in some marine creatures as a natural phenomenon. It 
was used for the first time  to detect protein-protein interaction in living 
cells in 1999 by Xu et al (Xu et al., 1999). The principle of this technique 
is similar to FRET assay with the advantage of avoiding external excitation 
of the donor and its problems. In BRET, luciferase is used as a donor, 
which in the presence of a substrate, produces bioluminescence to excite 
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the acceptor fluorophore by the same mechanism of energy transfer that 
occurs in FRET (Milligan and Bouvier, 2005). Many studies have reported 
the use this technique to measure GPCR oligo/dimerization (Kroeger et al., 
2001, Ayoub et al., 2002, Issafras et al., 2002, Babcock et al., 2003, McVey 
et al., 2001, Angers et al., 2000). 
 
1.9.3 Functional complementation techniques: 
The principle of this approach is the regaining of the functionality 
after co-expression of receptors that are mutant and functionless when 
expressed individually (Lee et al., 2002, Dickenson et al., 2013, Carrillo et 




1.10 Aim of the study and the hypothesis: 
We aim to determine: 
1- If C5a1 receptor is interacting with C5a2 and whether the interaction is 
due to formation of heterodimers. 




Human C5a2 receptor affects C5a1 receptor signalling directly by 
dimerization or indirectly by sequestering both ligand and signalling 
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2 Chapter 2: Materials and methods 
2.1 Materials: 
2.1.1 Instruments and equipment: 
Equipment Supplier 
Centrifuges -SIGMA 3K15 
Microscopes -Confocal microscopy (Nikon A1 confocal 
microscopy) 





Micro plate reader LabTech LT-4000 
Flow cytometers -LSRII (BD-Bioscience) 
-Attune autosampler (Life technologies) 
-FACS Caliber (BD-Bioscience) 
-FACS Aria (BD-Bioscience) 
Electroporator -Biorad gene pulser II 
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BBN   
 
Hank’s balanced salt solution (HBSS) (with divalents 






   




10g tryptone, 10g NaCl and 5g yeast extract 
Made up to 1L in water (for agar, 15g agar added) 
Kanamycin  Stock solution prepared in ultrapure water. Used at 25 
µg/ml in LB media 
Carbenicillin  Stock solution prepared in ultrapure water. Used at 50 








Used at 0.5-1 mg/ml in DMEM 
Tris buffer 1M 
(pH9.0) 
121.14g of Tris dissolved in 800ml dH2O,  
adjust to 9.0 with HCl and make up to 1Litre 
Triton-X buffer 0.5% Triton-X100 
Citrate buffer, 
pH4.5 (0.2M) 
250ml (5.85g citric acid and 6.47g sodium citrate) 
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2.1.3 Standard reagents, chemicals, solutions and kits: 
Name Product no. Company composition 
Mouse anti-human 
C5a1  





B147507 Biolegend  
Mouse IgG1 
isotype 
GR76062-1 Abcam  
Mouse IgG 2a 
isotype 
Cat. 401502 Biolegend  
Alexa fluor@633  




Foetal calf serum 10846 Biosera Sterile, filtered, 
heat inactivated 



















Sigma   
Fluo 3-AM F 1241 Invitrogen  
Pluronic F- 127  Lot 1084328 Invitrogen  
Chapter two  Materials and methods 
43 
 














(Ca2+ and Mg2+) 




Neomycin 13200 Cayman  
Cell dissociation 
solution (CDS) 
S-044-B MilliPore  
Hi Speed Plasmid 
Midikit 
12643 Qiagen  
Substrate solution 
for release assay 
N9376 Sigma P-nitrophenyl N-
acetyl β-D-
glucosaminide 
50  mM stock 
prepared in 
DMSO 
Trypsin 10X NE02-007E Lonza  













A-6661 Sigma  
Zeocin 1621193 Invitrogen  
Coelentrazine h S201A Promega  
RHYPYWR 
peptide 
P11001501 GenScript  
Cell-Based 
Human/Mouse/Rat 









Name  components Source 
pcDNA3-YFP Yellow fluorescent protein (YFP) 
in pcDNA3 vector 
Addgene (ID13033) 
pECFP-EYFP CFP linked to YFP  LMBP 8242 
Rluc8-hC5a1 Human C5a1 receptor attached to 
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2.2 Mammalian cell culture methods: 
2.2.1 Cell lines: 
 The rat basophilic leukemia cell line (RBL-2H3) is a widely-used cell 
line in many applications that involve inflammatory or allergic immunological 
reactions. It is frequently referred to as a mast cell line, although it originated 
from basophils (Passante and Frankish, 2009). Its secretory properties and 
simple growth conditions qualify it to be used in a broad range of studies. It 
has been used for degranulation assays; studying the interaction between IgE 
antibodies with their receptor (FcRI); and intracellular Ca2+ mobilization 
(Maeyama et al., 1986, Gao et al., 2010). Therefore, this cell line has been 
chosen to express various types of human complement C5a receptors to study 
the behavior of these receptors in response to C5a. The cell lines used were 
supplied kindly by Prof. Andreas Klos, MHH, Hannover: 
1-RBL-2H3-hC5a1 receptor: these cells are expressing wild type human C5a1 
receptor. 
2-RBL-2H3-hC5a1-CFP receptor: these cells are expressing human C5a1 
receptor tagged with cyan fluorescent protein (CFP).  
3- RBL-2H3-hC5a1-YFP receptor: these cells are expressing human C5a1 
receptor tagged with yellow fluorescent protein (YFP)   
4-RBL-2H3-hC5a2-YFP receptor: these cells are expressing human C5a2 
receptor tagged with yellow fluorescent protein (YFP)   
5-RBL-2H3-hC5a1-CFP+hC5a2-YFP receptor: these cells are expressing 
both human C5a1-CFP and human C5a2-YFP receptors. 
6- RBL-2H3-hC5a1-CFP+hC5a1-YFP receptor: these cells are expressing 
human C5a1-CFP and human C5a1-YFP receptors. 
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7-RBL-2H3-hC5a1+hC5a2 receptor: these cells are expressing both human 
C5a1 and human C5a2 receptors. 
In addition, RBL cell lines were made during this study expressing: 
1-pECFP-YFP plasmid. 
2-Rluc8-hC5a1 receptor: these cells are expressing human C5a1 receptor 
tagged with Renella luciferase enzyme 8 (Rluc 8). 
3-Rluc8-hC5a1+hC5a2-YFP receptor: these cells are expressing both human 
C5a1-Rluc8 and human C5a2-YFP receptors. 
4-hC5a1/YFP: these cells are expressing hC5a1 receptors and YFP separately. 
 
2.2.2 Cryopreservation and thawing of cryopreserved mammalian cell 
lines: 
        The cells were usually suspended in freezing solution at a density of 
about 5x106 cell/ml in a cryovials. The freezing solution is composed from 
90% foetal calf serum (FCS) and 10% dimethylsulphoxide (DMSO), which is 
used to decrease ice crystal formation during freezing to protect the cells. The 
mixture was cooled slowly in liquid nitrogen vapour to about -80ºC for about 
2 hours then transferred to liquid nitrogen for long-term storage (about -
196ºC). 
 Thawing the cryopreserved cells is a stressful procedure for the cells 
that needs to be done carefully and as quick as possible. The cells need to be 
placed into a 37°C water bath immediately after removing from the liquid 
nitrogen. When a small piece of ice remained, the vial was transferred to a 
laminar flow hood. After sterilizing the vial with 70% ethanol, the lid was 
opened and cells were transferred into a universal tube containing 9ml pre-
warmed complete media Dulbecco’s Modified Eagle’s media (DMEM) + 10% 
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FCS + penicillin/streptomycin diluted 1/100). After centrifugation (200xg for 
5 minutes at 4°C to remove the DMSO, which is toxic to the cells in solution) 
the supernatant was discarded and the pellet re-suspended in complete media 
and transferred into a 100mm petri dishes suitable for tissue cultures. The cells 
were then incubated at 37°C, 5% CO2 in humidified incubator. The medium 
was changed next day to remove the dead cells and cell debris due to 
cryopreservation. 
 
2.2.3  Maintenance of mammalian cell Lines: 
 The cell lines were grown in complete medium, which is composed of 
DMEM, 10% (v/v) foetal calf serum (FCS) and penicillin/streptomycin 
antibiotics (dilute stock solution 1/100). The FCS was added as a source of 
vitamins, minerals and growth factors, while the antibacterial agents were 
used to prevent accidental bacterial contamination. Moreover, selective 
antibiotics were added to the medium to keep selection of the transfected cells. 
These selective markers are toxic to mammalian cells, therefore allowing the 
growth of the cells that retain the plasmids with the corresponding antibiotic 
resistance.  
 The cells usually grow until confluent then the cells stop dividing and 
may start dying. They, therefore, need to be spilt and subcultured continuously 
in order to be maintained. When the cells were approximately 70%-90% 
confluent the medium was aspirated off and the cells were washed with 
sufficient sterile HBSS (Hank's buffered salt solution without Ca2+ or Mg2+). 
Then the cells were incubated with trypsin/EDTA solution (2.5 ml for 100 
mm petri dishes) for 7 minutes at 37°C, 5% CO2 in humidified incubator. The 
cells were dislodged and equal volume of complete medium was added to the 
Chapter two  Materials and methods 
48 
 
cell suspension and transferred to a 30ml universal tubes. Subsequently, the 
cells were centrifuged (400 xg, 5 minutes and at 4°C). After decanting the 
supernatant, the pellets were re-suspended in new complete medium and 
subcultured into a suitable vessel. 
 
2.2.4  Transfection of Mammalian Cells: 
2.2.4.1 Transfection by electroporation: 
 Mammalian cells (e.g. RBL-2H3) from nearly confluent flask or 100 
mm petri dishes were harvested using 2-3 ml trypsin/EDTA as in section 2.2.3. 
Then the cell suspension was centrifuged and 5x106 cells were   re-suspended 
in 0.8 ml complete media. Plasmid DNA (20 µg) was added to the cell 
suspension. The mixture was transferred into 4mm gap electroporation 
cuvette. The cuvette was incubated on ice for 15 minutes and then 
electroporated (250V and 960µF) once using electric pulse machine and 
returned back to ice quickly for another 15 minutes. Subsequently the cells 
were plated into 4x 100mm petri dishes and incubated at 37°C, 5% CO2 in 
humidified incubator in complete medium overnight. Next day, the medium 
was replaced with complete medium with suitable selective markers. The cells 
were kept under selective pressure by changing the selective media every 2 
days until the cells approach confluence and become ready for sorting using 
the fluorescence activated cell sorting (FACS) technique. 
 
2.2.4.2 Transfection by a chemical-based method: 
          RBL-2H3 cells were seeded in 6 well plates at a density of 2x105 
cell/well with complete medium (4 ml/well) for 24 hours at 37°C, 5% CO2 in 
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humidified incubator. A mixture of 400 µl/well plain DMEM, 4 µg/well 
plasmid DNA and 6 µl of Turbofect reagent (Thermo Scientific) was prepared, 
vortexed immediately and incubated for 15-20 minutes at room temperature. 
The mixture was then added to the wells drop wise when the cells were 70-
80% confluent and incubated overnight at 37°C, 5% CO2 in humidified 
incubator. Next day, the medium was changed with selective one that contains 
suitable antibiotic agent. The cells were kept under selection by changing the 
selective medium every 2 days until become confluent and ready for sorting 
by FACS method. 
 
2.2.5 Sorting RBL-2H3 cells after transfection:  
       The transfected RBL cells from two T75 confluent flasks were harvested 
using cell dissociation solution into two tubes and centrifuged at 400g and 
4°C for 5 minutes. The cells were then re-suspended in 10 ml HBSS with 
divalent (Ca2+and Mg2+) and re-centrifuged again as before. Then, primary 
antibodies (mouse anti-human C5a1 antibodies) was added to one tube and 
isotype (mouse IgG1) antibody control to the other (both were sterilized by 
filters and at concentration of 10 µg/ml) and incubated for 1 hour on ice. After 
incubation, the cells were washed with 10 ml HBSS with divalent and 
centrifuged as above. The cells were re-suspended in 1/400 diluted secondary 
antibodies (sterilized by filter) and incubated for further hour on ice in dark. 
Subsequently, the cells were washed with 10 ml HBSS with divalent cation 
and centrifuged. After re-suspension in 1ml cold medium the cells were 
transferred to the flow cytometer. The cells were sorted by the FACS-Aria 
machine. The cells then were re-plated in new dishes with fresh selective 
medium.  





2.2.6 Antibiotic sensitivity test for mammalian cells: 
        This test was used to determine the minimum dose of ZeocinTM antibiotic 
reagents can be used for selection of resistant mammalian cells. ZeocinTM 
antibiotic sensitivity test was done for RBL-2H3 cells wild type (Non-x) and 
RBL-2H3 expressing hC5a2-YFP plasmid. These cells were used because 
they will be transfected with Rluc8-hC5a1 plasmid that carries Zeocin 
resistance gene.  
 Zeocin is part of bleomycin/phleomycin family of antibiotics. To 
determine the minimum dose of Zeocin that can be used in mammalian cell 
selection, sensitivity test was done for cells that do not carry Zeocin-resistant 
gene. RBL-2H3 were seeded overnight in 24 well plate at 5*104 cell/well in 
complete medium. Next day, the medium was removed and replaced with 
selective medium that contains various concentrations of Zeocin (0, 50, 100, 
200, 400, 600, 800, and 1000 µg/ml) to respective well. The selective media 
was then changed every 2 days and cell survival is observed. The minimum 
concentration of Zeocin that is needed to kill the majority of the cells was 50 
µg/ml for RBL-2H3-Non-x cells and 100 µg/ml for the RBL-2H3-hC5a2-YFP 
(Figure 2.1).  
  























































 Figure 2.1: Zeocin antibiotic sensitivity test. RBL-2H3 cells wild type (Non-x) or RBL-2H3 
expressing hC5a2-YFP plasmid were grown overnight in 24 well plate at 5*104 cell/well. The 
cells were then treated with different concentration of Zeocin (0, 50, 100, 200, 400, 600, 800, 
and 1000 µg/ml) for 7days. The background was subtracted from images after converting the 
images to 8-bit grayscale using image J (FIJI) software (Schindelin et al., 2012) and then 









2.3.1 Receptor expression assay by flow cytometer: 
 Staining of the receptors with antibodies was used to confirm cell 
surface expression of the receptors. Therefore, primary anti-human C5a 
receptors antibodies were used to target the specified receptors and then 
fluorescently-tagged secondary antibodies were used to attach to the primary 
antibodies in order to be detected by the flow cytometer. First, the cells were 
harvested using cell dissociation solution and re-suspended in BBN at 1x105 
cells/well and plated into 96-well U-bottom plate. The cells were then 
centrifuged (200xg for 5 minutes at 4˚C) and washed with 150 µl/well BBN 
and centrifuged again as previously. The supernatant was discarded and 50 µl 
BBN, isotype [for anti-human C5a1: mouse IgG1 isotype (Abcam); for anti-
human C5a2: mouse IgG2a isotype (Biolegend)] or primary antibody [mouse 
anti-human C5a1(Santa Cruz biotechnology) or mouse anti-human C5a2 
(Biolegend)] was added to the wells. After incubation on ice for one hour, the 
cells were washed with BBN as above. Subsequently, secondary antibodies 
(Alexa fluor@633 rabbit anti-mouse IgG, Life Technology) were added and 
incubated for further hour on ice in dark. After spinning down, the cells were 
re-suspended in 300 µl BBN and transferred to flow cytometer. 
 
2.3.2 Ligand binding assay: 
 C5a labelled with Alexa 488, as described (Bell, 2017), was used to 
assess the ability of the transfected receptors to bind to their ligand. The 
binding was detected by measuring the fluorescence using flow cytometer. 
The cells were harvested using cell dissociation solution; plated (1x10 5 
cell/well) into 96 U-bottomed plate; and washed in the same way as mentioned 
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in section 2.3.1. Mixtures of 100 nM Alexa 488 C5a and serial dilutions (1 
µM, 300 nM, 100 nM, 30 nM, 10 nM, 1 nM, 0.1 nM and 0 nM) of unlabeled 
C5a were added to the cells at a volume of 50 µl per well and incubated for 
15 minutes on ice in a dark place. The cells were transferred to flow cytometer 
after adding 150 µl of BBN to each well. 
 
2.3.3 Intracellular Ca2+ mobilization assay: 
 This assay was done to assess the cellular response to C5a through C5a 
receptors.  After harvesting the cells with CDS, the cells re-suspended in 
HBSS (+0.1% BSA) at a count of 5 x 105 cell/ml. The cells washed once with 
HBSS (+0.1% BSA) and centrifuged at 400xg for 5 minutes at 4˚C. After re-
suspension in 10 ml HBSS (+0.1% BSA), 4 µl of 20% pluronic (Invitrogen) 
and 11 µl Fluo3-AM (Invitrogen) were added to the cells. The cell suspension 
was incubated for 30 minutes in dark on ice. The cells were then washed with 
HBSS (+1% BSA), centrifuged as above and re-suspended in HBSS (+1% 
BSA) at 5x105 cell/ml. Subsequently, 0.5 ml was transferred into flow 
cytometer tubes on ice. At the FACS Caliber flow cytometer, each sample was 
warmed for 2 minutes before starting the measurements. After loading the 
samples, the basal fluorescence was measured for 20 second and then after the 
addition of C5a (0.1, 0.5, 1, 5, 10 nM) for 2 minutes. The fluorescence rise 
was then calculated by subtracting the basal fluorescence from the peak 
fluorescence after C5a stimulation. 
  
2.3.4 RBL-2H3.1 β-hexosaminidase release assay: 
 Degranulation is a known function of mast cells during the innate 
immune respose. The degranulation process can be stimulated by at least two 
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types of receptors: 1) the IgE receptors and 2) the GPCR. Therefore, the 
degranulation assay can be used to examine one functional step in C5a 
receptors signalling. Mast cells and basophils release a range of mediators 
upon crosslinking of their IgE-bound FcεRI through several allergens. RBL-
2H3 cell line, which is derived from basophils, has been widely used to test 
degranulation for both IgE and GPCR receptors in allergy and inflammatory 
research. The RBL-2H3 granules contain many mediators such as histamine, 
serotonin and β-hexosaminidase enzyme. Beta-hexosaminidase enzyme is an 
exoglycosidase that is commonly used to monitor degranulation in RBL-2H3 
cells as it is released in parallel with histamine (Passante and Frankish, 2009). 
It can work at pH of about 4.5, which is typical condition during inflammation. 
The enzyme activity can be measured through the production of yellow colour 
p-nitrophenol from the colourless hexosaminidase substrate (p-nitrophenyl-
N-acetyl-β-D-glucosamide). The resultant colour can be quantified by 
measuring the absorbance at 405nm.   
 In this study, this method was performed to check a functional step in 
the downstream signalling pathway of C5a1 receptors, which is the secretion 
of intracellular mediators such as β-hexosaminidase in response to C5a 
stimulation. The RBL-2H3 cells, which are transfected with wild type or 
tagged hC5a receptor, were plated in a sterile flat bottom 96 well plate at 5x104 
cell per well and incubated overnight at 37ºC, 5% CO2 in humidified incubator. 
Next day, the cells were washed with 50 µl/well warm (37ºC) release buffer 
twice. Then, 40 µl/well release buffer was added to the cells and incubated for 
10 minutes at the same conditions above. Subsequently, 10 µl C5a (at a serial 
dilution of 1/3 in release buffer starting with 1 µM was added to the cells. 
Alternatively, 10 µl release buffer or 0.5% Triton-X100 were added as 
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negative and positive controls respectively. The plate was incubated for 15 
minutes at the same conditions as above. After incubation, 40 µl of the cells 
supernatant was removed and added to the 40 µl substrate solution (diluted 
1/25 with 0.2 M citrate buffer pH 4.5) in new flat-bottom 96 well plate and 
incubated for 2-3 hours at 37°C, 5% CO2 in humidified incubator. Then, the 
reaction was stopped by addition of 120 µl/well of 1 M Tris (pH 9.0). 
Consequently, the absorbance was measured at 405 nm using a plate reader. 
Release was calculated as a percentage of total cell associated enzyme activity 
as in the following equation: 
Enzyme release = [(supernatant of C5a treated cells – supernatant of buffer 
treated cells)/supernatant and lysate of Triton-X100 treated cells] x100 
 The degranulation assay was also performed to examine enzyme 
release in response to IgE binding. In this assay, the RBL cells were grown on 
flat bottom 96 well tissue culture treated plated at a density of 5x104 cell/well 
in 100 µl. The cells were then incubated at 37°C, 5% CO2 in humidified 
incubator for 2 hours to allow the cells to adhere to well bottom. After that, 
100 µL of DNP-A-specific IgE antibody solution (diluted 1/500) was added 
to the wells at final concentration of (1ng/ml) and incubated for 16 hours at 
37°C, 5% CO2 in humidified incubator. This incubation is to allow the IgE 
antibodies to bind to FcεRI receptors. After the incubation time, the cells were 
washed twice and incubated with 40 µl release buffer for 10 minutes at 37°C, 
5% CO2 in humidified incubator. Then, 10 µL of 5x DNP-A was added to the 
cells in 1/10 serial dilutions (starting with 1µg maximum final concentration) 
and incubated for 15 minutes at 37°C, 5% CO2 in humidified incubator to 
allow degranulation to occur. The other steps of detecting the release of β-
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hexosaminidase enzyme are the same as in C5a-mediated degranulation 
mentioned above. 
 
2.3.5 Internalization assay: 
 This test was used to measure the percentage of surface receptors 
internalized in response to various treatments. RBL-2H3 cells expressing 
either hC5a1, hC5a2, hC5a1+hC5a2, hC5a1-CFP, or hC5a1-Rluc8 surface 
receptors were used. The cells were detached using non-enzymatic cell 
dissociation solution and resuspended at 2 x106 cell/ml. The cells were then 
incubated with appropriate dilutions of anti-hC5a1 or anti-hC5a2 antibodies 
on ice for 30 minutes. The effect of pre-treatment of the cells with antibodies 
was checked and did not appear to affect the ligand-induced internalization as 
illustrated in chapter 6. Subsequently, the cells were washed with ice-cold 
internalization buffer (HBSS + 0.2% BSA). After that, different treatments 
500 nM C5a, 500 nM C5adesArg, selective C5a2 receptor ligand (100 µM 
peptide RHYPYWR) or control buffer were added to the cells and incubated 
part on ice (0°C) and part at 37°C, 5% CO2 in humidified incubator. The cells 
were removed from the incubator at appropriate time points (5, 15, 30, 45, or 
120 minutes) and quenched with ice-cold buffer on ice. Subsequently, the 
cells were then washed with ice cold buffer and incubated with Alex633 
secondary antibodies for 30 minutes on ice in dark. After washing with ice-
cold buffer, the fluorescence intensity was measured using flow cytometer. 
The percentage of internalization was measured as [(MFI of cells incubated 
on 0°C - MFI of cells incubated at 37°C)/ MFI of cells incubated on 0°C] x 
100.  
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 Internalization assay was also used to measure the behaviour of both 
C5a receptors internalization in the presence of C5a1 receptor inhibitor 
PMX53 (gift from Associate Professor Trent Woodruff, University of 
Queensland, Australia), which has no discernible activity on C5a2 receptor 
(Scola et al., 2007, Klos et al., 2013). This assay may indicate whether C5a2 
receptor is working in dimer with C5a1 or not. Therefore, RBL-2H3 cells co-
expressing hC5a1 and hC5a2 receptors were treated with 1µM PMX53 for 10 
minutes before adding 500 nM C5a or C5a desArg ligands and incubating the 
cells for another 45 minutes. The cell surface receptors were stained and 
quantified by indirect immunostaining and flow cytometer as above.  
   
2.3.6 Fluorescence resonance energy transfer (FRET) measurements: 
 The dimerization between hC5a1 and hC5a2 receptors was explored in 
different methods, which are confocal microscopy and spectrofluorimetry as 
described below. In all methods RBL cells expressing C5a receptors tagged 
to fluorescent proteins CFP or YFP were used. These fluorescent proteins 
share a significant spectral overlap, which makes them suitable for such 
experiment. In the ideal situation, excitation of CFP by an external source 
leads to emission of wavelength that is suitable for YFP excitation. 
Consequently, YFP emission can be detected, which is called “FRET” 
emission, when the two fluorophores are in close proximity (Figure 2.2). 
However, many factors, such as crosstalk, limit this process and make 
detecting “FRET” a challenging procedure.  
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2.3.6.1 FRET measurement using confocal fluorescent microscopy: 
 Confocal microscopy has several advantages over the conventional 
wide-field fluorescent microscopy. The key element is that it can measure 
light emission from a very small spot in a focal plane and image can be built 
up by scanning across the sample. In addition, the out of focus light from 
above and below the focal plane can be blocked. This results in measuring a 
very shallow section and several sections can be obtained for thick samples.  
  
 
Figure 2.2 Fluorescence resonance energy transfer (FRET) illustration. The figure 
demonstrates the principle of FRET between CFP and YFP fluorophores. The two 
fluorophores are attached to two homologous or heterologous proteins. If the two 
proteins are not interacting, the CFP and YFP will be too far away for FRET to occur (left 
panel) and only CFP emission (~480 nm) can be detected. When the two proteins 
approach each other to a distance <100Å, FRET occurs and YFP (~530 nm) emission can 
be detected (right panel). 
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In this experiment RBL cells co-expressing hC5a1-CFP and hC5a2-
YFP were used. Cells expressing only one of the fluorophores (either CFP or 
YFP) were also used for correction of the bleed-through between different 
wavelengths. RBL cells expressing CFP physically linked to YFP were used 
as a positive FRET control (pECFP-YFP). Cells were seeded in 8 chamber 
Labtech slides at a density of 10 x 104 cell/chamber overnight. Next day, the 
cells were treated with 500 nM C5a or control buffer and incubated for 10 or 
20 minutes at 37°C, 5% CO2 in humidified incubator. The cells were then 
washed twice with PBS and fixed using 2% paraformaldehyde for 15 minutes. 
The chambers were then washed with PBS twice and the plastic chamber was 
removed as per manufacturer’s instructions. Mounting medium for 
fluorescence with DAPI was added to each well, covered with a cover slip and 
sealed with nail varnish. The slides stored at 4°C until visualised by Nikon A1 
fluorescence confocal microscopy using 60x oil immersion objective.  
 The CFP (FRET donor) was excited using laser with a wavelength of 
457 nm and the emission was detected at 482 nm. The YFP (FRET acceptor) 
was detected using the 540 nm detector. The normal YFP emission was 
detected at 540 nm after excitation by the 514 nm laser.  
 The images obtained from the confocal microscopy were in nd2 format. 
These images can be opened using image J (Fiji) (Schindelin et al., 2012) or 
by NIS-Element viewer software. For FRET measurement, an Image J plugin 
was used, which is “FRET and colocalization analyser” (Hachet-Haas et al., 
2006, Schindelin et al., 2015, Schneider et al., 2012). This software can 
calculate FRET index pixel by pixel. The plugin corrects the donor and 
acceptor bleed-through and subtracts it from the raw FRET channel image. It 
requires images taken from cells expressing the donor and acceptor 
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individually. It can show only the pixels that correspond to co-localization and 
produce a “colocalized FRET index” image. 
 
2.3.6.2 FRET measurement using spectrofluorimetric method: 
 Spectrofluorimetry is a useful method to examine the spectrum of 
fluorescent proteins. It is known that CFP has emission spectrum that peaks 
around 476 nm and YFP at around 529 nm (Dye, 2005). Therefore, in cells 
expressing either CFP or YFP, the fluorescence spectrum should be 
corresponding to the fluorophore present inside the cells if it is excited with 
its appropriate wavelength. However, in the cells co-expressing CFP and YFP, 
the detection of YFP emission spectrum upon CFP excitation may indicate 
FRET happening between CFP and YFP. Therefore, the spectrofluorimetric 
method was used to detect possible FRET between CFP and YFP in cells co-
expressing hC5a1 tagged with CFP and hC5a2 tagged with YFP by measuring 
the emission spectrum of the resulting fluorescence. 
 RBL-2H3 expressing either hC5a1 (mock), hC5a1-CFP, hC5a2-YFP, 
hC5a1-CFP+hC5a2-YFP or hC5a1-CFP+hC5a1-YFP were used in this 
experiment.  Control cells expressing CFP directly linked with YFP were also 
used. Cells from nearly confluent 100 mm culture petri dishes were detached 
using non-enzymatic cell dissociation solution and re-suspended in 1 ml 
HBSS. The cells were washed twice with HBSS and distributed into 96 well 
black plates at a volume of 200 µl/well. The cells stimulated with either 500 
nM C5a final concentration or buffer control for 20 minutes. The fluorescence 
spectrum was measured using a spectrofluorimeter (Varioskan, 
Thermoscientific). The emission spectrum of cells expressing untagged 
receptors was subtracted from the fluorescence spectrum of cells expressing 
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fluorescent tagged receptors. This was done to eliminate nonspecific 
fluorescence and light scattering of the cells. In order to do this, the cells were 
excited by 430 nm wavelength and the emission intensity measured at 450 nm. 
This emission wavelength was used considering that the CFP and YFP 
emission is negligible at this wavelength and only the emission of light 
scattering is detected at such a wave length. The correction factor of the 
background fluorescence F(BG) was then calculated by dividing the emission 
at 450 nm of untagged receptors (mock) containing cells by the FP-tagged 
receptors containing cells (I). 
(I) F(BG)=mock cells/FP-cells 
  After that, the spectrum of mock transfected cells was divided by the 
correction factor F(BG) and then subtracted from the spectra of cells 
expressing FP-tagged receptors. A second normalization step was applied to 
the cells co-expressing CFP and YFP fusion proteins to normalise their CFP 
and YFP expression. To do so, correction factors F(CFP) and F(YFP) were 
calculated. The F(CFP) was measured by dividing the CFP emission of cells 
expressing CFP alone by the CFP of cells expressing both CFP and YFP 
proteins (II). The F(YFP) was calculated by measuring the ratio between YFP 
of cells expressing YFP alone and the cells expressing both CFP and YFP (III). 
Then, the fluorescence spectra of cells expressing either CFP or YFP was 
divided by the corresponding correction factor (IV) and (V).  
(II) F(CFP)= CFP of CFP alone cells/CFP of CFP&YFP cells 
(III) F(YFP)= YFP of YFP alone cells/YFP of CFP&YFP cells 
(IV) Normalised CFP (NCFP)=CFP spectrum of CFP alone cells/F(CFP) 
(V) Normalised YFP (NYFP)=YFP spectrum of YFP alone cells/F(YFP) 
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 After these normalization steps, the FRET was calculated by 
subtracting normalised CFP and YFP spectra from the spectra of cells co-
expressing CFP and YFP after excitation at 430 nm (VI). The resulting 
spectrum from the cells expressing both donor and acceptor can be considered 
as exclusively FRET spectrum. FRET ratio was then calculated using the ratio 
of YFP(FRET) to YFP emission spectrum between 520 nm and 530 nm (VII). 
(VI) FRET curve= spectrum of CFP&YFP cells-NCFP-NYFP 
(VII) FRET ratio=YFP(FRET)/YFP 
 
2.3.7 Bioluminescence resonance energy transfer (BRET) assay: 
 BRET is a naturally occurring phenomenon between a luminescent 
donor and a fluorescent acceptor. The energy is nonradiatively transferred 
from the donor to the acceptor. The luminescence from the sea pansy Renilla 
reniformis occurrs due to the catalytic degradation of the substrate 
coelenterazine by the enzyme luciferase. 
Coelentrazine + O2        
Luciferase            Coelentramide + CO2+ light 
 The emitted light energy is transferred to green fluorescent protein or 
its derivatives (such as YFP) when the two proteins dimerize (Figure 2.3).  
 




Figure 2.3: Bioluminscence resonance energy transfer (BRET). Two proteins are linked to 
either Renella luciferase (Rluc) or YFP. When the two proteins are far from each other, 
BRET does not occur and only Rluc emission (~480 nm) can be detected (left panel). When 
the two proteins are interacting, and are in close proximity (<100Å), BRET can occur and 
both Rluc and YFP emission (~530) can be detected. 
This method, like FRET, needs strict proximity between the donor and 
acceptor in order for the BRET phenomenon to occur. It was first applied by 
Xu et al.to monitor protein-protein interactions in intact cells (Xu et al., 1999). 
In this BRET approach, the red-shifted GFP (YFP) was used as acceptor for 
the luminescence emission of Renilla luciferase (Rluc) to measure the 
cyanobacteria clock protein KaiB homodimerization in Escherichia coli.  
 In the current study, C5a heterodimerization was assessed using hC5a1 
tagged with Renilla luciferase 8 (Rluc8), which is an improved version of Rluc 
enzyme as a donor. In addition, hC5a2-YFP fusion protein was used as BRET 
acceptor. RBL cells expressing either Rluc8-hC5a1 alone or both Rluc8-
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hC5a1+hC5a2-YFP were used in this experiment. Cells were grown at 5x104 
cells/well overnight on 96 well white plates. Next day, the cells were washed 
twice with HBSS and treated with coelentrazine (5 µM final concentration) 
for 10 minutes at room temperature. The cells were then stimulated with 1 µM 
C5a and emission was measured at 480 nm and 525 nm at different time points 
by Varioskan plate reader (Thermoscientific). The ratio of emission signal 
detected at 525 nm versus emission at 480 nm was calculated for cells 
expressing donor only (Rluc8-hC5a1) or both donor and acceptor (Rluc8- 
hC5a1+hC5a2-YFP). Then the ratio of cells expressing only donor were 
subtracted from cells expressing both donor and acceptor to calculate the 
BRET ratio. 
 
2.3.8  Cell-based ERK1/2, JNK, p38 MAPK Phosphorylation assay: 
This assay was performed to test intracellular protein phosphorylation 
in response to the signal transmitted after ligand binding. Protein 
phosphorylation is an essential step in activation or regulation of signal 
transduction. Many cellular kinases or phosphatases have been explored to 
test their role in regulating protein functions. Among these proteins are the 
mitogen activated protein kinases (MAPK). Three main enzymes are involved 
in signal transduction after being phosphorylated. These are the ERK1/2, JNK, 
and p38 MAPK. Determining the specific protein phosphorylation suggests 
pathway activation in the experimental model system.  
 This assay is a cell-based assay ELISA assay and does not need the 
preparation of a cell lysate. The RBL cells that express C5a receptors were 
grown overnight in 96 well plates at 37°C. The cells were then washed with 
HBSS (with divalent cations and 0.1% BSA) twice. After that, the cells were 
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incubated with 500 nM C5a or C5a desArg for 0, 5, 10 or 15 minutes at 37˚C. 
Subsequently, the ERK1/2 (Thr202/Tyr204), JNK (Thr183/Tyr185) and p38 
MAPK (Thr180/Tyr182) phosphorylation assay was performed as per 
manufacturer instructions. Briefly, the cells were fixed after the treatment 
with C5a/C5a desArg. Then, after blocking, primary anti-phospho-specific 
protein or anti-pan protein were added. After washing, HRP-conjugated 
secondary antibody was added. Consequently, TMB enzyme substrate was 
added, which results in production of colour that can be measured at 450 nm.  
 
2.4 Molecular biology methods: 
2.4.1 Bacterial transformation: 
 This method aims to transform an artificially-competent bacterium with 
plasmid DNA. M15 [pREP4] E. coli (0.25 ml) were thawed on ice for 30 
minutes. Then 1 µl of plasmid (about 1 µg) was added to the cells and gently 
mixed. The mixture was then incubated on ice for 30 minutes. The bacteria 
were heat shocked using water bath at 42ºC for 30 seconds then immediately 
returned back to the ice for 2 minutes. Subsequently, LB recovery medium 
(250 µl) was added to the cells and mixed carefully. The cells were then 
incubated in a shaking incubator for one hour at 37ºC. After that, the bacteria 
were plated on agar media containing antibiotics (kanamycin 25 mg/ml and 
carbenicillin 50 mg/ml) and incubated overnight at 37ºC. Next day, a single 
colony was transferred into 10 ml LB medium containing the same antibiotic 
concentrations as above and incubated for 16 hours at 37ºC inside a shaking 
incubator. Next day, 1 ml of this cell culture was transferred into 100 ml 
antibiotic containing LB medium (same antibiotics as above) and incubated 
overnight at 37ºC. The cell culture was checked next day and glycerol stock 
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was generated (see section 2.4.2) and plasmid purification using Midiprep kits 
(Qiagen) were performed per manufacturer’s instructions. 
  
2.4.2 Glycerol stocks: 
 This procedure was done for long-term storage of the transformed 
bacteria. A mixture of 500 µl of 50% glycerol and 500 µl of overnight culture 
(from 2.4.1) was prepared and then frozen at -80 ˚C.  
 
2.4.3 Designing hC5a1 receptor tagged with luciferase enzyme Rluc8: 
 The construct of C5a receptor linked with luminescence donor (Rluc8) 
was needed to measure C5a receptors dimerization using the BRET technique 
mentioned above (2.3.7). To generate such a fusion protein, the human C5a1 
receptor coding region (http://www.cdna.org/files/data/C5R0100000seq.pdf) 
was cloned in frame with Renilla luciferase 8 (Rluc8)  
(http://www.ncbi.nlm.nih.gov/nuccore/127951035). Rluc8 is a new version of 
the original Renilla luciferase (Rluc) with eight mutations from the Rluc. 
These mutations result in higher stability and quantum yield (Loening et al., 
2006). 
  The two genes were linked with a PVAT (proline, valine, alanine and 
threonine) linker sequence. The DNA sequence was synthesized by 
InvitrogenTM Life Technology and inserted into pcDNA3.1/Zeo (+) vector. 
This vector carries a Zeocin antibiotic resistant gene for mammalian cells 
transfection (Figure 2.4). The plasmid was received lyophilised and handled 
as per manufacturer instructions.  
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 The structure of the fusion protein was predicted using online software 
RaptorX (Kallberg et al., 2012) (Figure 2.5).  
 
 
Figure 2.4: The structure of C5aR1-Rluc8-Zeo plasmid. The C5aR1-Rluc8 gene was inserted 
in pcDNA3.1/Zeo vector. The insert is under the CMV promotor. The plasmid encodes for 
bacterial antibiotic resistance for ampicillin (AMP) and mammalian antibiotic resistance 








Figure 2.5: Predicted Rluc8-hC5a1 fusion protein structure. The construct structure was 
predicted using online software RaptorX (Kallberg et al., 2012) and shown in secondary 
structure (red, helix; yellow, sheets; TM, transmembrane). 
 
2.5 Statistical Analysis: 
 Statistical analysis and curve fitting were computer assisted using 
GraphPad Prism 6 for windows. Data are presented as mean±SEM (standard 
error of the mean). Unpaired t test, one-way ANOVA or two-way ANOVA 
were used as indicated in the graphs. P value less than the 0.05 level of 
significance was considered statistically significant and marked as stars: *, p 
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3 Chapter 3: Characterization of fluorescent protein-tagged 
receptors 
3.1 Introduction: 
Protein-protein interactions can be measured in several different ways. 
One of these methods is fluorescence resonance energy transfer (FRET). In 
order to study the interaction between the C5a1 and C5a2 receptors using this 
method, human C5a receptors tagged with fluorescent proteins (FP) such as 
cyan fluorescent protein (CFP) and yellow fluorescent proteins (YFP) were 
used. The following transfected cell lines were available: RBL2H3-hC5a1-
CFP; RBL2H3-hC5a2-YFP; RBL2H3-hC5a1-CFP+hC5a1-YFP; and 
RBL2H3-hC5a1-CFP+hC5a2-YFP.  
 Before starting studying the FRET between these FP-receptors, it was 
necessary to characterize these cell lines. First, confirming the expression of 
the receptors. Then, testing the tagged-receptor ligand binding capability. 
Other cellular functions were also explored to examine the potential effects of 
FP tagging on receptor functions. It was also necessary to develop a control 
cell line that co-expressed hC5a1 receptors and fluorescent proteins such as 
YFP separately. Therefore, pcDNA3-YFP plasmid was used to transform 
competent bacteria (E. coli) and then the plasmid was purified and transfected 
into RBL-2H3-hC5a1 by electroporation. Subsequently, the newly transfected 
cell line (hC5a1/YFP) was sorted and the expression of the receptor and YFP 
was examined by flow cytometer. Then the effect of presence of fluorescent 
proteins on receptors function was explored. 
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3.2 Detection of receptor expression by flow cytometry: 
In order to confirm the presence of hC5a1 and hC5a2 receptors expressed 
on the surface of RBL-2H3 cells transfected with FP-tagged hC5a1 or 2 receptors, 
anti-hC5a1 and anti-hC5a2 antibodies were used as described in section 2.3.1.    
Alexa Fluor@633 antibodies were used as a secondary antibody because the 
higher emission wavelength does not overlap with the emission of either 
fluorescent protein (CFP or YFP). A flow cytometer was used to detect the Alexa 
633 secondary antibodies (Figure 3.1 and 3.2).  The graphs show the expression 
of hC5a1 or hC5a2 receptors in cells expressing different fusion constructs of 




Figure 3.1: Expression of human C5a1 receptor on RBL-2H3 cells by flow cytometry. A. Dot 
plots show RBL cells expressing either hC5a1, hC5a1-CFP or hC5a1-CFP+hC5a2-YFP treated 
with antihuman C5a1 antibodies, isotype or buffer control. B. Bar chart for hC5a1 receptor 
expression shows the percentage of positive cells. a, buffer control. b, isotype control. c, 
anti-hC5a1 antibodies. 





             B. 
 
Figure 3.2: Expression of human C5a2 receptor on RBL-2H3 cells by flow cytometry. A. Dot 
plots show RBL cells expressing either hC5a2-YFP or hC5a1-CFP+hC5a2-YFP treated with 
antihuman C5a2 antibodies, isotype or buffer control. B. Bar chart for hC5a2 receptor 
expression shows the percentage of positive cells. t test was used to test statistical 
significance. *, p ≤0.05 and ***, p ≤0.001. a, buffer control. b, isotype control. c, Anti-hC5a2 
antibodies. 
 
3.3 C5a binding assay: 
The ligand binding assay was performed as described in section 2.3.2 to 
compare the capability of the CFP-tagged hC5a1 receptor and the wild type 
hC5a1 receptor to bind to C5a. Figure 3.3 shows that there is no significant 
difference between the hC5a1-CFP and the wild type receptor in the binding to 
ligand. 










Figure 3.3 C5a binding assay for hC5a1-CFP in RBL-2H3 cell line determined by competitive 
488-hC5a binding study. a. Dose response (inhibitory) curve of serial dilutions (starting with 1 
µM) of unlabelled hC5a with 100 nM of Alexa488 labelled hC5a. b. Bar chart to compare IC50 
of hC5a-CFP with the control. Unpaired t test is used to test statistical significance. ns, non-
significant 
 
3.4 Intracellular Ca2+ mobilization assay: 
One of the steps in some G protein-coupled receptor signalling is the 
mobilization of Ca2+ and it was used to test the effect of the FP tagging to the C5a 
receptors on their signalling at this level. As mentioned in chapter 2.3.3, Ca2+ 
mobilization was measured after adding C5a at 10, 5, 1, 0.5, 0.1 nM final 
concentration. The dose response curve is shown in Figure 3.4. There was a 
significant difference in EC50 between the CFP tagged C5a1 receptors and the 
wild type. 
 




               Intracellular Ca2+ mobilization assay 
   
              
b.       
                        
Figure 3.4: Intracellular Ca2+ mobilization assay for RBL-2H3 hC5a1-CFP cells.  The graph shows 
the increase in Ca2+ after adding C5a to both hC5a1-CFP cells and the wild type receptor cells. 
C5a was added after 20s to allow recording of the baseline fluorescence. The Ca2+ mobilization 
was measured after addition of agonists. a. Dose response curve for the increase in Ca2+ in 
response to various dilutions of C5a. b. Bar chart for the log EC50 for the Ca2+ response. 
Unpaired t test is used to test statistical significance. *, p ≤0.05. 
 
3.5 β-hexosaminidase release assay: 
3.5.1 C5a induced release assay for RBL-2H3 transfected with 
fluorescently tagged hC5a1 receptors:  
This assay was used as a functional output of activation of the C5a 
receptors in response to stimulation by C5a. The assay is described in section 
2.3.4 and different FP-tagged hC5a receptors were used and compared to the 
hC5a1 control. The maximum responses measured in the presence of hC5a1-CFP 
(16.22±6.23), hC5a1-YFP (31.73±6.95), hC5a1-CFP+hC5a1-YFP (18.14±4.61), 
and hC5a1/YFP (2.11±0.21) receptors, were all significantly lower than enzyme 
release in the presence of the wild type receptor (68.59± 3.94) (Figure 3.5). 
 







Figure 3.5:  C5a-induced enzyme assay for fluorescent tagged/untagged hC5a1 receptors on 
RBL-2H3 cell line. a. Dose response curve for hC5a1, hC5a1-CFP, hC5a1-YFP, hC5a1-CFP+ 
hC5a2-YFP, and hC5a1/YFP receptors. Beta-hexosaminidase release was measured in response 
to 1/3 serial dilutions of hC5a starting with 1 µM. b. Bar chart for the maximum β-
hexosaminidase release. One-way ANOVA is used to test statistical significance. *, p ≤0.05 and 
****, p ≤0.0001.  
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3.5.2 IgE-mediated enzyme release assay for RBL-2H3 cells transfected 
with YFP: 
The previous experiments showed the effect of FP on C5a receptor 
mediated hexosaminidase release. In order to explore the effect of FP on cell 
function mediated by other pathways, the RBL-2H3 cells expressing YFP were 
tested for enzyme release by IgE pathway. The cells were incubated with DNP-
A-specific IgE overnight and then stimulated with DNP-A. The hexosaminidase 
enzyme was then measured in the supernatant as described in section 2.3.4. Figure 
3.6 shows the effect of fluorescent protein expression (YFP) on the RBL cell 






Figure 3.6. IgE-mediated enzyme release assay for RBL-2H3 hC5a1 cell line co-expressing YFP 
separately. a. Dose response curve for RBL cells with or without expression of YFP. Beta-
hexosaminidase release was measured in response to 1/10 serial dilutions of DNP. b. Bar chart 
for maximum enzyme release. Unpaired t test was used to test statistical significance. **, p ≤
0.01. 
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3.6 The effect of protein tagging on internalization: 
The C-terminus of C5a receptor was reported to be involved in receptor 
internalization (Bock et al., 1997). Therefore, the C-terminus tagged receptors 
were tested for their internalization capability. Figure 3.7 shows that the tagged 
receptor endocytosis was less than that of the untagged wild type receptor.  
 
The effect of CFP tag on C5a1 receptor internalization 




Figure 3.7: C5a-induced internalization of fluorescent protein tagged receptors. RBL-2H3 cells 
expressing CFP tagged hC5a1 receptors were compared with cells expressing untagged hC5a1 
receptors. Cells were stimulated with C5a for 15 and 30 minutes. Two-way ANOVA followed 
by Dunnett’s multiple comparison are used to test statistical significance. *, p ≤0.05. 
 
The internalization of C5a1 receptor was then further analysed in cells co-
expressing untagged C5a receptor and YFP separately. The expression of the 
fluorescent protein appeared to have no effect to the receptor when expressed 
separately (Figure 3.8). 
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The effect of separate expression of FP on human C5a1 internalization 
in RBL cells 
 
Figure 3.8 C5a-induced internalization for hC5a1 receptors when co-expressed with FP 
separately. RBL-2H3 cells co-expressing YFP and wild type hC5a1 receptors were compared 
with cells expressing only the wild type hC5a1 receptors. Cells were stimulated with C5a for 
30 minutes.     
 
3.7 Discussion: 
Fluorescent proteins (FPs) are one of the most commonly used reporter 
molecules for observing gene expression, localization  of proteins as well as 
monitoring protein-protein interactions in various cells and organisms such as 
bacteria, yeast, fish and mammals (Tsien, 1998). The first fluorescent protein to 
be used was the green fluorescent protein, which was discovered by Shimomura 
et al.(Shimomura et al., 1962), and its gene was cloned by Prasher et al. (Prasher 
et al., 1992). Since then, many other fluorescent proteins have been developed to 
satisfy the evolving need for new tools for biological imaging (Zhang et al., 1996a, 
Cormack et al., 1996, Shaner et al., 2005, Chudakov et al., 2010). Mutation of the 
wild type GFP resulted in different colour emitting mutants such as cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP). In this part of 
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the study, the CFP and YFP tags were used to study the effects fluorescent tagging 
of the C5a receptor on receptor function. 
 Generally, CFP and YFP have been extensively used to examine protein-
protein interactions (Chan et al., 2000, Chan et al., 2001, He et al., 2003, Onuki 
et al., 2002, Croker et al., 2013, Luo et al., 2001, Ting et al., 2001), considered as 
innocuous to the cells both in vivo and in vitro. In fact, GFP was believed to be 
nontoxic even to transgenic mice that globally express GFP (Okabe et al., 1997). 
However, it has been reported that these FPs and in particular GFP has various 
side effects (Liu et al., 1999, Agbulut et al., 2007, Baens et al., 2006, Zhang and 
Crandall, 2007, Dave et al., 2016, Sokolovski et al., 2015, Swulius and Jensen, 
2012, Landgraf et al., 2012, Agbulut et al., 2006, Huang et al., 2000). It has been 
demonstrated that apoptosis can be induced by GFP although the exact 
mechanism is still unclear (Liu et al., 1999). In rat adult hepatic stem cells, it was 
difficult to establish a stable cell line that expressed EGFP (Taghizadeh and 
Sherley, 2008). In addition, other studies reported an increase in COX-2 
expression followed by PGE2 production in endothelial cells due to the 
introduction of GFP (Zhang et al., 2003). Furthermore, dilated cardiomyopathy 
was described in transgenic mice (Huang et al., 2000),  which was thought to be 
due to the impairment of actin-myosin interaction in the presence of GFP 
(Agbulut et al., 2006). There is also concern regarding the natural tendency of the 
wild type FPs to oligomerize. This is a problem if the protein of interest occurs 
in a dimeric or oligomeric state because this will result in aberrant aggregations. 
This problem has been addressed by introducing mutations to produce FP 
monomers (Shaner et al., 2004). Baens et al. demonstrated that polyubiquitination 
can be inhibited by EGFP and EGFP fusion proteins (Baens et al., 2006). 
Ubiquitination, an important post-translational modification for proteins in which 
ubiquitin is attached to the protein, affects many cellular responses such as kinase 
signalling, protein degradation, protein interaction or change cellular location of 
Chapter three  Results 
80 
 
proteins. Those studies support the finding of this study regarding the defective 
signal transduction in cells expressing FP in comparison to the cells that do not 
express FP as shown in the Ca2+ and degranulation assays. Therefore, the use of 
fluorescent proteins should be carefully considered in experiments that involve 
cellular signalling and protein functions.  
 The CFP and YFP were attached to the C-terminus of the receptors. This 
attachment may affect the binding of various intracellular signalling molecules 
such as the G proteins or β-arrestins or may disturb the phosphorylation of the 
receptors.  The C-terminus also contains the major receptor phosphorylation sites 
(Giannini et al., 1995). It has been shown that mutations of some of the residues 
in the C-terminus reduced phosphorylation by 80% (Giannini et al., 1995) in 
addition to the inhibition of internalization of the receptor (Naik et al., 1997). This 
might support the result of the current study that shows that less internalisation 
occurred in the tagged receptors in comparison to the wild type. In addition, the 
disturbance in the interaction with some intracellular partners such as β-arrestin, 
dynamin and clathrin may be the reason behind the inhibition of the 
internalization. It has been suggested that in phosphorylation deficient C5a1 
receptors, β-arrestin 1 and 2 still can associate with the receptors albeit more 
weakly in comparison to the wild type (Braun et al., 2003).  
 It has been reported that GPCR can activate MAP kinase via β-arrestin 
independently from G proteins (Rosenbaum et al., 2009). In fact, the G protein 
signalling pathway may be inhibited by the β-arrestins while transducing 
downstream signalling. This multifunctional behaviour of β-arrestin may be due 
to conformational changes in its structure and post-translational modification, 
(Shenoy and Lefkowitz, 2011) which could be affected by defective 
ubiquitination as a consequence of the presence of FPs (as mentioned previously). 
In C3a receptors, it has been demonstrated that β-arrestin have different functions. 
In human mast cells, the silencing of β-arrestin 2 led to the prevention of 
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internalization  and desensitization, which resulted in prolonged increase in Ca2+ 
(Vibhuti et al., 2011) but no effect on degranulation. However, degranulation can 
be inhibited by silencing β-arrestin 1. In addition, it was demonstrated that 
arrestin is necessary for CXCR1-mediated degranulation (reviewed in Vines and 
Prossnitz, 2004). Therefore, in this study, it could be speculated that the FPs could 
have an effect on the receptors directly when attached to the C-terminus of the 
C5a receptors, or indirectly, when FP is expressed separately, that may have 
affected the interaction with β-arrestins or G proteins and resulted in the observed 
defect in degranulation. 
 The rise in intracellular Ca2+ is known to induce exocytosis (reviewed in 
Passante and Frankish, 2009). In this study, the tagging effected the intracellular 
Ca2+ mobilization, which could be the cause for the defect in the enzyme release. 
 The GPCR was thought to exert their function exclusively from the cell 
membrane. However, a growing body of evidence suggests that many receptors 
can continue their signalling process in the endocytic compartment (reviewed in 
Calebiro et al., 2010). For example, expression of dynamin dominant negative 
mutant with β2-adrenergic receptors resulted in inhibition of activation of ERK 
pathway (Daaka et al., 1998). Furthermore, it has been suggested that signalling 
from internalized receptors is distinct quantitatively and qualitatively from the 
signalling from the plasma membrane. In thyroid stimulating hormone receptors, 
the signalling at the cell surface was reported to be rapidly reversible, while the 
signalling from the internalized receptor continues after removal of the ligand  
(Calebiro et al., 2009, Calebiro et al., 2010). In the current study, the tagged 
receptors showed lower internalization rate. This could partly explain the 
defective signalling, which might suggest signalling possibility during 
internalization of C5a1 that was decreased by decrease in internalization.  
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 In the current study, the presence of the FP tag does not seem to affect 
receptor expression. This was also reported in other studies (Zhang and Crandall, 
2007), which showed that although the GFP linking to CD36 affected ligand 
binding, the CD36 expression was normal. Therefore, the FP tagged receptors 
can still be used to assess the di/oligomerization of the C5a receptors despite the 
possible limitation due to the presence of FP tag and its potential effect on 
receptor signalling. This is because receptor signalling and interaction with other 
intracellular partners are not required for the formation of receptors dimers or 
oligomers (Floyd et al., 2003, Klco et al., 2003, Rabiet et al., 2008). Floyd et al, 
(2003) demonstrated the C5a receptor di/oligomerization in the lower eukaryote 
Saccharomyces cerevisiae and this di/oligomerization occurred without the need 
for ligand, G proteins or other mammalian accessory proteins (Floyd et al., 2003). 
In addition, Rabiet et al. (2008) showed that both ligand binding deficient and 
phosphorylation deficient C5a1 receptor mutants can form dimers (Rabiet et al., 
2008). Furthermore, it has been reported that C5a receptor di/oligomerization is 
an early event that occurs at their biosynthesis at the level of endoplasmic 
reticulum and the receptors are expressed as di/oligomers (Floyd et al., 2003). 
Therefore, when the receptors are expressed, they are expressed in their final form 
whether in dimer or oligomers and signalling could not be necessary or 
responsible for the dimerization or oligomerization (reviewed in Milligan, 2010, 
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4 Chapter 4: Fluorescence resonance energy transfer (FRET) 
study for receptor dimerization 
4.1 Introduction 
 FRET is one of the techniques that can be used to measure protein-protein 
interaction. This technique requires several conditions to be met before this 
energy transfer can happen such as spectral overlap, proximity and suitable 
orientation between the donor and acceptor.   
  In this chapter, C5a1 receptors tagged with CFP and C5a2 tagged with YFP 
were used to study possible receptors dimerization using FRET. First, spectra of 
the donor (CFP) and acceptor (YFP) fluorophores were tested and the localization 
of the CFP or YFP tagged hC5a1 or hC5a2 receptors within the cells was explored 
by confocal microscopy. A plasmid encoding CFP directly linked to YFP 
(pECFP-YFP) was transfected into RBL cells in order to be used as a FRET 
positive control.  Then the possible FRET was examined using different methods, 
such as spectrofluorimetry and confocal microscopy. 
 
4.2 Emission spectra of chimeric fluorescent hC5a receptor: 
The cells that express CFP tagged hC5a1 receptors and YFP tagged hC5a2 
receptors were tested for the emission spectra of the fluorophores. The 
spectrofluorimeter was used to measure the emission of the CFP and YFP (Figure 
4.1). The CFP expressing cells were excited at 430 nm and the emission was 
scanned between 450 nm and 600 nm. The YFP emission was measured between 
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CFP and YFP emission spectra 
 
Figure 4.1: Fluorescence spectra of fluorescently tagged receptors. Cyan, spectrum from cells 
expressing hC5a1-CFP after excitation by 430 nm; Yellow, spectrum from cells expressing 
hC5a2-YFP after excitation with 480 nm.  
4.3 Localization of hC5a1 and hC5a2 receptors within the cells: 
The localization of C5a receptors was determined using cells expressing 
different FP tagged receptors. RBL-2H3 expressing hC5a1-CFP, hC5a1-YFP, 
and hC5a2-YFP were used. The fluorescence was measured using confocal 
microscopy. Figure 4.2 demonstrates the expression of C5a1 receptors mainly on 





     b.  
 
c. 
Figure 4.2: Localization of YFP tagged C5a receptors. a. cells expressing hC5a1 tagged with 
YFP. b. cells expressing hC5a1 tagged with CFP. c. cells expressing hC5a2 tagged with YFP.  
Images were obtained using Nikon A1 confocal fluorescence microscope at 60x oil immersion 
objective. 
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4.4 FRET measurement using spectrofluorimetric technique: 
4.4.1 RBL-2H3 co-expressing hC5a1-CFP and hC5a2-YFP:  
The spectrofluorimetric method was used to measure the possible 
resonance energy transfer between CFP and YFP tagged receptors. Cells 
expressing untagged hC5a1, hC5a1-CFP, hC5a2-YFP, hC5a1-CFP+hC5a2-YFP, 
or linked CFP-YFP (pECFP-YFP) were used for this experiment. The cells were 
treated with 500 nM C5a or buffer control for 20 minutes. The emission spectra 
were measured upon excitation at 430 nm. The potential bleed-through and 
background artefacts were corrected as described in section  2.3.6.2. The resultant 
spectrum of pECFP-YFP expressing cells shows two peaks, the first one around 
475nm (CFP region) and the other around 530 nm (YFP region). The appearance 
of the second peak at the YFP region with the use of CFP excitation at 430 nm 
suggests that this YFP emission was induced emission because of FRET (Figure 
4.3a). However, cells co-expressing hC5a1-CFP and hC5a2-YFP did not show a 
peak emission at YFP spectrum peak region with or without C5a treatment 
(Figure 4.3b & c). This might suggest FRET has not occurred between the CFP 
and YFP because the two receptors are not close to each other. The data were 
further analysed to measure the FRET curves and FRET ratio (Figure 4.4). The 
FRET curves were calculated after subtracting the CFP (red) and YFP (green) 
spectra from the sensitized YFP emission spectrum (blue). The FRET curve of 
the pECFP-YFP positive control was higher than FP-tagged receptors co-
expressing cells (Figure 4.4a) and the FRET ratio was significantly different 
(Figure 4.4b).   
 






Figure 4.3: Spectral study of cells co-expressing hC5a1-CFP and hC5a2-YFP by spectrofluorimeter. 
RBL-2H3 expressing either pECFP-YFP linked plasmid (A); hC5a1-CFP+hC5a2-YFP with control 
treatment for 20 minutes (B); or hC5a1-CFP+hC5a2-YFP with 0.5 µM C5a treatment for 20 
minutes (C).  Blue, spectrum from cells co-expressing both hC5a1-CFP and hC5a2-YFP or linked 
pECFP-EYFP plasmid; RED, cells expressing hC5a1-CFP (Normalized as indicated in method 
chapter); Green, cells expressing hC5a1-YFP (Normalized as indicated in method chapter). 











Figure 4.4 Fluorescence resonance energy transfer measurements. (a) FRET curves of 
the RBL cells co-expressing hC5a1-CFP+hC5a2-YFP treated with C5a or control buffer 
were compared with FRET curve of cells expressing the FRET positive control pECFP-
YFP. (b) FRET ratio of cells co-expressing FP tagged receptors treated with C5a or control 
buffer in comparison to the pECFP-YFP positive control. The results are from 3 
independent experiments. One-way ANOVA was used to test statistical significance. ns, 
non-significant and ****, p ≤0.0001. 
Chapter four Results 
89 
 
4.4.2 RBL-2H3 co-expressing hC5a1-CFP and hC5a1-YFP:  
The FRET method was used to measure the possible homodimerization of 
C5a1 receptors. The same procedure was used as for the measurement of 
heterodimerization in the previous section, but with RBL cells co-expressing 
hC5a1-CFP and hC5a1-YFP. The fluorescence spectra were measured by 
spectrofluorimetry after treatment with 0.5 µM C5a or control buffer for 20 
minutes. The spectra were detected after excitation at 430 nm and corrected for 
bleed-through and background as in 2.3.6.2. The positive control cells that 
express linked CFP and YFP (pECFP-YFP) showed one peak for CFP (around 
475nm) and one peak for FRET (around 530 nm) (Figure 4.5 a).  The cells that 
co-express hC5a1-CFP and hC5a1-YFP demonstrated the same pattern (Figure 
4.5 b and c). The appearance of the peak at the YFP region after excitation with 
430 nm strongly suggests FRET emission (Figure 4.5 b). This is because 430 nm 
is the excitation wavelength for CFP and the appearance of YFP emission means 
it is a sensitized emission (FRET). Interestingly, the treatment with C5a or buffer 
control did not affect the amount of FRET. This may suggest a constitutive FRET, 
which is not ligand induced. The FRET curves of the hC5a1-CFP+hC5a1-YFP 
were similar to the positive control and the FRET ratio was not significantly 
different (Figure 4.6).







Figure 4.5 Spectral study of cells co-expressing hC5a1-CFP and hC5a1-YFP by spectro-fluorimeter. 
RBL-2H3 expressing either pECFP-YFP linked plasmid (A); hC5a1-CFP+hC5a1-YFP with control 
treatment for 20 minutes (B); or hC5a1-CFP+hC5a1-YFP with 0.5 µM C5a treatment for 20 
minutes (C).  Blue, spectrum from cells co-expressing both hC5a1-CFP and hC5a2-YFP or linked 
pECFP-EYFP plasmid; RED, cells expressing hC5a1-CFP (Normalized as indicated in method 
chapter); Green, cells expressing hC5a1-YFP (Normalized as indicated in method chapter) 
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 Figure 4.6 Fluorescence resonance energy transfer measurements. (a) FRET curves of the 
RBL cells co-expressing hC5a1-CFP+hC5a1-YFP treated with C5a or control buffer were 
compared with FRET curve of cells expressing the FRET positive control pECFP-YFP. (b) FRET 
ratio of cells co-expressing FP tagged receptors treated with C5a or control buffer in 
comparison to the pECFP-YFP positive control. The results are from 3 independent 
experiments. One-way ANOVA was used to test statistical significance. ns, non-significant. 
4.5 Localization of the possible receptor dimerization using confocal 
microscopy: 
4.5.1 RBL-2H3 expressing pECFP-YFP:  
Confocal microscopy was used to visualise the possible sites of FRET 
signals within the cells. The cells expressing the positive control for FRET were 
first examined. The cells were grown on chamber slides overnight as in section 
2.3.6.1. The fluorescence was measured using two lasers (one for CFP and one 
for YFP excitation) and three detectors (CFP, YFP, FRET). The FRET image was 
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corrected for bleed-through using Image J plugin software and co-localised FRET 
index (Figure 4.7). The figure shows the FRET in three cells, which is diffused 
all over the cells, possibly due the distribution of the protein (pECFP-YFP) all 
over the cells. 
 
a. CFP  
 
b. YFP  
 
c. FRET  
 
d. Co-localised FRET  
Figure 4.7 FRET measurement for RBL cells expressing pECFP-YFP plasmid. The fluorescence 
was detected through three channels, CFP (a), YFP (b), and FRET channel (c) by confocal 
microscopy. The co-localised FRET (d) was analysed using FRET and co-localization analyser 
plugin of Image J (Hachet-Haas et al., 2006). The image shows possible FRET in three cells and 
is distributed homogenously within the cells. 
 
 
Chapter four Results 
93 
 
4.5.2 RBL-2H3 co-expressing hC5a1-CFP and hC5a2-YFP without C5a 
stimulation: 
The heterodimerization of hC5a1 with hC5a2 receptors was examined by 
confocal microscopy. RBL cells co-expressing hC5a1-CFP and hC5a2-YFP were 
used.  Figure 4.8 shows the CFP, YFP and FRET channels and the co-localised 
FRET image after correction. The CFP channel shows that hC5a1 is distributed 
mainly on the cell surface, while the hC5a2 in the YFP channel appeared mainly 
intracellular (perinuclear). Although the FRET channel showed a few areas of 
FRET but it seems that it was cross talk or a bleed-through, which did not appear 
after correction in the co-localised FRET image. These data suggest that without 
C5a treatment no dimerization occurred between hC5a1-CFP and hC5a2-YFP 
receptors.




a. CFP  
 
b. YFP  
 
c. FRET  
 
d. Co-localised FRET 
Figure 4.8: FRET measurement for RBL cells co-expressing hC5a1-CFP and hC5a2-YFP 
receptors without C5a treatment. The fluorescence was detected through three channels, CFP 
(a), YFP (b), and FRET channel (c) by confocal microscopy. The co-localised FRET (d) was 
analysed using FRET and co-localization analyser plugin of Image J (Hachet-Haas et al., 2006). 
The graph does not show resonance energy transfer in any of the cells after correction. 
4.5.3 RBL-2H3 co-expressing hC5a1-CFP and hC5a2-YFP with C5a 
stimulation: 
Heterodimerization was also examined after treatment with 500 nM C5a 
for 10 minutes ( Figure 4.9) and 20 minutes (Figure 4.10). Confirming the 
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a. CFP  
 
b. YFP  
 
c. FRET  
 
d. Co-localised FRET 
Figure 4.9 FRET measurement for RBL cells co-expressing hC5a1-CFP and hC5a2-YFP receptors 
after C5a treatment for 10 minutes. The fluorescence was detected through three channels, 
CFP (a), YFP (b), and FRET channel (c) by confocal microscopy. The co-localised FRET (d) was 
analysed using FRET and co-localization analyser plugin of Image J (Hachet-Haas et al., 2006). 
The co-localised FRET image does not show resonance energy transfer in any of the cells after 
correction. 
 




a. CFP  
 
b. YFP  
 
c. FRET  
 
d. Co-localised FRET 
Figure 4.10 FRET measurement for RBL cells co-expressing hC5a1-CFP and hC5a2-YFP 
receptors after C5a treatment for 20 minutes. The fluorescence was detected through three 
channels, CFP (a), YFP (b), and FRET channel (c) by confocal microscopy. The co-localised FRET 
(d) was analysed using FRET and co-localization analyser plugin of Image J (Hachet-Haas et al., 
2006).  
 
4.5.4 RBL-2H3 co-expressing hC5a1-CFP and hC5a1-YFP without C5a 
stimulation:  
The FRET assay was used to explore the possibility of homodimer 
formation by hC5a1 receptors. The assay was performed in RBL cells co 
expressing hC5a1-CFP and hC5a1-YFP. The FRET signal was first analysed for 
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cells without C5a treatment. Figure 4.11 shows FRET signals that are mostly at 
the boundaries of the cells. This may suggest that the hC5a1 receptors are possibly 
expressed as homo-di/oligodimers on the cell surface. 
 
a. CFP  
 
b. YFP  
 
c. FRET  
 
d. Co-localised FRET 
Figure 4.11 FRET measurement for RBL cells co-expressing hC5a1-CFP and hC5a1-YFP 
receptors without C5a treatment. FRET measurement for RBL cells co-expressing hC5a1-CFP 
and hC5a1-YFP receptors without C5a treatment. The fluorescence was detected through 
three channels, CFP (a), YFP (b), and FRET channel (c) by confocal microscopy. The co-localised 
FRET (d) was analysed using FRET and co-localization analyser plugin of Image J (Hachet-Haas 
et al., 2006). The co-localised FRET image shows FRET in many cells after correction. 
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4.5.5 RBL-2H3 co-expressing hC5a1-CFP and hC5a1-YFP with C5a 
stimulation: 
The hC5a1 receptor homodimerization was further examined for ligand 
effect on dimerization. After C5a treatment, the receptors were probably 
internalised as shown in CFP and YFP channel and the FRET signal was detected 
at the region of internalization (Figure 4.12). 
 
a. CFP  
 
b. YFP  
 
c. FRET  
 
d. Co-localised FRET 
Figure 4.12 FRET measurement for RBL cells co-expressing hC5a1-CFP and hC5a1-YFP 
receptors after C5a treatment for 20 minutes. FRET measurement for RBL cells co-expressing 
hC5a1-CFP and hC5a1-YFP receptors after C5a treatment for 20 minutes. The fluorescence 
was detected through three channels, CFP (a), YFP (b), and FRET channel (c) by confocal 
microscopy. The co-localised FRET (d) was analysed using FRET and co-localization analyser 
plugin of Image J (Hachet-Haas et al., 2006). The co-localised FRET image shows FRET signal in 
all cells. 




Protein-protein interaction is thought to play an important role in regulating 
cellular functions. There are many methods that can be used to detect this 
interaction.  The interaction could be weak and transient and might occur only in 
natural cellular milieu of molecules. In this case, it is not easily measured by the 
traditional biochemical methods. Co-localization by fluorescent microscopy 
historically was the common method. Nevertheless, the resolution of fluorescent 
microscopy is about several hundred nanometres although the interacting proteins 
might be few nanometres in size.  In addition, the presence of one molecule in the 
vicinity of another does not mean that they are interacting. It has been thought 
that “typical fluorescence imaging experiment yields information equivalent to 
knowing that two students are present in a large lecture hall: merely localizing 
the two students to the same classroom yields no information about whether the 
students know each other or not” (Piston and Kremers 2007). 
 The FRET technique has been developed to overcome the limitations of 
other methods such as the lack of labelling or appropriate resolution. FRET can 
occur only when the distance between the interacting molecule is ~10 Å to100 Å 
(Clegg, 1996) when they are appropriately labelled. The ease of use and the 
variety of fluorescent proteins have led to the increased popularity of this 
technique. The fluorescent proteins are now genetically designed to be expressed 
at one or both ends of a protein. Therefore, FRET can be used to measure 
intermolecular or intramolecular interactions. In this chapter, CFP and YFP 
linked to either hC5a1 or hC5a2 were used to explore the interaction between the 
two receptors. CFP and YFP have been used for many years as FRET donor and 
acceptor. There are many factors that contribute to their suitability for FRET 
experiments. The most important is the spectral overlap that they share. This 
makes the emission maximum of the CFP near the excitation maximum of the 
YFP, which is necessary for FRET to occur. The second characteristic is that their 
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excitation maxima are well separated. Therefore, there should be minimal 
excitation of one of the fluorophore with the wavelength intended for excitation 
of the other. In addition, their emission maxima are also well separated. This 
makes the FRET emission easily distinguished from the donor emission (Pollok 
and Heim, 1999, Sekar and Periasamy, 2003). These properties allow CFP and 
YFP to be used using excitation wavelengths and filter sets that are commonly 
available in most fluorescent measuring machines such as microscopes, 
spectrofluorimeters and flow cytometers. Moreover, the fusion of CFP and YFP 
to proteins do not affect the native localization of these proteins within the cells 
(van Rheenen et al., 2004). This might be due to their high stability and compact 
structure. 
CFP and YFP tagged hC5a1 and hC5a2 receptors were used in the current 
study to show the localization of the receptors within cells. The hC5a1 receptor 
was expressed mainly on the cell surface. However, C5a2 receptors were mainly 
intracellular. This result is in support of other studies that reported predominant 
peripheral positioning of the C5a1 receptors, similar to the majority of GPCR, on 
the cell surface, while the C5a2 tend to keep more intracellular location (Li et al., 
2013, Bamberg et al., 2010, Scola et al., 2009, Croker et al., 2013). This has been 
reported in primary cell lines and transfected cells. The staining was by either 
using antibodies or, as in our study, by receptor-reporter fusion proteins. 
Moreover, it was reported in animal and human native cells (Li et al., 2013). This 
different localization may not support the possibility of the heterodimerization 
between the two receptors. Most of the GPCR, which have been reported to form 
dimers, are expressed on the cell surface and they attach to each other through 
their transmembrane (TM) regions (Gomes et al., 2001, Angers et al., 2002). For 
example, the contact surfaces for D2 receptors are in the TM4-5; histamine H1 
receptors at TM5-6; and β2-adrenoceptors contact domains are mainly at the 
TM1-4 (reviewed in Dickenson et al., 2013).  
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The site of the formation of receptor dimers is still a controversial subject. 
There are two theories in this context. The first, is that the receptors form the 
dimers at their destination where they are expressed at the cell surface. This 
theory also suggests that this dimerization process could be a dynamic process 
that can be induced, increased or even decreased upon ligand stimulation 
(Rocheville et al., 2000b, Patel et al., 2002, Cvejic and Devi, 1997, AbdAlla et 
al., 1999). On the other hand, the second theory suggests that the receptor 
dimerization is an early event that happens during the biogenesis and maturation 
of the receptors. It is probably occurring at the level of endoplasmic reticulum 
and the receptors are delivered as dimers to the cells surface. In this theory, the 
receptors may form constitutive dimers and their formation is perhaps ligand-
independent  (reviewed in Milligan, 2004, Drinovec et al., 2012, Floyd et al., 
2003). Following heterologous expression, many GPCR are not delivered to the 
cell membrane in model cell lines. For example, the GABAB receptor when first 
cloned and then expressed in heterologous systems, failed to reach surface 
expression and failed to signal (Couve et al., 1998). These receptors were retained 
in the endoplasmic reticulum. After one year, a second GABAB2 receptor was 
discovered. This receptor did not bind to GABA ligand, but it was able to 
physically interact with first receptor GABAB1 and both receptors were able to 
reach cell surface and transduce signal (Marshall, 2001). This was because the 
GABAB1 has an endoplasmic retention signal at its C-terminus that prevent its cell 
surface expression. However, when co-expressed with GABAB2, the retention 
signal is masked by coil-coil interactions allowing both receptors to release from 
the ER and be expressed as heterodimer on the cell surface. 
In the present study, C5a receptors appeared to have a tendency toward the 
formation of homodimers rather than heterodimers. This was explored by two 
different methods, specrofluorimetry and confocal microscopy. Several studies 
reported that hC5a1 receptors form homodimers (Klco et al., 2003, Floyd et al., 
2003, Rabiet et al., 2008). In addition, C5a homodimerization was reported to be 
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constitutive and not dependent on intracellular proteins, which is in agreement 
with the result of the current study and with the second theory mentioned above. 
C5a1 receptor heterodimerization with C5a2 was recently reported to be 
upregulated by C5a, but not C5a desArg (Croker et al., 2013). This was performed 
using a BRET method in HEK cells. However, the C5a receptor interaction could 
not be detected by another study (Chen et al., 2007). Since C5a1/C5a2 
heterodimerization was not clear using FRET method in this section, it was 
decided to construct a C5a receptor BRET system, which is explained in the next 
section. This was done to develop a tool to explore the nature of this dimerization 
and testing some pharmacological preparations, such as novel peptides that could 
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5 Chapter 5: Investigating the dimerization of C5a receptors 
using bioluminescence resonance energy transfer (BRET) 
5.1 Introduction: 
 BRET is another method for measurement of protein-protein interaction 
with several advantages over the previously described FRET method. As with 
any fluorescence technique, many of the drawbacks of FRET techniques results 
from the use of external source of light for excitation of the donor. This may result 
in auto-fluorescence, photobleaching or even damage to the tissue. In addition, in 
FRET, the acceptor may be excited directly by the wavelength used for donor 
excitation. All these factors may limit the usefulness of the FRET technique and 
require correction steps to produce the final results. Therefore, BRET, which is a 
naturally occurring phenomenon, has been developed to be used to measure in 
vivo and in vitro proteins interactions and possibly avoid the consequences of 
fluorescence excitation with external light, by replacing the donor fluorophore 
with an enzyme. This enzyme emits light upon interaction with its substrate.  
 The BRET method has been widely used to monitor protein-protein 
interactions including GPCR dimerization and oligomerization (Hebert et al., 
1996, Mercier et al., 2002, Calebiro et al., 2013, Cussac et al., 2012, Croker et al., 
2013, Harikumar et al., 2016, Angers et al., 2000). In this study, the BRET 
method was used to confirm the results from the FRET study in the previous 
chapter. In order to develop hC5a1 receptor tagged with Renella luciferase 
enzyme (Rluc8, as a luminescent donor), the construct was designed as described 
in section (2.4.3). RBL-2H3 cell line was transfected using Turbofect method as 
described in section (2.2.4). The cells were then sorted by a FACS Aria cell sorter. 
Then the sorted cells were regrown and tested for the functionality of the Rluc8 
tagged hC5a1 receptor. The construct was tested for receptor expression, C5a 
binding, and C5a induced degranulation, and compared with IgE-mediated 
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degranulation. The hC5a receptors interactions were then measured in cells 
expressing both Rluc8 tagged hC5a1 and YFP tagged hC5a2 receptors. 
 
5.2 The expression of hC5a1-Rluc8 receptors in transfected cells: 
The new plasmid construct that contains the Rluc-8 tagged hC5a1 receptor 
was first transfected into RBL-2H3 cells. Consequently, the expression was tested 
after transfection and selection using immunostaining. The fluorescence was 
detected using the red laser and RL1-A filter set of an Attune flow cytometer 
(Figure 5.1). This result demonstrated that the transfection was successful and the 
tagging of the hC5a1 receptor with luciferase enzyme did not affect its expression 
at the cell surface. 
 
 The expression of hC5a1 receptor tagged with luciferase (Rluc8) 
transfected into RBL-2H3 cells 
 
Figure 5.1: The expression of hC5a1 receptor in RBL-2H3 cells transfected with Rluc8-hC5a1. 
Red, cells treated with buffer. Green, cells were treated with isotype antibody. Purple, cells 
were treated with mouse anti-hC5a1 primary antibodies. The graph shows combined dot plot 
and histograms for each treatment. Alexa fluor 633 rabbit antimouse secondary antibody was 
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 In order to develop the BRET assay to explore the possible 
heterodimerization of hC5a1-hC5a2 receptors, the Rluc8-hC5a1 plasmid was 
transfected into RBL-2H3 expressing hC5a2-YFP. The co-expression was then 
analysed by flow cytometry after immunostaining of the surface receptors. The 
receptors were treated with either mouse anti-hC5a1 antibodies, isotype 
antibodies control, or buffer control. Subsequently, the receptors stained using 
anti-mouse secondary antibodies. Figure 5.2 shows the shift in hC5a1 receptors 
fluorescence when treated with primary anti-hC5a1 antibodies (green) in 
comparison to the isotype (red) or buffer (cyan) control treatment. All these cells 
co-express hC5a2-YFP as represented by the histogram shift in the BL1-A axis 
in comparison to control cells (purple), which do not express YFP. The flow 
cytometric analysis revealed receptor expressions of >90% of the transfected cells 
after the cell sorting (Figure 5.3). 
Co-expression of Rluc8-hC5a1 and hC5a2-YFP in RBL-2H3 cells 
 
Figure 5.2: The co-expression of C5a receptors in RBL-2H3 cells. Dot plot with corresponding 
histograms to show Rluc8-hC5a1 expression (RL1-A) and hC5a2-YFP expression (BL1-A). 
Control cells expressing wild type (untagged) hC5a1 receptor (Purple),  RBL-2H3-Rluc8-hC5a1+ 
hC5a2-YFP were treated with either buffer (cyan); isotype antibody (red); or mouse anti-hC5a1 
primary antibodies (green).  
Untagged hC5a1 
Buffer control  
Anti-hC5a1 Ab 
Isotype Ab 




Figure 5.3: The expression of hC5a1 in RBL-2H3 cell lines. Cells expressing either wild type 
hC5a1 receptors (control); Rluc8-hC5a1; or both Rluc8-hC5a1+hC5a2-YFP were used. Cells 
were treated either with buffer control, isotype antibody control or anti-hC5a1 antibodies. 
Alexa633 secondary antibodies were used to stain the receptors to be detected by flow 
cytometer. Data are mean±SEM of 3 independent experiments in duplicate. 
 
 The luminescence of hC5a1-Rluc8 in the transfected cells was also 
measured. RBL cells that express either hC5a1-Rluc8 or hC5a1-Rluc8+hC5a2-
YFP were tested. The treatment with coelenterazine substrate resulted in 
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Luminescence after treatment with or without  
coelenterazine substrate 
 
Figure 5.4: Luminescence of Rluc8 tagged hC5a1 receptor. RBL-hC5a1 and RBL-hC5a1-
Rluc8+hC5a2 were tested. Luminescence was measured after treatment with or without 
coelenterazine substrate. 
 
5.3 C5a binding assay by the Rluc8-hC5a1 receptor: 
 The ligand binding assay was performed to check whether the hC5a1 
receptor retains the ability to bind C5a after tagging with luciferase enzyme 
(Rluc8). Competitive ligand binding assay was done as described in section (2.3.2) 
and the result shows that IC50 for the tagged receptor was significantly lower 



















Figure 5.5: C5a binding assay for Rluc8 tagged hC5a1 receptor determined by competitive 488-
hC5a binding study. a. dose response (inhibitory) curve of serial dilutions (starting with 3 µM) 
of unlabelled hC5a with 100 nM of Alexa488 labelled hC5a. b. bar charts to compare the IC50 
of Rluc8-hC5a1 with the wild type hC5a1 control. Data are mean±SEM of 3 independent 
experiments in duplicate. Unpaired t-test is used to test statistical significance. *, P≤0.05; ns, 
non-significant. 
5.4 RBL-2H3 cell degranulation assay: 
 The degranulation assay was performed to test the function of the Rluc8-
hC5a1 receptor. C5a-mediated enzyme release was used to test the Rluc8-tagged 
C5a1 receptor signalling. In addition, IgE-mediated enzyme release was also 
examined: 
5.4.1 C5a-mediated degranulation assay for Rluc8-hC5a1 receptor 
transfected cells: 
 As previously described in section (2.3.4), the enzyme release in the 
supernatant of RBL-2H3 cells was measured after incubation with C5a for 15 
minutes at 37˚C. Figure 6 demonstrates the response to the stimulation in cells 
expressing either wild type hC5a1 or Rluc8-tagged hC5a1 receptors. Both the 
EC50 and maximum enzyme release were significantly lower in the tagged 
receptors. 








Figure 5.6: C5a-mediated degranulation assay for RLuc8-tagged hC5a1 receptors on RBL-2H3 
cells. a. dose response curve for expressing either the wild type or RLuc8 tagged hC5a1 
receptor. Beta-hexosaminidase enzyme release was measured in response to 1/3 serial 
dilutions of C5a starting with 1 µM. b. Bar charts for maximum enzyme release. Data are 
mean±SEM of 3 independent experiments in duplicate. Unpaired t-test is used to test 
statistical significance. ****, P≤0.0001.  
5.4.2   IgE-mediated degranulation assay: 
 The hexosaminidase enzyme release was performed in response to IgE 
stimulation as a comparison to the C5a-mediated response of the tagged hC5a 
receptor. The current data shows that the EC50 and maximum enzyme release 
were not significantly different in the Rluc8-hC5a1 transfected cells from the wild 
type hC5a1 receptors (Figure 5.7). This might suggest that Rluc8 tagging resulted 
in receptor specific rather than general cellular side effects.









Figure 5.7: IgE-mediated degranulation assay for Rluc8-tagged hC5a1 receptors on RBL-2H3 
cells. a. dose response curve for cells expressing either the wild type hC5a1 or Rluc8 tagged 
hC5a1 receptor. Enzyme release was measured in response to 1/10 serial dilutions of DNP 
starting with 1 µg maximum. b. and c. are the bar charts for EC50 and maximum enzyme 
release, respectively. Unpaired t-test is used to test statistical significance. Data are 
mean±SEM of 3 independent experiments in duplicate  
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5.5 The effect of luminescent protein tagging on hC5a1 receptors 
internalization: 
 In this experiment, the effect of the protein tagging on internalization of 
the receptor was examined. Human C5a receptors are rapidly internalised after 
ligand binding. However, the presence of protein tag on the C-terminus of hC5a 
receptors in the Rluc8-hC5a1 chimera results in significant decrease in receptor 
endocytosis (Figure 5.8).   
 
C5a-induced hC5a1 receptor internalization for luminescent  
protein (Rluc8) tagged and wild type hC5a1 receptors 
 
Figure 5.8: C5a-induced internalization of luminescent-tagged receptors. RBL-2H3 cells 
expressing Rluc8 tagged hC5a1 receptors were compared with cells expressing wild type 
hC5a1 (control) receptors. Cells were stimulated with C5a for 15 and 30 minutes. Data are 
mean±SEM of 3 independent experiments in duplicate Two way ANVOVA followed by 
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5.6   BRET assay for hC5a receptors dimerization: 
 In this experiment, the dimerization between hC5a1 and hC5a2 was 
measured using the BRET assay. The C5a receptors that were used in this assay 
were hC5a1 and hC5a2 tagged to luminescent donor (Rluc8) and YFP acceptor, 
respectively. The assay was performed as a time course before and after adding 
C5a or buffer control to the cells that co-expressing the tagged receptors. There 
was no obvious difference between the two treatments over time (Figure 5.9). 
This result confirms the previous FRET results regarding the lack of tendency of 
C5a receptors to exist or work in heterodimers. 
 
 
BRET assay for RBL cells co-expressing 
Rluc8-hC5a1 and hC5a2-YFP 
 
 
Figure 5.9: BRET assay in RBL-2H3 expressing Rluc8-hC5a1+hC5a2-YFP. Time course of the BRET 
ratio after adding 1 µM of C5a or buffer control. Luminescence was measured after incubating 
the cells with 5 µM coelenterazine substrate. Data are mean±SEM of 3 independent 
experiments in duplicate 




 The starting point of this chapter was to generate cells with stable co-
expression of both luminescent-tagged hC5a1 and fluorescent-tagged hC5a2 
receptors. This cell line could be used to measure C5a receptor 
heterodimerization using BRET technique. The luminescent tag used to generate 
the hC5a1 construct BRET donor is Renella luciferase enzyme (Rluc8). The 
addition of such protein, which is about 314 aa, to the C-terminus of C5a receptors 
may have an influence on receptor pharmacology, G protein coupling or 
interaction with other intracellular partners. Therefore, in this study, this fusion 
construct Rluc8-hC5a1 was tested for different pharmacological and signalling 
properties.  
 Luciferase has been used in biological research in many applications as a 
reporter molecule for gene expression when its gene is inserted into the gene of 
interest and transfected into cells (reviewed in Fan and Wood, 2007). It is used as 
a high throughput screening for drug discovery as it can be used to monitor 
cellular events and gene transcription regulation. Numerous major drug targets 
such as GPCR and nuclear receptors have been assessed using luciferase assays 
(Katso et al., 2005, Hill et al., 2001, Dinger et al., 2003, Grover et al., 2003). It 
has been even used for studying cell populations in live animals (Greer & Szalay 
2002). However, in this study it appeared that the luciferase tag on hC5a1 
receptors had effects on receptor function. 
   Several effects have been reported for many of the commonly used 
protein tags (Zhu et al., 2013, Ledent et al., 1997, Zhang and Crandall, 2007). It 
has been reported that tagging of CD36 with GFP did not affect protein 
expression. However, the tagging influenced the binding of its ligand (oxLDL) 
(Zhang and Crandall, 2007). These findings are compatible with this study, which 
showed that the intracellular tagging of the hC5a1 receptor (C-terminal tagging) 
did not affect the fusion protein expression, whereas the ligand binding was 
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disturbed. In addition, ligand binding could be affected when the receptor 
interaction with its intracellular partners is affected. It has been suggested that G 
proteins could have an allosteric effect on the ligand binding affinity of some 
receptors (reviewed in  Chabre et al., 2009). Moreover, β-arrestins have also been 
shown to influence ligand binding to the receptors (Gurevich et al., 1997). This 
might suggest that the tagging of hC5a1 receptors at the C-terminus may have a 
direct or indirect influence on receptor physiological and pharmacological 
function.  
          The cytosolic C-terminus is essential for many receptor activities such as 
receptor internalization for majority of G protein-coupled receptors (Benya et al., 
1993, Chabry et al., 1995, Huang et al., 1995, Negishi et al., 1993, Nussenzveig 
et al., 1993, Parker et al., 1995, Thomas et al., 1995a, Thomas et al., 1995b, Tseng 
et al., 1995). Therefore, it could be speculated that the decreased internalization 
of the tagged receptor is due to the effect of the tag on the receptor C-terminus. 
In addition, it could be due to the disturbance in ligand binding as shown in the 
ligand binding assay. In addition, the C-terminus contains the predominant 
phosphorylation sites shared with third intracellular loop. These sites are 
important sites for protein kinase activities (PKC and PKA). In addition, they are 
the targets for phosphorylation by G protein-coupled receptor kinase (GRK). 
Therefore, the C-terminus plays an essential role in regulating receptor 
desensitization in addition to probable role in G protein coupling. Moreover, a 
splice variant of a GPCR receptor (neuropeptide Y receptor) which lacks part of 
the transmembrane region and the C-terminal tail failed to couple to second 
messenger systems such as Ca2+ release or MAP kinase stimulation (Dickenson 
et al., 2013). This might explain the results of the current study regarding the 
abnormality in signal transduction of the C-terminal tagged C5a1 receptors in 
terms of defective enzyme release from RBL cells.  
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 The concept of class A GPCR dimerization/oligomerization is a 
controversial one. This could be partially related to the lack of complete 
understanding of the methodology used to address the subject. For example, the 
existence of β2 adrenergic receptor dimer/oligmerization was both supported 
(Hebert et al., 1996, Mercier et al., 2002, Dorsch et al., 2009, Calebiro et al., 2013, 
Angers et al., 2000) and failed to be supported (James et al., 2006, Kawano et al., 
2013, Lan et al., 2011, Gavalas et al., 2013, Felce et al., 2014). The C5a receptor 
heterodimerization is no exception from this type of controversy. Human C5a 
receptor heterodimerization was reported to be upregulated by C5a ligand 
(Croker et al., 2013). However, it was shown by Poursharifi et al. that C5a 
heteromer formation was not affected by ligand treatment (Poursharifi et al., 
2013). In addition, this form of C5a receptor interaction could not be detected in 
another study and indirect interactions or parallel functions were suggested (Chen 
et al., 2007). This discrepancy in reporting interaction between integral 
membrane proteins may arise from the methods used to study this kind of 
interaction.  
 The temporal and spatial factors for the formation of receptors dimerization 
has been explored in many studies. GPCR dimerization could start at early stages 
of protein formation and processing at endoplasmic reticulum (ER) and before 
trafficking to the cell surface (reviewed in Milligan, 2010, Van Craenenbroeck, 
2012). For example, as a model for class A GPCR, the β2 adrenergic receptors 
dimerization is considered as prerequisite for cell surface delivery (Salahpour et 
al., 2004). The lack of endoplasmic reticulum export motif inhibited trafficking 
of wild type receptors to the cell membrane. In addition, inhibition of 
dimerization or disruption of the putative dimerization motifs resulted in 
inhibition of receptors trafficking to the cell surface. Another example, from class 
C GPCR, is the metabotropic glutamate receptor-like GABAB receptors. It was 
the first GPCR recognised that its delivery to the cell surface require quaternary 
structure (Pin et al., 2005). GABAB R1 is retained in ER when expressed alone. 
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However, cell surface delivery occurs when co-expressed with GABAB R2 
(Milligan, 2010). These findings suggest that once the receptors are expressed on 
cell surface, they are in their final forms whether they are monomers, dimers or 
oligomers and the signal transduction capability of the receptors probably has no 
role in the di/oligomerization. In the current study, the luminescent protein 
tagging of the receptors does not seem to affect the expression of the receptor. 
This was also the case with FP tagging as discussed in chapter 3. Other studies 
also reported similar findings. The tagging of CD36 with GFP did not affect 
CD36 expression, although it affected ligand binding (Zhang and Crandall, 2007). 
Therefore, although the presence of luminescent or fluorescent tag could be a 
limiting factor due to the effect on receptor signal transduction, the receptors can 
still be used to assess di/oligomerization. This is because the formation of 
receptor di/oligomers does not depend on the signalling capability of the receptors 
(Floyd et al., 2003, Klco et al., 2003). C5a receptor dimerization was detected 
using C5a receptor mutants that lack ligand binding or phosphorylation capability 
(Rabiet et al., 2008). This can be supported further by the reports that 
demonstrated that receptor self-association is not required for signalling through 
G proteins and arrestins (Hanson et al., 2007, Kuszak et al., 2009, Whorton et al., 
2007, Whorton et al., 2008).  
Using luminescent and fluorescent tagged receptors, the BRET assay could 
not detect hC5a1 and hC5a2 receptor dimerization. This could be supported by 
the previous FRET results from chapter 4, which showed a tendency of hC5a1 
receptors to form homodimers or oligomers rather than heterodimers with hC5a2. 
In addition, the discrepancy of the localization of the two receptors within the 
cells (hC5a1 mainly expressed on the cell surface, while hC5a2 is mainly 
intracellular in unstimulated cells) does not support the heterodimerization theory. 
To further confirm this finding, and to rule out the effect of tags on the receptors, 
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6 Chapter 6: Receptor interaction during internalization in 
RBL-2H3 cells co-expressing untagged hC5a1 and hC5a2 
receptors 
6.1 Introduction: 
GPCR are known to internalize upon stimulation with their ligands similar 
to other receptors. This internalization could be through various pathways that 
involve interaction with intracellular proteins such as β-arrestins. The 
internalization could be part of a desensitization process of the receptors, 
although other functions were reported for internalization such as receptor re-
sensitization. In addition, receptors can interact and influence the internalization 
and trafficking of each other. In this chapter, possible hC5a receptors interactions 
were tested by observing receptor internalization after treatment with different 
ligands. These ligands involve C5a, C5a desArg, RHYPYWR peptide, a selective 
hC5a2 ligand that is thought to stimulate β-arrestin2 (Croker et al., 2016). The 
internalization was measured in RBL cells that expressed either one of the hC5a 
receptors (RBL-hC5a1 or RBL-hC5a2) or both (RBL-hC5a1+hC5a2).  
  The internalization assay was also used to test whether the receptors 
internalize as dimers or as monomers. Many studies reported that GPCR 
heterodimerization can be expected if co-internalization of two receptors occurs 
upon stimulation of either of them (Pfeiffer et al., 2003, Stanasila et al., 2003, 
Jordan et al., 2001). In this study, the selective hC5a1 inhibitor (PMX53) was 
used to allow hC5a2 receptor to be activated more selectively by C5a and C5a 
desArg in RBL cells co-expressing both hC5a1 and hC5a2 receptors. 
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6.2 Ligand-induced hC5a1 receptor internalization when co-expressed 
with hC5a2: 
Ligand-induced internalization was performed as described in section 2.3.5 
at different time points. The RBL cells that express either hC5a1 or both 
hC5a1+hC5a2 receptors were treated with various ligands. At 5 minutes, there 
was no significant difference in hC5a1 receptor internalization between either 
hC5a1 alone or hC5a1+hC5a2 expressing cells. In addition, the different ligand 
treatments did not result in significant change (Figure 6.1a). After 15 minutes, the 
cells showed significant hC5a1 internalization in both cell lines (hC5a1 alone or 
hC5a1+hC5a2) in response to either C5a or C5a desArg, but not to the peptide 
(Figure 6.1 b). The cells expressing both receptors (hC5a1 and hC5a2) displayed 
less hC5a1 internalization than cells that express only hC5a1 (Figure 6.1 b). The 
difference in the hC5a1 internalization between RBL-hC5a1 and RBL-hC5a1+2 
was statistically significant in response to ligand treatment compared to buffer 
treatment (Figure 6.1c). This may indicate that hC5a1 is less internalized when 
co-expressed with hC5a2 and hC5a2 may have a role in this process. With time, 
hC5a1 receptor internalization rate appeared to be slowing down and it was 
slower when hC5a2 was co-expressed with hC5a1. In case of C5a treatment, 
although RBL-hC5a1 showed significantly more hC5a1 internalization compared 
to buffer treatment, RBL-hC5a1+2 showed less hC5a1 internalization than RBL-
hC5a1 at 45 minutes, which was not significant (Figure 6.1 d). The difference in 
the hC5a1 internalization between RBL-hC5a1 and RBL-hC5a1+2 became 
statistically insignificant in response to ligand treatment compared to buffer 
treatment at 45 minutes (Figure 6.1 e). In case of C5a desArg treatment, the 
increase in hC5a1 internalization in response to ligand treatment was absent in 
both cell lines at 45 minutes. This might be due to the lower potency of C5a 
desArg in comparison to C5a (Figure 6.1 d).   
Chapter six Results 
121 
 











Figure 6.1: hC5a1 receptor internalization. ligand induced internalization in response to either 
C5a, C5a desArg or RHYPYWR peptide for 5 min (a) 15 min (b) and 45 min (d). Cell expressing 
either hC5a1 alone or hC5a1+2 were used. Two-way ANOVA test with Sidak's multiple 
comparisons test were performed to test statistical significance. c. and e. are the hC5a1 
receptor internalization difference between RBL-hC5a1 alone or RBL-hC5a1+2 at 15 min or 45 
min, respectively. Unpaired t test was used to test statistical significance. Data are mean±SEM 
of 3-4 independent experiments in duplicate. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 
0.0001, ns, non-significant. 
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In summary, in case of C5a stimulation, hC5a1 receptor internalization 
increase rapidly between 5 to 15 minutes in both cell lines and was significantly 
higher than control treatment at 15 minutes. However, the internalization rate 
appeared to slow down between 15 to 45 minutes, which still significantly higher 
than the control treatment in cells expressing only hC5a1 receptors. However, the 
co-expression of hC5a2 affected hC5a1 internalization at 45 minutes and 
rendered it insignificantly different from the control treatment. In case of C5a 
desArg treatment, hC5a1 receptor internalization follows nearly similar pattern. 
However, at 45 minutes it becomes not significantly different from buffer control 
in both cell lines. This could be due the lower potency of C5a desArg in 
comparison to C5a. 
 
6.3 Ligand-induced hC5a2 receptor internalization when co-expressed 
with hC5a1:  
 hC5a2 receptor internalization was explored in RBL expressing either 
hC5a2 alone or co-expressing both hC5a1+hC5a2. hC5a2 internalization was 
measured at different time points after treatment with different ligands. The 
ligands used in this assay were: C5a, C5a desArg or peptide RHYPYWR. At early 
time point (5 minutes) of the internalization course of the receptor, the hC5a2 
receptor did not internalize at significant percentage upon treatment with any of 
the ligands (Figure 6.2 a). Although hC5a2 receptors showed higher percentages 
of internalization at 15 minutes than in 5 minutes, it did not reach statistical 
significance. This could be because of the higher percentage of constitutive 
hC5a2 internalization (internalization without ligand stimulation) at this stage 
(Figure 6.2 b). After 45 minutes, it appeared that hC5a2 underwent high levels of 
ligand-induced internalization by C5a and C5a desArg, but not for the peptide 
alone (Figure 6.2 c). This internalization was similar in cells expressing both 
receptors hC5a1+hC5a2 or cells with only hC5a2. C5a and C5a desArg showed 
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similar effects on hC5a2 internalization and this is because hC5a2 binds both 
ligands with similar affinities (Scola et al, 2007). In addition, hC5a2 recruitment 
of β-arrestin2 was reported to be similar for C5a or C5a desArg treatment (Croker 
et al., 2014) 
 In summary, at early time points, 5 and 15 minutes, the C5a/C5a desArg-
induced internalization was not significant. However, hC5a2 continued to 
internalize upon C5a/C5a desArg stimulation and became significant for the 
difference between ligand and control at 45 minutes incubation with C5a or C5a 
desArg. In addition, the hC5a2 internalization was similar for C5a or C5a desArg 
stimulation. 
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Internalization of hC5a2 receptor  
a. 
                           
Treatment for 5 min 
b. 
 
Treatment for 15 min 
c. 
 
Treatment for 45 min 
Figure 6.2: hC5a2 receptor internalization. Ligand induced internalization using either C5a, 
C5a desArg or RHYPYWR peptide for 5 min (a), 15 min (b) and 45 min (c). Cell expressing either 
hC5a2 alone or hC5a1+2 were used. Data are mean±SEM of 3 independent experiments in 
duplicate. Two-way ANOVA test with Sidak's multiple comparisons test were performed to 
test statistical significance. ****, P≤0.0001, ns, non-significant. 
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6.4  Comparison between hC5a1 and hC5a2 receptor internalization when 
co-expressed in RBL cells: 
The behaviour of hC5a1 and hC5a2 receptors internalization over time was 
examined and compared when the two receptors are co-expressed in RBL cells. 
In case of hC5a1 receptor, it appeared that C5a stimulation induced higher 
receptor internalization than control treatment over time (Figure 6.3 a). On the 
other hand, hC5a2 behaves differently in response to different treatment. When 
there is no C5a, hC5a2 internalizes for about 45 minutes and then probably 
recycles back to the cell surface (constitutive internalization and recycling; Scola 
et al., 2009) (Figure 6.3 b). However, when C5a is present in the extracellular 
(EC) compartment, hC5a2 receptor continues to internalize for longer time points. 
This probably suggests scavenging role of hC5a2 for removing C5a from the EC 
compartment to prevent long-term stimulation for hC5a1 receptor as discussed in 












Figure 6.3: Receptors internalization time course for hC5a1 or hC5a2 co-expressed on RBL 
cells. The graphs describe the different patterns of hC5a1 (a) or hC5a2 (b) receptors 
internalization when co-expressed on RBL. Two-way ANOVA test was performed to test 
statistical significance. The table shows: interaction, the systematic changes (pattern) of 
receptor internalization over time in response to different treatment; time, receptor 
internalization over time; and treatment, receptor internalization upon C5a or control 
treatment. Data are the mean±SEM for 3 independent experiment in duplicate. ns, non-
significant, ***, P≤0.001 and ****, P≤0.0001. 




To further illustrate the internalization patterns of hC5a receptors after C5a 
stimulation, the C5a-induced hC5a1 and hC5a2 receptor internalization was 
compared after subtracting constitutive (control treatment) internalization (Figure 
6.4). The receptors behaviour was different per the receptor type and at various 
time points. At early time points, both hC5a1 and hC52 displayed ligand 
dependent internalization. However, hC5a1 receptor internalization slows down 
after 15 minutes and probably reaches plateau phase. In contrast, hC5a2 continues 
to internalize after 15 minutes (Figure 6.4).  This could explain why hC5a1 
internalization slows down after 15 minutes: possibly, hC5a2 receptor uptakes 
the C5a from the EC compartment and internalizes it for degradation (Scola et 
al., 2009). Therefore, hC5a1 is not exposed to C5a at late time points and stops 
activation and subsequent internalization. Therefore, this could be part of the 
desensitization process of hC5a1 receptor. This role of hC5a2 could be supported 
more by the previous result that showed when hC5a1 expressed alone, its C5a-
mediated internalization continued to be significant after 15 minutes to reach 45 
minutes (Figure 6.1 c). However, when hC5a2 co-expressed with hC5a1, the C5a-
mediated hC5a1 internalization became insignificant at 45 minutes in comparison 










Figure 6.4: C5a-induced hC5a1 and hC5a2 receptors internalization. RBL-2H3 co-expressing 
hC5a1 and hC5a2 receptors treated with C5a or control buffer at 5,15,30,45 and 120 minutes. 
The C5a-induced receptor internalization was calculated by subtracting the buffer treated 
from C5a treated internalization. hC5a1 and hC5a2 show different patterns of internalization 
upon ligand treatment. hC5a1 internalize rapidly within 15 minutes and reaches probable 
plateau phase. However, hC5a2 internalization continues after 15 minutes with C5a 
stimulation. Data are the mean±SEM for 3 independent experiment in duplicate. Two-way 
ANOVA test with Sidak's multiple comparisons test were performed to test statistical 
significance. The table shows: interaction, the systematic changes (pattern) of C5a-induced 
receptor internalization in hC5a1 and hC5a2 over time; time, receptor internalization over 
time; and receptor type, hC5a1 or hC5a2 receptor internalization.  * P ≤ 0.05, ** P ≤ 0.01, 
**** P ≤ 0.0001. 
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6.5 Exploring C5a receptors heterodimerization using receptors 
internalization assay: 
 This test was performed to examine the internalization forms in which 
hC5a receptors internalize i.e. whether in monomers or heterodimers. 
Internalization was measured at 15 and 45 minutes in cells expressing either 
hC5a1 alone or both hC5a1+2. C5a1 receptor inhibitor PMX53 was used to allow 
C5a to work selectively on the C5a2 receptor. Figure 6.5 shows the effect of 
hC5a1 receptor inhibition on receptor endocytosis. C5a induced hC5a1 receptor 
internalization was inhibited significantly at both time points and in both cell lines 
in the presence of C5a1 receptor inhibitor PMX53. C5a desArg induced hC5a1 
internalization was also inhibited but the difference did not reach the statistical 
significance at 15 minutes (Figure 6.5 a), probably because C5a desArg is a 
partial agonist for hC5a1 and the internalization is not as high as the 
internalization induced by C5a at this time point. However, it became significant 
in RBL-hC5a1 cells at 45 minutes because the difference in internalization 
between the PMX53-treated and non-treated at this time point was high (Figure 
6.5 b). 
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The internalization of hC5a1 receptor in the presence  






Figure 6.5: hC5a1 receptor internalization in the presence of hC5a1 receptor inhibitor PMX53. 
The graph shows the hC5a1 receptor internalization at 15 minutes (a) and 45 minutes (b) in 
RBL expressing hC5a1 alone or co-expressing hC5a1+hC5a2. Cells were pre-incubated with 1 
µM PMX53 for 10 minutes before adding C5a or C5a desArg. Data are the mean±SEM for 3 
independent experiment in duplicate. Two-way ANOVA was performed with Tukey’s multiple 
comparison to test statistical significance. *, P=≤0.05, **, P=≤0.001, and ns, non-significant. 
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 hC5a2 receptor internalization was also tested in the presence of the hC5a1 
inhibitor PMX53. Cells co-expressing both receptors had been pre-incubated with 
1 µM PMX53 for 10 minutes and then C5a or C5a desArg were added. 
Internalization was measured at 45 minutes because hC5a2 receptor 
internalization is significant at 45minutes (based on previous work, Figure 6.2 c). 
There was no significant difference in hC5a2 receptor internalization in the 
presence or absence of the hC5a1 inhibitor PMX53 (Figure 6.6).  
 
 
Figure 6.6: hC5a2 receptor internalization in the presence of hC5a1 receptor inhibitor PMX53. 
The graph shows hC5a2 internalization in cells co-expressing both hC5a1 and hC5a2 at 45 
minutes in response to C5a or C5a desArg with or without pre-treatment with PMX53 for 10 
minutes. Data are the mean±SEM for 4 independent experiment in duplicate. One way ANOVA 
was used with Tukey’s multiple comparison to test statistical significance. ns, non-significant. 
 
 Taken together, it appeared that inhibition of hC5a1 receptor hindered its 
internalization, but it did not affect hC5a2 internalization in cells co-expressing 
both hC5a receptors. Therefore, it could be speculated that the two receptors are 
not in direct physical contact, at least when they are internalizing. This is because 
it would be expected (if the receptors work in heterodimers) that either both 
receptors are inhibited from internalization when hC5a1 is inhibited, or both are 
internalized when the internalization of hC5a2 occurs.  




 Many GPCR undergo internalization, which is manifested by decrease in 
the receptor expression on the cell surface. This could be induced by ligand or 
could be constitutive (without ligand binding). In this chapter, the internalization 
of hC5a receptors was studied during a time course with or without ligand 
treatments. It seems that C5a1 and C5a2 receptors behave differently in terms of 
their constitutive and ligand-induced internalization. First, the constitutive 
internalization of C5a2 was higher than C5a1. This could be due to constitutive 
complexing with β-arrestin2 (Croker et al., 2013). Second, C5a-induced 
internalization of hC5a1 reached a maximum and then plateaued at earlier stages, 
while hC5a2 internalization became significant at later time points, in comparison 
to hC5a1, and continued for a longer time. All these findings may suggest a 
possible scavenger function of hC5a2. It could be speculated that after exposure 
to C5a, hC5a1 receptor responds to C5a and internalizes rapidly. hC5a2 
endocytosis is less significant directly after exposure to C5a, allowing, hC5a1 to 
function. However, after long exposure to C5a, hC5a2 starts to uptake C5a and 
internalizes at a higher rate to decrease hC5a1 exposure to the agonist. In addition, 
the higher rate of hC5a2 internalization could affect the availability of the 
intracellular internalization machinery for hC5a1. It was reported that GPCR 
internalization via clathrin-coated pits was inhibited by expression of a dominant 
suppressor mutant of β-arrestin1. This mutant β-arrestin1 resulted in 50% 
reduction in receptor internalization. On the other hand, ligand-induced 
internalization of β2-adrenergic receptors was modestly increased when wild type 
β-arrestin1 was overexpressed. In addition, expression of dynamin mutant 
resulted in reduction of receptors sequestration by about 70% (Daaka et al., 1998, 
Ferguson et al., 1996, Zhang et al., 1996b). Thus, hC5a2 may compete for the 
internalization machinery proteins, such as β-arrestin1, dynamin, and so affect 
hC5a1 endocytosis. Therefore, hC5a1 did not continue to internalize and reached 
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plateau phase. In this case, hC5a2 is playing the role of a decoy receptor to 
prevent further inflammation that could lead to tissue damage. These findings are 
in agreement with the finding of Scola et al who demonstrated that C5a2 is a 
recycling decoy receptor (Scola et al., 2009). This has been suggested by several 
observations. First, C5a2 was completely unable to couple to G proteins even 
after inserting C5a1 motifs at the critical G protein activation sites. Second, C5a2 
could take up C5a and C5a desArg from the extracellular fluid and accumulated 
them within the cell through clathrin-dependent internalization. Then, these 
ligands were retained and degraded intracellularly. Nevertheless, C5a 
internalization by C5a1 was slower and it was released back to the extracellular 
environment without apparent degradation (Scola et al., 2009). Therefore, C5a2 
seems to play a role in removal of the active receptor agonist from the surrounding 
environment to probably prevent chronic inflammatory response.    
   
 One of the difficulties in exploring and clarifying the controversy around 
C5a2 function is the lack of selective ligands. Recently, peptides have been 
reported to selectively target C5a2 and thought to induce recruitment of β-
arrestin2 to C5a2 receptor (Croker et al., 2016). One of these peptides was used 
in the current study to explore its effect on C5a-mediated receptors internalization. 
This peptide did not show discernible effects in this test. This could be due to 
different β-arrestins subtypes being involved in receptor endocytosis. The 
expression of β-arrestin1 mutant resulted in inhibition of β2 adrenergic receptors 
internalization (Daaka et al., 1998). Therefore, internalization function of the 
receptors is mediated by different β-arrestin subtypes (β-arrestin1) from the one 
that is the peptides probably induce C5a2 receptor to work on (β-arrestin2). 
  The internalization of the receptors can also be used to assess potential 
physical interactions such as heterodimerization. This could be assessed by 
examining the possibility of co-internalization of the two receptors upon ligand 
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binding of either receptors (Figure 6.7). This concept was used to examine 










Figure 6.7: The concept of co-internalization of heterodimers upon stimulation of one 
receptor. If two receptors are working in dimers, internalization of both receptors should 
occur upon stimulation of either of them. The figure shows co-internalization of receptor 1 
(R1) and receptor 2 (R2) after using R1 ligand (a) or R2 ligand (b).  
 
 For example, internalization of δ-opioid receptors (DOP) was reported 
after stimulation of β-adrenergic receptors with isoproterenol when co-expressed 
together. This co-internalization was specific to DOP receptors because 
isoproterenol did not cause internalization of κ-opioid receptors (KOP) when co-
expressed with β-adrenergic receptors (Jordan et al., 2001). Similarly, co-
internalization of NK1 receptors and μ-opioid receptors (MOP) was detected 
when stimulating either receptors (Pfeiffer et al., 2003). To use this concept to 
explore hC5a receptors heterodimerization, hC5a1 receptor inhibitor PMX53 was 
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the outcome of such treatment (Figure 6.8). First, if the two receptors did not 
internalize this means that they are in dimer form and internalization of hC5a2 
was inhibited because it is in contact with hC5a1. Second, if both receptors 
internalized this may mean again that the receptors are in dimer form and hC5a1 
was internalized indirectly by hC5a2 internalization. Third, if hC5a1 receptor was 
inhibited and only hC5a2 internalized, this might suggest that they are not in 
dimer form or direct physical contact during the internalization process at least. 
What happened after treatment with C5a1 inhibitor PMX53 is that hC5a1 
internalization was inhibited, while hC5a2 was not, which supports the third 
possibility. However, this could be due to dissociation of surface receptor dimers 
that occurs after internalization. A similar scenario was suggested for the β-
adrenergic receptors (Lan et al., 2011). Nevertheless, previous chapters’ results 
suggested that the C5a receptors were not delivered to the cells surface as 
heterodimers.  



















Figure 6.8: The possibilities of C5a-induced C5a receptors internalization after pre-treatment 
with PMX53 C5a1 inhibitor. RBL cells co-expressing C5a1 and C5a2 receptors were pretreated 
with PMX53 for 10 minutes before adding C5a. If the two receptors did not co-internalize and 
both of them remained on the cell surface after inhibition C5a1 with PMX53, this means they 
are working in dimers and hindering one of the receptors prevented the interaliztion of the 
other one (a).  If the two receptors co-internalized, it means they are also working in dimers 
and internaliztion of C5a1 happened due to internaliztion of C5a2 (b). However, if C5a2 
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7 Chapter 7: The effect of C5a receptor interaction on signal 
transduction 
7.1 Introduction: 
In this chapter, the possible effect on signal transduction of co-expressing 
hC5a2 receptor with hC5a1 receptor on RBL-2H3 cells was explored using 
untagged wild type receptors. The possible receptor interaction was tested by 
examining various cellular responses. These involve ligand binding and the signal 
transduction of the receptors upon ligand stimulation such as intracellular Ca2+ 
mobilization and enzyme release from the RBL cells. The enzyme secretion was 
examined in RBL cells expressing either hC5a1, hC5a2 or both hC5a1+hC5a2 in 
response to C5a and compared to stimulation by IgE. The release assay was also 
used to test the possible effect of peptide that selectively target hC5a2 receptors 
(RHYPYWR), which is thought to be work through recruitment of β-arrestin 2 
(Croker et al., 2016). The effect of hC5a2 on hC5a1 was also examined using 
MAPK pathways assays.  MAPK pathways involve three well-characterized 
pathways that regulate many physiological processes in response to various 
stimuli such as inflammatory mediators and cytokines. These pathways include: 
the extracellular signal-regulated kinases (ERKs); the c-jun amino terminal 
kinases (JNKs); and the p38 pathway. These MAPKs are regulated by 
phosphorylation. The phosphorylated MAPKs can be measured using various 
techniques. In this chapter, the total and phosphorylated MAPKs were measured 
in response to C5a and C5a desArg treatment and compared in cells expressing 
either hC5a1 or both hC5a1+hC5a2 to examine the potential influence of hC5a2 
on hC5a1.   
Chapter seven Results 
139 
 
7.2  hC5a1 receptor expression assay: 
 The assay was done to compare the expression level of hC5a1 receptor on 
the RBL transfected with hC5a1 with or without hC5a2 receptor. The cells were 
treated with primary mouse anti-hC5a1 antibody for 1 hour and then stained with 
secondary antibody. The median fluorescent intensity was measures by flow 
cytometer and did not show difference between the two cell lines (Figure 7.1). 
The data show that hC5a1 receptor expression was similar in cells that express 
hC5a1 alone or hC5a1+hC5a2. 
 
 
Figure 7.1: Human C5a1 receptor expression. The graph shows the flow cytometric results of 
hC5a1 receptor stained with Alexa-633 anti-mouse antibody after treatment with primary 
mouse antihC5a1 antibody. Data are the mean±SEM of 3 independent experiments in 
duplicate. MFI, median fluorescence intensity. 
 
7.3 Ligand binding assay in RBL co-expressing hC5a1 and hC5a2 
receptors: 
The ligand binding assay was performed as described in section (2.3.2) to 
investigate the ligand binding affinity of cells that co-express both hC5a receptors 
in comparison to cells expressing hC5a1 alone. The result shows that the ligand 
binding affinity of RBL-RBL-hC5a1 and RBL-hC5a1+2 were nearly similar, 
IC50= 17.2 nM (-logIC50=7.763) and 13.1 nM (-logIC50=7.883), respectively 
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(Figure 7.2). This could be due the more intracellular localization of hC5a2 or 







Figure 7.2: C5a binding assay for RBL cells co-expressing hC5a1 and hC5a2 receptors using 
competitive fluorescent-labelled C5a binding assay. a. The graph shows the inhibitory dose 
response curves for the cells treated with mixtures of serial dilutions of unlabelled C5a with 
100 nM Alexa-488 labelled C5a. b. Bar chart for the IC50. Data are the mean±SEM of 3 
independent experiments in duplicate. 
 
7.4 Intracellular Ca2+ mobilization assay: 
 This test was used to test the signalling of the hC5a1 receptor at the level 
of intracellular Ca2+ release in the presence or absence of hC5a2 receptor. The 
test was performed as described in section (2.3.3). There was no obvious 
difference in response in ligand stimulation in the presence or absence of hC5a2 
with approximately similar EC50 1.67 nM and 1.40 nM for hC5a1 and hC5a1+2 









Intracellular Ca2+ mobilization assay  





Figure 7.3: Intracellular Ca2+ mobilization assay for RBL cells co-expressing hC5a1 and hC5a2 
receptors. a. The stimulatory dose response curves show the intracellular Ca2+ response to 
serial dilutions of C5a. C5a was added after 20 second of measuring basal fluorescence. b. the 
EC50 bar chart. Data are the mean±SEM of 3 independent experiments in duplicate. 
 
7.5 Enzyme release assay for RBL-hC5a1+hC5a2:  
 The effect of hC5a2 receptor co-expression with hC5a1 was further 
explored by testing another functional response, the ligand-induced degranulation. 
RBL cells, which express both hC5a1 and hC5a2, were tested for β-
hexosaminidase enzyme release after stimulation with C5a for 15 minutes. Two 
control cell lines were used, RBL cells expressing either hC5a1 or hC5a2 
receptors. There was a significant difference in maximum enzyme release 
between cells expressing both hC5a1+hC5a2 receptors from those who 
expressing only hC5a1, while cells expressing only hC5a2 receptor showed no 
response to C5a in terms of enzyme release (Figure 7.4).  
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 The enzyme release property of RBL cells in response to C5a was then 
compared to enzyme release in response to IgE sensitization. This was performed 
to check if the difference in enzyme release was specific to the C5a stimulation 
and whether hC5a1 expression renders the cells more sensitive to all 
degranulation stimuli. The same cell lines, RBL-hC5a1 and RBL-hC5a1+hC5a2, 
were tested for IgE-mediated enzyme release. The pattern of enzyme release was 
similar to the C5a-mediated response i.e. the hC5a1 alone expressing cells 
showed higher enzyme release in comparison to cells co-expressing both 
receptors (Figure 7.5 a). Furthermore, the IgE-mediated enzyme release was 
explored for RBL cells expressing either no receptors (non-x) or other receptors 
such as hC5a2, hC3a and hC5a1.  The results demonstrated that hC5a1 receptor 
expressing cells always have the highest percentage of enzyme release in 
comparison to other cell lines (Figure 7.5 c). However, the co-expression of 
hC5a2 with hC5a1 decreased the enzyme release to the levels of RBL-non-x cells. 
These data suggest that hC5a1 receptor expression could increase the sensitivity 
of RBL cells for degranulation and it could exert a constitutive activity that is 
increased upon stimulation and that the co-expression of hC5a2 with hC5a1 
decreases this sensitivity to the basal level. The constitutive activity of hC5a1 
could be expected because hC5a1 was reported to be pre-coupled to G proteins 














Enzyme release assay for RBL cells  







Figure 7.4: C5a-mediated enzyme release assay for RBL cells express both hC5a1 and hC5a2. 
a. Dose response curve for hC5a receptors. Enzyme release was measured in response to 1/3 
serial dilutions of hC5a starting with 2 µM. b. and c. bar charts for the EC50 and maximum 
enzyme release, respectively. Data are mean±SEM from 3 independent experiments in 
duplicate triplicate. Unpaired t test was used to test statistical significance. **, P ≤ 0.01. 
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Figure 7.5: IgE-mediated degranulation assay for RBL cells expressing different receptors. a. 
comparison between hC5a1 alone or hC5a1+2 transfected RBL cells. b. Bar chart for maximum 
enzyme release from the cells in graph (a). t test was used. c. Comparison between 
untransfected RBL (non-X), hC5a1, hC5a2, and hC3a receptors. d. Bar chart for maximum 
enzyme release from the cells in graph (c). One way ANOVA was used to test statistical 
significance. Data are mean±SEM from 3 independent experiments in duplicate. 
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7.6 C5a-induced enzyme release assay in presence of peptide RHYPYWR:  
 The same enzyme release assay was performed but in this case the cells 
were pre-incubated with 100 µM peptide RHYPYWR (a selective agonist for 
hC5a2 receptor) for 10 minutes before treatment with C5a. The idea is to see if 
there is any effect of this peptide on cells expressing hC5a2 receptor in addition 
to hC5a1. There is no obvious difference in enzyme release between RBL cells 
that express both hC5a1+hC5a2 or only hC5a1, when treated with either peptide 







Figure 7.6: Enzyme release assay for RBL cells express both hC5a1 and hC5a2 (a) or hC5a1 (b) 
in the presence of peptide RHYPYWR. Cells were pre-incubated with 100 µM peptide 
RHYPYWR for 10 minutes before adding C5a. Enzyme release was measured in response to 
1/3 serial dilutions of hC5a starting with 1 µM. Data are mean±SEM from 3 independent 
experiments in duplicate. 
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7.7 MAPK signalling: 
The effect of hC5a2 expression on hC5a1 signalling was further analysed 
using MAPK signalling pathways. The three major MAPK signalling pathways 
(ERK1/2, P38 and JNK) were tested after treatment with C5a or C5a desArg. The 
results were as follows: 
7.7.1 C5a-mediated MAPK signalling: 
7.7.1.1 ERK1/2 phosphorylation assay: 
The C5a-mediated ERK1/2 activation was measured in RBL cells 
expressing hC5a1 alone or co-expressing both hC5a1+hC5a2 receptors. The cells 
were stimulated with C5a at 0.5 µM for 5, 10, 15 minutes. The phosphorylation 
of ERK1/2 increased from 5 minutes in both cell lines (Figure 7.7 a and b). 
However, the phosphorylated ERK1/2 was lower in cells co-expressing 
hC5a1+hC5a2 receptors (Figure 7.7 c).









Figure 7.7: C5a-mediated ERK1/2 phosphorylation assay. RBL cells expressing either hC5a1 (a.)  
or both hC5a1+2 receptors (b.) were used. Cells were incubated with 0.5 µM C5a for different 
time points. Phosphorylated (p-ERK1/2) and total ERK1/2 (pan ERK1/2) were measured using 
cell-based ELISA assay. c. The percentage of ERK1/2 phosphorylation was compared between 
hC5a1 alone or hC5a1+2 cell lines. Data are mean±SEM from 3 independent experiments in 
duplicate. Two-way ANOVA with Sidak’s multiple comparison test were used to test statistical 
significance. *, P≤0.05 and **, P≤0.01. 




7.7.1.2 p38 phosphorylation assay: 
The p38 phosphorylation assay was performed using hC5a1 alone or 
hC5a1+2 RBL cell lines after incubation with 0.5 µM C5a. The phosphorylated 
and total p38 were measured at different time points. The activation of p38 
pathway in RBL-hC5a1+2 was lower than RBL cells expressing hC5a1 alone 
after 10 and 15 minutes treatment (Figure 7.8).









Figure 7.8: C5a-mediated p38 phosphorylation assay. RBL cells expressing either hC5a1 (a.)  or 
both hC5a1+2 receptors (b.) were used. Cells were incubated with 0.5 µM C5a for different 
time points. Phosphorylated (p-p38) and total p38 (pan-p38) were measured using cell-based 
ELISA assay. c. The percentage of p38 phosphorylation was compared between hC5a1 alone 
or hC5a1+2 cell lines. Data are mean±SEM from 3 independent experiments in duplicate. Two-
way ANOVA with Sidak’s multiple comparison test were used to test statistical significance. 
**, P≤0.01. 




7.7.1.3 JNK phosphorylation assay: 
The phosphorylation of JNK was examined in hC5a receptors expressing 
RBL cells after stimulation with C5a 0.5 µM. The phosphorylated and total JNK 
were measured at several time points.  There were no significant changes in JNK 
phosphorylation on both cell lines at all time course (Figure 7.9).









Figure 7.9: C5a-mediated JNK phosphorylation assay. RBL cells expressing either hC5a1 (a.)  or 
both hC5a1+2 receptors (b.) were used. Cells were incubated with 0.5 µM C5a for different 
time points. Phosphorylated (p-JNK) and total JNK (pan JNK) were measured using cell-based 
ELISA assay. c. The percentage of JNK phosphorylation was compared between hC5a1 alone 
or hC5a1+2 cell lines. Data are mean±SEM from 3 independent experiments in duplicate. Two-
way ANOVA with Sidak’s multiple comparison test were used to test statistical significance. 
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7.7.2 C5a desArg-mediated MAPK signalling: 
7.7.2.1 ERK1/2 phosphorylation assay: 
The ERK1/2 phosphorylation assay was performed as described in section 
2.3.8. The cells were stimulated with 0.5 µM C5a desArg for 15 minutes. The 
effect of hC5a2 receptors expression was observed using RBL cells co-expressing 
both hC5a1 and hC5a2 receptors and compared with cells expressing only hC5a1 
receptors. The cells that co-express both receptors showed less ERK1/2 










Figure 7.10: C5a desArg-mediated ERK1/2 phosphorylation assay. RBL cells expressing either 
hC5a1 (a.)  or both hC5a1+2 receptors (b.) were used. Cells were incubated with 0.5 µM C5a 
desArg for 15 minutes. Phosphorylated (p-ERK1/2) and total ERK1/2 (pan ERK1/2) were 
measured using cell-based ELISA assay. c. The percentage of ERK1/2 phosphorylation was 
compared between hC5a1 alone or hC5a1+2 cell lines. Data are mean±SEM from 3 
independent experiments in duplicate. Two-way ANOVA with Sidak’s multiple comparison test 
were used to test statistical significance. **, P≤0.01. 
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7.7.2.2 p38 phosphorylation assay: 
C5a desArg was used to measure p38 signalling pathway in cells co-
expressing hC5a1+hC5a2 and compared with RBL-hC5a1. At 15 minutes 
stimulation with 0.5 µM C5a desArg, the difference in phosphorylated p38 












Figure 7.11: C5a desArg-mediated p38 phosphorylation assay. RBL cells expressing either 
hC5a1 (a.)  or both hC5a1+2 receptors (b.) were used. Cells were incubated with 0.5 µM C5a 
for 15 minutes. Phosphorylated (p-p38) and total P38 (pan-p38) were measured using cell-
based ELISA assay. c. The percentage of p38 phosphorylation was compared between hC5a1 
alone or hC5a1+2 cell lines. Data are mean±SEM from 3 independent experiments in 
duplicate. Two-way ANOVA with Sidak’s multiple comparison test were used to test statistical 
significance. 
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7.7.2.3 JNK phosphorylation assay: 
The JNK activation pathway was also tested in response to C5a desArg 
stimulation. Like C5a treatment, C5a desArg treatment did not induce 











Figure 7.12: C5a desArg-mediated JNK phosphorylation assay. RBL cells expressing either 
hC5a1 (a.)  or both hC5a1+2 receptors (b.) were used. Cells were incubated with 0.5 µM C5a 
for different time points 15 minutes. Phosphorylated (p-JNK) and total JNK (pan JNK) were 
measured using cell-based ELISA assay. c. The percentage of JNK phosphorylation was 
compared between hC5a1 alone or hC5a1+2 cell lines. Data are mean±SEM from 3 
independent experiments in duplicate.  
 
Chapter seven Results 
155 
 
7.7.3 Comparison between C5a and C5a desArg effect on MAPK 
phosphorylation assay: 
To show the effect of different ligand treatments on the MAPK pathways 
activation, the C5a-mediated MAPK signalling was plotted with C5a desArg-
mediated MAPK signalling. These treatments were compared between the two 
cell lines, RBL-hC5a1 alone and RBL-hC5a1+2 (Figure 7.13). Both C5a and C5a 
desArg stimulated ERK1/2 phosphorylation in RBL cells expressing hC5a1 
alone, which was abolished when hC5a2 co-expressed with hC5a1 receptor 
(Figure 7.13 a and b).  
Although it did not reach statistical significant at 15 minutes stimulation, 
ERK1/2 phosphorylation after C5a desArg treatment was less than C5a treatment 
in RBL-hC5a1 cells (Figure 7.13 a). However, RBL hC5a1+2 did not show any 
observed difference (Figure 7.13 b). This is because C5a1 receptor has lower 
affinity for C5a desArg than C5a, while C5a2 binds C5a and C5a desArg in nearly 
similar affinity (Scola et al., 2007). 
All other MAPK pathways did not show differences in response to different 
treatments (Figure 7.13 c, d, e and f).   
 





Figure 7.13: Ligand-induced MAPK phosphorylation assay. RBL cells expressing either only 
hC5a1 or both hC5a1 and hC5a2 were used. The ERK1/2 (a, b); p38 (c, d); and JNK (e, f) 
signalling was measured after 15 minutes C5a or C5a desArg stimulation. Data are mean±SEM 
from 3 independent experiments in duplicate. Two-way ANOVA with Sidak’s multiple 
comparison test were used to test statistical significance. *, P≤0.05 and **, P≤0.01. 




In this chapter, untagged receptors were used to explore the possible 
signalling interactions between hC5a1 and hC5a2. Although both receptors have 
the seven-transmembrane domains of GPCR, C5a1 can productively couple with 
G proteins, while C5a2 cannot (Cain and Monk, 2002, Okinaga et al., 2003). This 
is confirmed in this study by  showing that hC5a2 receptor failed to induce 
degranulation, which is a known function of some G protein-coupled receptors 
(GPCR) found predominantly in mast cells, basophils, neutrophils and 
macrophages (Vines and Prossnitz, 2004). This was thought to be due to the lack 
of the DRY and NPXXY motifs, which are the highly-conserved motifs among 
GPCR. In C5a2 receptor, a DLC motif replaces the DRY in the third 
transmembrane domain. The arginine residue appeared to have important role in 
interaction with G proteins. In several receptors, such as histamine H2, CCR5, 
FPR, the mutation of the arginine residue greatly affects their G proteins binding 
capabilities (Prossnitz et al., 1999, Alewijnse et al., 2000, Rovati et al., 2007, 
Lagane et al., 2005). When the leucine is mutated to arginine in C5a2, the receptor 
partially regains the ability to bind to Gα16 when co-expressed in HEK cells and 
low level of Ca2+ mobilization was induced (Okinaga et al., 2003). However, 
when C5a2 mutant at this motif transfected into RBL, other study reported that G 
protein coupling potential is completely absent in C5a2 even when the C5a1 G 
protein coupling motifs were inserted and no Ca2+ signalling was observed in 
response to C5a or C5a desArg (Scola et al., 2009). Therefore, the present study, 
in addition to others mentioned above, suggest a comprehensive inability of the 
C5a2 receptor to induce G protein signalling. 
 The expression of hC5a1 receptor in RBL caused a high percentage of 
enzyme secretion upon stimulation with C5a. In addition, hC5a1 receptor 
increased the sensitivity of RBL cells for degranulation in response to other 
stimuli such as IgE. However, when hC5a2 was co-expressed in RBL cells with 
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hC5a1, the hC5a1-mediated enzyme release was decreased significantly. This 
may suggest that hC5a2 receptors can possibly modulate the signalling of hC5a1 
receptor. This effect could be through signalling pathway that does not involve G 
protein coupling because C5a2 lacks the ability to activate G proteins. This result 
is in agreement with the reports that demonstrated that C5a2 can modulate C5a1 
signalling (reviewed in Li et al., 2013, Bamberg et al., 2010). Bamberg and 
colleagues suggested a model in which C5a2 affects the C5a1 signalling through 
β-arrestin. Translocation of β-arrestin in response to C5a2 was reported in HEK 
cells transfected with C5a2 (Kalant et al., 2005, Croker et al., 2014, Croker et al., 
2016) and in polymorphonuclear cells (Bamberg et al., 2010). It has been 
postulated that both C5a1 and C5a2 receptors are phosphorylated by G protein 
receptor kinases (GRKs) after ligand binding of C5a1 receptors. This triggers β-
arrestin association. The binding of β-arrestin to C5a1 activates ERK1/2, while 
C5a2- β-arrestin association inhibits ERK1/2 signalling. The final signal depends 
on the net signal of the two pathways (Bamberg et al., 2010). 
The possible role of hC5a2 on hC5a1 mediated degranulation was further 
examined by using the hC5a2 selective peptide. However, this peptide did not 
show effect on C5a-mediated degranulation in RBL cells that co-express hC5a2 
and hC5a1 receptors. This could be due to the β-arrestin subtype that is involved 
in enzyme release signalling. It was reported that silencing β-arrestin1 inhibited 
degranulation in mast cell in response to C3a (Vibhuti et al., 2011). The C5a2 
selective peptide was reported to cause translocation of β-arrestin2 towards C5a2. 
Therefore, the difference in the target protein (β-arrestin) subtypes could explain 
the results of the present study.  
 The present study illustrated that although the cells that co-expressing both 
C5a1 and C5a2 showed less enzyme release, the intracellular Ca2+ mobilization 
response was similar. This might indicate that the effect of C5a2 intervention is 
occurring at a later event after Ca2+ mobilization or through alternative pathway 
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and that Ca2+ mobilization is not the only trigger for degranulation. It has been 
shown that some GPCR respond differently after Ca2+ mobilization. For example, 
after stimulation of formyl peptide receptors (FPR) and adenosine type 3 
receptors (A3R), inositol triphosphate (IP3) was produced through a pertussis 
toxin sensitive Gαi-mediated pathway. This led to Ca2+ signalling in response to 
both stimulated receptors. However, degranulation was different in response to 
activation of each receptor. The FPR stimulation induced degranulation in RBL 
cells, while A3R did not (reviewed in Vines and Prossnitz, 2004) (Figure 7.14). 
Therefore, intracellular Ca2+ mobilization could be necessary but not sufficient to 






Figure 7.14: The relation between Ca2+ response and degranulation. a. Upon ligand binding, 
both FPR and A3R stimulated IP3 production and then Ca2+ response. However, FPR induced 
degranulation, while A3R did not. b. Similarly, RBL cells that expressing hC5a1 only or co-
expressing hC5a1+2 induced Ca2+ response. However, the cells that co-expressing both 
hC5a1+2 showed impaired degranulation. FPR, formyl peptide receptors. A3R, adenosine type 
3 receptors. IP3, inositol triphosphate. 
 




        C5a is known to induce MAPK activation (Riedemann et al., 2004, Maeda 
et al., 2015). Three distinct intracellular signaling pathways are involved in 
MAPK activation. These involve ERK1/2, p38 and JNK (Widmann et al., 1999). 
They are a family of kinases that are activated by a series of protein kinase 
reactions (Widmann et al., 1999). MAPK activation was found to be related to 
increase IL6 and TNF-α production (Riedemann et al., 2004, Clemente et al., 
2015, Choi et al., 2015, Fehr et al., 2015, Yang et al., 2015). In addition, they are 
involved in chemotactic migration of macrophages after stimulation with C5a 
(Chiou et al., 2004). These effects were thought to be predominantly through the 
ERK1/2 and p38 pathways, although JNK phosphorylation was found to be 
nonessential (Chiou et al., 2004). Another study has demonstrated that C5a 
induced the phosphorylation of MAPK but not p38 (Francis et al., 2008). Taken 
together, these findings agree with findings of the current study, which 
demonstrated that C5a and C5a desArg stimulated the phosphorylation of 
ERK1/2, but not p38 or JNK. 
 
C5a-mediated ERK1/2 phosphorylation was reported to be decreased in 
bone marrow-derived macrophages from C5a1-/- and C5a2-/- mice and the 
depletion of C5a2 was thought to ameliorate the acute inflammation in mice with 
induced colitis (Hsu et al., 2014). However, inhibiting MAPK signaling pathways 
could also have an anti-inflammatory effect by inhibiting cell migration (Tsai et 
al., 2004). In the present study, the co-expression of hC5a2 with hC5a1 resulted 
in a decrease in MAPK signalling and enzyme release, which may support the 
idea of a modulatory effect of hC5a2 on hC5a1 signalling. The results of the 
current study are supported by the findings of two other groups. The blockade of 
C5a2 was found to be associated with a dramatic increase in C5a-mediated 
ERK1/2 phosphorylation in human PMNs (Bamberg et al., 2010). In addition, in 
human monocyte-derived macrophages, C5a2 was suggested to modulate 
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ERK1/2 signalling at C5a concentrations that could induce C5a1 and C5a2 
interactions (Croker et al., 2014). In both publications, this modulatory effect was 
thought to involve β-arrestins. Therefore, C5a2 could play distinct roles in 
different environments or disease conditions, which may explain the diverse and 
conflicting reports regarding its function. 
In the current study, the ERK1/2 signalling was affected by the co-
expression of hC5a2 with hC5a1, whereas the Ca2+ signalling was not. This could 
suggest that the signalling via ERK1/2 and Ca2+ is through separate pathways. 
The C5a2 effect might be through β-arrestin rather than G proteins. Other studies 
also reported similar findings. C5a2 blockade was demonstrated to increase in 
ERK1/2 phosphorylation, while Ca2+ mobilization was not affected (Bamberg et 
al., 2010).  
To sum up, the co-expression of hC5a2 with hC5a1 seems to affect the 
functions of hC5a1 differentially. The effect was mainly on the ERK1/2 
signalling and the degranulation, while Ca2+ response was spared. Therefore, it 
could be speculated that the MAPK signalling is one of the factors that could be 
involved in degranulation in RBL cells. In addition, the MAPK pathway may be 















Figure 7.15: The possible hC5a1 signalling pathways that are affected by the hC5a2. In RBL 
cells that express only hCa1, the Ca2+, ERK1/2 and degranulation response were normal (a). 
However, in RBL-hC5a1+2, the ERK1/2 and degranulation responses were decreased, while 
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8 Chapter 8: General discussion 
During the inflammatory process, many inflammatory mediators are released 
such as the anaphylatoxins, C3a and C5a. In normal conditions, the effects of 
these mediators are controlled after the removal of the danger that triggers the 
inflammatory reaction. However, in some cases the inflammatory process 
continues and results in a chronic destructive process.  
The complement system plays important roles in many inflammatory diseases. 
Complement involvement, including C5a, has been reported in many diseases 
(see section 1.6). Therefore, studying and understanding factors that are involved 
in the inflammatory process may be of great help to decrease the morbidity and 
mortality of affected patients. One of the central factors is the release of 
anaphylatoxins both locally in inflamed tissues and systemically. This study deals 
with the paramount anaphylatoxin, complement fragment C5a. This protein is 
produced during the activation of the complement cascade in inflammatory 
conditions and is known to have a proinflammatory function through its classical 
receptor, C5a1. Nevertheless, anti-inflammatory effects of C5a has been also 
reported (Bosmann et al., 2012, An et al., 2016). A second receptor for C5a, C5a2, 
was then discovered, but its function is still complex and controversial. The C5a 
receptors are among the large GPCR family that is characterised by heptahelical 
transmembrane domains connected by intracellular and extracellular loops. These 
receptors have significant physiological functions and are major pharmacological 
targets.   
 The RBL cell line was used as a model to study C5a receptors functions and 
interaction. In this study, a cell culture model represented by rat basophilic 
leukaemia cell line stably expressing human complement C5a receptors was used. 
This cell line has been widely used for studying GPCR signalling and functions. 
It was used to test the response of expression of  wild type or mutant human C5a1 
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receptors by measuring several cellular responses such as intracellular Ca+2 
mobilization, actin polymerization (Monk et al., 1994b, Cain and Monk, 2002), 
and granule release such as serotonin (Monk et al., 1994a), hydroxytryptamine 
(Monk et al., 1994b) and hexosaminidase (Cain and Monk, 2002). Therefore, in 
the current study, this cell line was used to measure various C5a receptors 
responses using wild type and tagged receptors. In addition, the behaviour of 
hC5a1 receptor when co-expressed with hC5a2 was also explored, which could 
reflect the in vivo situation where the two receptors are expressed concomitantly.   
The C5a1-mediated degranulation is probably a multifactorial signalling 
pathway, Ca2+ and MAPK signalling could be among these factors. Ligand 
binding to GPCR results in G proteins and/or β-arrestin activation that leads to a 
cascade of signalling steps, which result in various functions for the receptors. 
These signalling steps involve Ca2+ mobilization, MAPK activation and 
degranulation in some immune cells. Many reports investigated the link between 
these signalling pathways or the dependence of these signalling events on each 
other. In the current study, the signalling of human C5a receptors was explored 
in RBL cells expressing various types of these receptors. This study found that 
when the Ca2+ signalling was disturbed for various reasons, the degranulation was 
disturbed. This was the case for the FP-tagged hC5a1 receptors in chapter 3. 
However, the degranulation was disturbed even when the Ca2+ signalling was 
normal as in the case of cells co-expressing untagged hC5a1 and hC5a2 receptors. 
This may suggest that Ca2+ signalling is necessary for degranulation from RBL 
cells but not sufficient and that the degranulation is stimulated through complex 
and multifactorial pathways (Figure 8.1). It has been shown that inhibition of Ca2+ 
influx resulted in inhibition of degranulation in RBL cells (Tanifuji et al., 2010, 
Ito et al., 2002). In addition, many antiallergic drugs exert their inhibitory effect 
on degranulation via the inhibition of Ca2+ influx (Kim et al., 2008, Matsubara et 
al., 2004, Paulussen et al., 1998, Fischer et al., 1998, Spataro and Bosmann, 
Chapter eight General discussion 
166 
 
1976). Furthermore, IgE-mediated Ca2+ mobilization and degranulation was 
almost completely inhibited after chelating Ca2+ with EGTA (Ozawa et al., 1993, 
Nishida et al., 2005). Therefore, impairment of degranulation could result from 
defects in Ca2+ mobilization, albeit degranulation could be affected by other 
factors when the Ca2+ response is normal. 
 
a.                                            b.                                         c. 
 
Figure 8.1. The multifactorial nature of degranulation signalling pathway. When the Ca2+ and 
other factors are normal, the degranulation is normal (a). If the Ca2+ response is disturbed 
(red), the degranulation is disturbed (red) (b). If the Ca2+ response is normal but one of the 
other factors is disturbed, for example F2 (red), the degranulation is disturbed (red) (c). 
 
 Other factors that may affect degranulation could be the MAPK signalling. 
The role of MAPK  signalling  in eicosanoids release and cytokine production 
was reported (Gilfillan and Tkaczyk, 2006) but its role in degranulation is a 
controversial subject. The release of histamine from mast cells or human 
basophils was reported to be not regulated by MAP kinases (Stempelj and Ferjan, 
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2005, Miura et al., 1999). On the other hand, correlation between ERK 
phosphorylation and granule release was demonstrated in RBL cells (Hanson and 
Ziegler, 2002), and mast cells (Choi and Kim, 2004, Koo et al., 2006). This could 
be in support of the current study as the co-expression hC5a2 with hC5a1 resulted 
in lower ERK1/2 signalling in addition to decrease in enzyme release.   
 
The GPCR internalization plays several roles in many biological processes. 
It has been suggested that receptors internalization has implications for β2 
adrenergic receptors re-sensitization after their desensitization (Lefkowitz, 1996, 
Lefkowitz, 1998). In addition, it is an important step in MAPK activation by the 
receptors. When β2 adrenergic receptors co-expressed with κ opioid receptors, 
isoproterenol-mediated β2 trafficking and MAPK activation were lost. 
Furthermore, when internalization inhibited by the expression of β-arrestin1 and 
dynamin mutants, β2 adrenergic receptors-mediated MAPK signaling was 
attenuated without affecting the early plasma membrane-delimited signaling 
events (Daaka et al., 1998). On the same manner, in the current study, the hC5a1 
receptor internalization was decreased when co-expressed with hC5a2.  This may 
explain the decrease in MAPK activation and enzyme release when both hC5a1 
and hC5a2 are co-expressed on RBL cells. 
     Human C5a1 receptors possibly exist at the cell surface in homodimers or 
oligomers. GPCR were first believed to work as monomeric entities, which after 
ligand binding can activate G proteins. However, a growing body of evidence 
suggests that they may exist or function as dimers or oligomers (Devi, 2001, 
Milligan, 2004, Prinster et al., 2005, Pin et al., 2007, Dalrymple et al., 2008, 
Milligan, 2009, Vischer et al., 2011, Maurice et al., 2011). In the present study, 
the possibility of hC5a receptor homo- and heterodimerization was investigated. 
Using the FRET technique, hC5a1 receptors showed possible homodimerization, 
which is in agreement with other reports that used co-immunoprecipitation to 
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detect C5a1 homodimers in HEK cells (Rabiet et al., 2008). It is also possible that 
the FRET signal that was detected in the present study resulted from oligomer 
formation by hC5a1 and not only dimers. This can be supported by the findings, 
of  Klco et al., 2003, which proposed the formation of hC5a1 high-order 
oligomers using disulphide-trapping (Klco et al., 2003). In addition, using hC5a1 
receptors expressed on Saccharomyces cerevisiae, Floyd et al., 2003 showed that 
hC5a1 receptor oligomerization did not require mammalian accessory proteins 
(Floyd et al., 2003). That is because the lower eukaryote organism used in that 
study does not express potential scaffolding proteins such as arrestins and 
caveolins that might play a role in GPCR oligomerization. Furthermore, hC5a1 
receptor oligomerization was found to be constitutive and was not significantly 
affected by G proteins. Moreover, these hC5a1 oligomers were believed to be 
formed early in their biosynthesis, probably at the level of endoplasmic reticulum, 
because the oligomerization signal was detected in yeast endoplasmic membranes 
similar to the levels detected on the plasma membranes (Floyd et al., 2003). This 
may suggest early formation of oligomers that are delivered to the cell surface as 
oligomers and do not need interaction with other intracellular proteins. Therefore, 
the tagged receptors that were used in this study, which perhaps exerted poor 
interaction with intracellular proteins as appeared from the disturbance in some 
of their signalling properties, could still be used to explore receptor dimerization 
or oligomerization. In addition, Floyd et al. reported that the level of receptors 
self-association was not affected by ligand stimulation. The same result was 
observed in the current study, which suggests constitutive 
dimerization/oligomerization.  
         Human C5a receptor heterodimerization could not be detected in this study. 
Although the FRET technique confirmed the homo-di/oligomerization of hC5a1, 
it did not indicate heteromerization with C5a2. The BRET technique was also 
used to explore possible hC5a1 and hC5a2 association. This technique has the 
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advantage of avoidance of excitation of the donor because the donor in this 
method is an enzyme that can emit light directly after interaction with its 
substrate. Therefore, the side effects of using an external light source such as 
direct excitation of the acceptor will have no role in such experiments. Although 
this technique has been used previously to detect C5a receptor heterodimerization 
(Poursharifi et al., 2013, Croker et al., 2013), in the current study this 
heterodimerization could not be detected. This could be due to different 
experimental conditions such as the cell lines. The use of different cell lines, 3T3-
L1 adipocytes and J774 macrophages, showed different effects in one study 
(Poursharifi et al., 2013). The ligand-dependent colocalization of C5a1 and C5a2 
was observed in 3T3-L1 adipocytes. However, in J774 macrophages, little and 
transient C5a-dependent colocalization was observed. Furthermore, the C5a1 and 
C5a2 colocalization in macrophages was increased by the use adipocyte-
conditioned medium (Poursharifi et al., 2013).  
 The potential dimerization interaction between hC5a1 and hC5a2 receptors 
was then explored with a different technique that uses untagged C5a receptor co-
internalization. There are many examples of receptor dimerization measured 
using such a technique (reviewed in Milligan, 2004).  In this study, C5a1 receptor 
inhibitor (PMX53) was used to make hC5a2 receptor selectively bind C5a. If 
hC5a1 is in direct physical contact with hC5a2 (heterodimers), it is expected that 
either both receptors internalize upon internalization of hC5a2 or both of them  
are inhibited from internalization due to the effect of PMX53 on hC5a1. The 
result was that hC5a1 did not co-internalize with hC5a2 after treatment with 
PMX53, which suggests no physical contact between the two receptors. This 
confirms the FRET and BRET results of this study, which suggest that hC5a1 and 
hC5a2 heterodimerization does not occur in RBL cells. In addition, other studies 
could not detect interaction between C5a2 and the classical anaphylatoxin 
receptor C5a1 (Chen et al., 2007). Therefore, other possible mechanisms may 
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explain the effect of C5a2 on C5a1 signalling, which could be through 
contribution to signalling in parallel with the classical receptor. For example, in 
rat astrocytes, C5a2 was shown to be regulated with noradrenaline and was found 
to have anti-inflammatory function (Gavrilyuk et al., 2005). In addition, the co-
expression of β2 adrenergic receptors with κ opioid receptors resulted in loss of 
MAPK activation and β2 adrenergic receptor internalization. However, the cells 
were still able to activate adenylyl cyclase. This is in support of the results of the 
current study, which showed a decrease in MAPK activation and hC5a1 
internalization when hC5a2 was co-expressed with C5a1, although the Ca2+ 
signalling was not affected. This variability in the effects of hC5a2 on hC5a1 
could explain some of the variability of the function of C5a2 in the literature.  
 
C5a1 receptor self-association could prevent or compete with association 
with hC5a2. The GPCR are thought to form dimers or oligomers through 
specialized structures. These could be disulphide bonding (Romano et al., 1996, 
Kunishima et al., 2000)  or interaction of the carboxy-terminal (coil-coil) 
(Margeta-Mitrovic et al., 2000). The dopamine D2 receptors were shown to 
crosslink through disulphide-trapping experiments (Guo et al., 2003b). This 
crosslinking was abolished by a single cysteine substitution on TM4. Using the 
same method, it was proposed that C5a1 receptors crosslinking is mediated by a 
cysteine in the IC2 loop (klco et al., 2003). The disulphide bond is the strongest 
bond that plays an essential role in protein stability and folding. If the C5a1 
receptor forms these bonds before its delivery to the cell membrane, then it could 
be speculated that ligand addition cannot change the level of receptor interaction 
as found in this study and others (Floyd et al., 2003, Rabiet et al., 2008). In 
addition, this could suggest that the C5a1 receptor self-association using their IC2 
cysteine residues in disulphide bonding, which occurs early in their biosynthesis 
(at the level of ER), might render this IC2 cysteine residue not available for other 
interactions to form heteromers with C5a2. This could explain tendency of the 
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C5a1 receptors to homo-di/oligomerize rather than heterodimerize in the present 
study. 
 
Receptor interaction is not necessarily through the formation of heterodimers. 
The theory of the possibility of cooperation of GPCR is thought to be not 
necessarily due to the dimerization. In fact, the relevance of such observations 
has been questioned and alternative interpretations have been suggested (Chabre 
et al., 2003, Chabre and le Maire, 2005, James et al., 2006, Gurevich and 
Gurevich, 2008, Chabre et al., 2009). Although it was suggested that many GPCR, 
especially group A, are capable of dimerization, the monomeric forms were 
shown to bind G proteins efficiently (Bayburt et al., 2007, Whorton et al., 2007, 
Ernst et al., 2007). Using pharmacological studies, when two receptors are co-
expressed, the ligand binding of one receptor can affect the affinity of the other 
receptor for its ligand, both positively and negatively. This was originally thought 
to be due the formation of heterodimers with the ligand of the first receptor having 
an allosteric effect on the second ligand-receptor interaction. However, this has 
been argued that this interaction could be interpreted in different way (Chabre et 
al., 2009).  It was thought that this apparent interaction could be due to interaction 
of the receptors with a shared G protein pool and not due to direct cross talk 
between the two receptors. In another word, it is due to simultaneous talk to the 
same G protein (Chabre et al., 2009). In addition, G proteins are not the sole 
mechanism that can affect receptor behaviour and arrestins could also play a role. 
It has been reported that arrestins can affect the ligand binding affinity of some 
GPCR (Gurevich et al., 1997). In addition, some GPCR have been shown to 
compete for arrestins (Schmidlin et al., 2002). In the current study, C5a2 could 
affect C5a1 indirectly through interaction with and/or competing for a β-arrestin 
pool. The association of β-arrestin 1 and 2 with C5a2 was reported using co-
immunoprecipitation and BRET techniques (Bamberg et al., 2010, Croker et al., 
2014). In addition, C5a2 was found to co-localize with β-arrestin and C5a1 
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intracellularly. Moreover, C5a-mediated ERK1/2 and chemotaxis signalling was 
increased upon C5a2 blockade, whereas Ca2+ was not (Bamberg et al., 2010). 
This could suggest a C5a2 role in the modulation of C5a1 signalling through the 
β-arrestin pathway. 
  
The C5a2 receptor could work as a scavenging decoy receptor. The 
anaphylatoxin C5a is thought to be removed from the circulation rapidly because 
its half-life is only 2-3 minutes, mainly due to C5a desArg formation (Webster et 
al., 1982, Weisdorf et al., 1981). This prompt removal mechanism may involve 
the participation of classical C5a receptor, C5a1 (Oppermann and Gotze, 1994). 
However, the lately discovered C5a2 receptor could play a role in this clearance 
mechanism. This could be due to the high affinity of C5a2 for C5a desArg and 
the lack of signal transduction capability. C5a2 could behave in similar way to 
that of the chemokine scavenging decoy receptor D6. Although it binds to several 
chemokines, D6 receptor cannot transduce G protein signals. However, it can 
carry ligands from the extracellular to the intracellular compartment through 
constitutive internalization. The ligand is then dissociated and degraded. Later, 
the receptor recycles back to the cell surface. The recycling mechanism is similar 
to that used by conventional G protein-coupled receptors that involves clathrin 
and arrestin (Galliera et al., 2004, Weber et al., 2004).  The data of the current 
study suggests a comparable role of C5a2 to the scavenging decoy receptor D6. 
This is because C5a2 did not show evidence of G protein signalling. In addition, 
C5a2 has a predominant intracellular localization similar to D6, while the 
classical receptors C5a1 and CCR5 are mainly expressed on the cell surface 
(Galliera et al., 2004, Weber et al., 2004). Furthermore, C5a2 showed higher 
constitutive and ligand-induced internalization, which continues for a longer time 
than that of C5a1. This result is supported by the finding of Scola et al. 2009, 
which also showed higher constitutive internalization of C5a2 compared to C5a1 
and, as for D6, this internalization led to degradation of the ligands especially 
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C5a desArg. The relatively low constitutive internalization of C5a1 did not lead 
to degradation of the ligand (Scola et al., 2009). All these findings suggest a 
scavenging role of C5a2 by eliminating the extracellular ligands C5a and C5a 
desArg (Bokisch and Muller-Eberhard, 1970, Budzko et al., 1971). Therefore, it 
could be speculated that C5a2 has a scavenging behaviour by decreasing the 
exposure of the classical C5a1 receptor to its ligand. This is supported by other 
reports that suggest a scavenging decoy function of C5a2 in different models such 
as mouse model of pulmonary inflammation (Gerard et al., 2005) and also in rat 
astrocytes (Gavrilyuk et al., 2005). Nevertheless, a pro-inflammatory function of 
C5a2 was also reported by other groups but it was not evident if it involved G 
proteins activation (Chen et al., 2007, Rittirsch et al., 2008, Poppelaars et al., 
2017). It should be noted that this study cannot rule out the potential multi-
functionality of C5a2 receptor in different cells, tissues, organs or even between 
species.  
 
Future work. The heterodimerization between C5a1 and C5a2 receptors 
can be further researched using primary cells that endogenously express the C5a 
receptors. A new approach could be used to examine the possible receptor 
dimerization in cells or tissues, namely the proximity ligation assay (PLA) 
(Weibrecht et al., 2010). This technique can detect protein-protein interactions at 
a distance similar to the FRET distance. In addition, it does not need the receptors 
to be extracted from the membranes or genetically engineered to be attached to 
fluorophores. In this technique, two probes, composed of antibody conjugated 
with oligonucleotides, are used to bind the target the proteins of interest. These 
antibody-conjugated oligonucleotides can hybridize, if they are in proximity 
close to FRET-distance, to connector oligonucleotides to form a circular DNA 
molecule. This circular DNA molecule can serve as an “endless” template for 
rolling circle amplification. The resultant single-stranded DNA molecule can be 
visualized by hybridization with fluorescently labelled detection oligonucleotides. 
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The potential heterodimerization should be compared in health and diseases states 
to explore the possible factors that affect its formation. If this form of interaction 
is confirmed between the C5a receptors, it would be interesting to investigate the 
possible dimerization interfaces to possibly test the effect of disturbance of such 
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